{"e727040251407b47374601cd024543066259c892": [["IntroductionAutomatic registration of histological images stained using several dyes is a challenging and important task that makes it possible to fuse information and potentially improve further processing and diagnosis.", [["histological images", "TEST", 38, 57], ["several dyes", "TREATMENT", 72, 84]]], ["The problem is difficult due to: (i) complex, large deformations, (ii) difference in the appearance and partially missing data, (iii) a very high resolution of the images.", [["deformations", "DISEASE", 52, 64], ["(i) complex, large deformations, (ii) difference in the appearance", "PROBLEM", 33, 99], ["the images", "TEST", 160, 170], ["large", "OBSERVATION_MODIFIER", 46, 51], ["deformations", "OBSERVATION", 52, 64]]], ["The provided dataset [1, [4] [5] [6] [7] consists of 481 image pairs annotated by experts, reasonably divided into the training (230) and the evaluation (251) set.", [["the evaluation", "TEST", 138, 152]]], ["There are 8 distinct tissue types that were stained using 10 different stains.", [["tissue", "ANATOMY", 21, 27], ["tissue", "TISSUE", 21, 27], ["8 distinct tissue types", "PROBLEM", 10, 33], ["8 distinct", "OBSERVATION_MODIFIER", 10, 20], ["tissue types", "OBSERVATION_MODIFIER", 21, 33]]], ["The image size varies from 8k to 16k pixels in one dimension.", [["The image size", "TEST", 0, 14], ["size", "OBSERVATION_MODIFIER", 10, 14], ["8k to 16k pixels", "OBSERVATION_MODIFIER", 27, 43], ["one dimension", "OBSERVATION_MODIFIER", 47, 60]]], ["The full dataset description, including the images size and the acquisition details, is available at [3] .", [["the images size", "TEST", 40, 55], ["the acquisition details", "TEST", 60, 83]]], ["The challenge organizers provide an independent, server-side evaluation tool that makes it possible to perform an objective comparison between participants and their solutions.IntroductionOne of the most difficult subproblems for the challenge participants was to calculate the initial, global transform.", [["participants", "SPECIES", 143, 155], ["participants", "SPECIES", 244, 256], ["server-side evaluation tool", "TEST", 49, 76]]], ["In this work, we propose a method based on deep learning which makes the process significantly faster, more robust, without the necessity to manually find a set of parameters viable for all the image pairs.IntroductionMedical image registration is an important domain in medical image analysis.", [["a method", "TREATMENT", 25, 33], ["deep learning", "TREATMENT", 43, 56], ["medical image analysis", "TEST", 271, 293]]], ["Much work was done in the area, resulting in good solutions to many important and challenging medical problems.", [["challenging medical problems", "PROBLEM", 82, 110]]], ["Medical image registration can be divided into classical algorithms, involving an iterative optimization for each image pair [11] or learning-based algorithms where the transformations are being learned and then the registration is performed during the inference [12] .", [["Medical image registration", "TEST", 0, 26], ["an iterative optimization", "TREATMENT", 79, 104], ["learning-based algorithms", "TREATMENT", 133, 158]]], ["The main advantage of the learning-based approach over the classical, iterative optimization is a fast, usually real-time registration, which makes the algorithms more useful in clinical practice.", [["the algorithms", "TEST", 148, 162], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["However, we think that it is reasonable to solve the problem using deep networks, potentially both improving the results and decreasing the computation time.IntroductionDeep learning-based medical image registration can be divided into three main categories, depending on the training procedure: (i) a supervised training [13, 14] , where a known transformation is applied and being reconstructed, (ii) an unsupervised training [15] [16] [17] , where a given similarity metric with a proper regularization or penalty terms is being optimized, (iii) an adversarial training [18, 19] , where both a discriminator and a generator are being trained to not only find the correct transformation but also learn a correct similarity metric.", [["deep networks", "MULTI-TISSUE_STRUCTURE", 67, 80], ["the training procedure", "TREATMENT", 272, 294], ["a proper regularization", "TREATMENT", 482, 505]]], ["The supervised approach does not require to define a similarity metric, however, in the case of multi-modal registration, the images must be first registered manually or by using a classical algorithm.", [["multi-modal registration", "TEST", 96, 120], ["the images", "TEST", 122, 132], ["a classical algorithm", "TEST", 179, 200]]], ["However, in the case of synthetic deformations, one must ensure that they correspond to the real deformations and in case of using deformation calculated by the state-of-the-art algorithms, it is unwise to expect better results, only a lower registration time.", [["deformations", "DISEASE", 34, 46], ["deformations", "DISEASE", 97, 109], ["synthetic deformations", "PROBLEM", 24, 46], ["the real deformations", "PROBLEM", 88, 109], ["deformation", "TEST", 131, 142], ["synthetic deformations", "OBSERVATION", 24, 46]]], ["In the case of unsupervised training, a differentiable similarity metric must be defined which for many imaging modalities is not a trivial task [20] .", [["unsupervised training", "TREATMENT", 15, 36], ["many imaging modalities", "TEST", 99, 122]]], ["The adversarial approach, just like the supervised approach, does not require defining a similarity metric but it still requires a ground-truth alignment that for many medical problems can not be determined.", [["The adversarial approach", "TREATMENT", 0, 24], ["many medical problems", "PROBLEM", 163, 184]]], ["The adversarial training provides much better generalization than the supervised one [19] .", [["The adversarial training", "TREATMENT", 0, 24]]], ["However, the disadvantage of the adversarial approach is the fact that training this kind of network is hard and much more time-consuming than the supervised/unsupervised alternatives because finding a good balance between the generator and the discriminator is usually a difficult, trial and error procedure.IntroductionWe decided to use the unsupervised approach because: (i) the state-of-the-art similarity metrics can capture the similarity of the histological images well, (ii) it does not require ground-truth to train the network, (iii) it is easy to train and has a great generalization ability.", [["error procedure", "TREATMENT", 293, 308]]], ["Currently, the most widely used approach for training the registration networks is to resize all the training images to the same shape using both resampling and image padding.", [["training the registration networks", "TREATMENT", 45, 79], ["the training images", "TEST", 97, 116], ["both resampling and image padding", "TREATMENT", 141, 174]]], ["As much as resampling the images makes sense, especially considering the initial alignment where the fine details are often not necessary, the padding is usually not a good idea, especially when the aspect ratio is high.", [["resampling the images", "TEST", 11, 32], ["the aspect ratio", "TEST", 195, 211], ["high", "OBSERVATION", 215, 219]]], ["It results in a high image resolution with much empty, unused space that then requires a deeper network to ensure large enough receptive field [21] .", [["a high image resolution", "PROBLEM", 14, 37], ["much empty, unused space", "PROBLEM", 43, 67], ["a deeper network", "TREATMENT", 87, 103], ["large", "OBSERVATION_MODIFIER", 114, 119]]], ["Therefore, we propose a network that can be trained using images with substantially different resolutions, without the necessity to perform the padding, while maintaining a relatively low number of network parameters, almost independent of the image resolution.IntroductionIn this work we propose a deep network to calculate the initial affine transform between histological images acquired using different dyes.", [["the padding", "TREATMENT", 140, 151], ["histological images", "TEST", 362, 381], ["different dyes", "TREATMENT", 397, 411]]], ["The proposed algorithm: (i) works well for images with different resolution, aspects ratios and does not require image padding, (ii) generalizes well to the evaluation set, (iii) does not require the ground-truth transform during training, (iv) is orders of magnitude faster than the iterative or descriptor-based approach, (v) successfully aligns about 98% of the evaluation pairs.", [["images", "TEST", 43, 49], ["aspects ratios", "TEST", 77, 91], ["image padding", "TEST", 113, 126], ["the evaluation", "TEST", 153, 167], ["the evaluation pairs", "TEST", 361, 381]]], ["We achieved this by proposing a patch-based feature extraction with a variable batch size followed by a 3-D convolution combining the patch features and 2-D convolutions to enlarge the receptive field.", [["a patch-based feature extraction", "TREATMENT", 30, 62], ["a variable batch size", "PROBLEM", 68, 89], ["a 3-D convolution", "TREATMENT", 102, 119], ["the patch features", "TREATMENT", 130, 148], ["size", "OBSERVATION_MODIFIER", 85, 89]]], ["We make both the training and inference code freely available [22] .General AspectsThe proposed method adheres strictly to the ANHIR challenge requirements, namely the method is fully automatic, robust and does not require any parameter tuning during the inference time.", [["the ANHIR challenge requirements", "TREATMENT", 123, 155], ["any parameter tuning", "TREATMENT", 223, 243]]], ["The method can be divided into a preprocessing and the following affine registration.", [["The method", "TREATMENT", 0, 10], ["a preprocessing", "TREATMENT", 31, 46]]], ["A step by step summary of the proposed registration procedure is described in Algorithm 1.PreprocessingThe preprocessing consists of the following steps: (i) smoothing and resampling the images to a lower resolution using the same, constant factors for each image pair, (ii) segmenting the tissue from the background, (iii) converting the images to grayscale, (iv) finding an initial rotation angle by an iterative approach.PreprocessingThe smoothing and resampling is in theory not strictly mandatory.", [["tissue", "ANATOMY", 290, 296], ["tissue", "TISSUE", 290, 296], ["the proposed registration procedure", "TREATMENT", 26, 61], ["resampling the images", "TEST", 172, 193], ["each image pair", "TEST", 253, 268], ["an initial rotation angle", "TEST", 373, 398], ["an iterative approach", "TREATMENT", 402, 423], ["tissue", "ANATOMY", 290, 296]]], ["Both the resampling and the smoothing coefficients were determined empirically, without an exhaustive parameter tuning.", [["the smoothing coefficients", "TEST", 24, 50], ["an exhaustive parameter tuning", "TREATMENT", 88, 118]]], ["After the resampling, the size across the larger dimension varies from \u223c600 to \u223c2000 pixels, depending on the tissue type.PreprocessingThe next step is to remove the background.", [["tissue", "ANATOMY", 110, 116], ["tissue", "TISSUE", 110, 116], ["the resampling", "TREATMENT", 6, 20], ["size", "OBSERVATION_MODIFIER", 26, 30], ["larger", "OBSERVATION_MODIFIER", 42, 48], ["dimension", "OBSERVATION_MODIFIER", 49, 58]]], ["This procedure significantly improves the results for mammary glands or mice kidneys because there are staining artifacts in the background that have a strong influence on the similarity metric.", [["mammary glands", "ANATOMY", 54, 68], ["kidneys", "ANATOMY", 77, 84], ["mammary glands", "ORGAN", 54, 68], ["mice", "ORGANISM", 72, 76], ["kidneys", "ORGAN", 77, 84], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["This procedure", "TREATMENT", 0, 14], ["staining artifacts in the background", "PROBLEM", 103, 139], ["mammary glands", "ANATOMY", 54, 68], ["kidneys", "ANATOMY", 77, 84], ["staining artifacts", "OBSERVATION", 103, 121], ["strong", "OBSERVATION_MODIFIER", 152, 158]]], ["In this work, we remove the background using smoothed Laplacian thresholding with a few morphological operations.", [["smoothed Laplacian thresholding", "TREATMENT", 45, 76], ["a few morphological operations", "TREATMENT", 82, 112]]], ["It works for all the cases and more advanced background removal algorithms are not necessary.", [["advanced background removal algorithms", "TREATMENT", 36, 74]]], ["For other digital pathology data sets, this step may be unnecessary or can look differently (e.g. a stain deconvolution or deep learningbased segmentation).PreprocessingFinally, after converting both images to grayscale, an initial rotation angle is being optimized.", [["a stain deconvolution", "TEST", 98, 119], ["deep learningbased segmentation)", "PROBLEM", 123, 155], ["grayscale", "TEST", 210, 219], ["an initial rotation angle", "TEST", 221, 246]]], ["We decided to use a simple procedure similar to [8, 9] because optimization of a single parameter can be done extremely fast and does not require any advanced optimization techniques.", [["a simple procedure", "TREATMENT", 18, 36], ["any advanced optimization techniques", "TREATMENT", 146, 182]]], ["The initial rotation angle is being optimized by the iterative rotation of the source image around the translated center of mass, with a given, pre-defined angle step.", [["the source image", "TEST", 75, 91], ["mass", "PROBLEM", 124, 128], ["mass", "OBSERVATION", 124, 128]]], ["Then, the angle with the largest global normalized crosscorrelation (NCC) is used as the best one.", [["angle", "OBSERVATION_MODIFIER", 10, 15], ["largest", "OBSERVATION_MODIFIER", 25, 32], ["global", "OBSERVATION_MODIFIER", 33, 39], ["normalized", "OBSERVATION", 40, 50]]], ["In practice, this step calculation time depends on the predefined angle step and can be optimized by performing it using a GPU.", [["a GPU", "TREATMENT", 121, 126]]], ["However, even considering an unoptimized, single-core CPU implementation, the computational time of this step is negligible compared to the data loading, initial resampling, and background removal.", [["initial resampling", "TREATMENT", 154, 172], ["background removal", "TREATMENT", 178, 196]]], ["The affine registration network was trained using the preprocessed data and therefore this step is required during inference.Affine RegistrationWe propose a network architecture that is able to calculate the correct affine transformation in a single pass, independently of the image size and the aspect ratio.", [["the preprocessed data", "TEST", 50, 71], ["affine transformation", "OBSERVATION", 216, 237], ["size", "OBSERVATION_MODIFIER", 283, 287]]], ["First, the images are passed to Fig. 1 .", [["the images", "TEST", 7, 17]]], ["An overview of the proposed network architecture.", [["network architecture", "MULTI-TISSUE_STRUCTURE", 28, 48]]], ["The source and target are unfolded and passed independently to the feature extractor where the batch size is equal to the number of patches after unfolding.", [["the batch size", "TEST", 91, 105], ["target", "OBSERVATION_MODIFIER", 15, 21], ["unfolded", "OBSERVATION", 26, 34], ["size", "OBSERVATION_MODIFIER", 101, 105], ["equal", "OBSERVATION_MODIFIER", 109, 114]]], ["Then, the extracted features are concatenated and passed to the feature combiner, patch combiner, and fully connected layers respectively.", [["layers", "TISSUE", 118, 124], ["feature combiner", "DNA", 64, 80], ["patch combiner", "DNA", 82, 96]]], ["The whole network has slightly above 30 million parameters, independently of the input image size. the network independently.", [["whole network", "MULTI-TISSUE_STRUCTURE", 4, 17], ["slightly", "OBSERVATION_MODIFIER", 22, 30], ["size", "OBSERVATION_MODIFIER", 93, 97]]], ["They are unfolded to a grid of patches with a given, predefined size (224 \u00d7 224 in our case) and stride equal to the patch size, the patches do not overlap.", [["unfolded", "OBSERVATION", 9, 17], ["size", "OBSERVATION_MODIFIER", 64, 68], ["size", "OBSERVATION_MODIFIER", 123, 127]]], ["Then, the patches are combined to a single tensor where the number of patches defines the batch size.", [["the patches", "TREATMENT", 6, 17], ["size", "OBSERVATION_MODIFIER", 96, 100]]], ["This step is followed by a feature extraction by a relatively lightweight, modified ResNet-like architecture [23].", [["ResNet", "PROTEIN", 84, 90], ["a feature extraction", "TREATMENT", 25, 45]]], ["The feature extractor weights are shared between the source and the target.", [["extractor weights", "OBSERVATION", 12, 29]]], ["Then, the features are concatenated and passed through additional 2-D convolutions to combine the source and target into a single representation.", [["2-D convolutions", "TREATMENT", 66, 82]]], ["Finally, the global correspondence is extracted by a 3-D convolution followed by a variable number of 2-D convolutions using the PyTorch dynamic graphs.", [["the PyTorch dynamic graphs", "TEST", 125, 151], ["global", "OBSERVATION_MODIFIER", 13, 19]]], ["The final step allows getting global information from the unfolded patches.", [["the unfolded patches", "TREATMENT", 54, 74]]], ["The number of final 2-D convolutions depends on the image resolution and can be extended dynamically to enlarge the receptive field.", [["number", "OBSERVATION_MODIFIER", 4, 10], ["final 2-D convolutions", "OBSERVATION_MODIFIER", 14, 36]]], ["In practice, on the resampled ANHIR dataset (the larger dimension contains from \u223c600 to \u223c2000 pixels) a single convolutional layer is sufficient.", [["ANHIR dataset", "DNA", 30, 43], ["a single convolutional layer", "TREATMENT", 102, 130]]], ["Eventually, the features are passed to adaptive average pooling and fully connected layers, which output the transformation matrix.", [["layers", "TISSUE", 84, 90], ["matrix", "CELLULAR_COMPONENT", 124, 130], ["adaptive average pooling and fully connected layers", "PROBLEM", 39, 90], ["layers", "OBSERVATION_MODIFIER", 84, 90], ["output", "OBSERVATION_MODIFIER", 98, 104], ["transformation matrix", "OBSERVATION", 109, 130]]], ["The network architecture and the forward pass procedure is presented in Fig. 1 .", [["network architecture", "MULTI-TISSUE_STRUCTURE", 4, 24], ["the forward pass procedure", "TREATMENT", 29, 55], ["architecture", "OBSERVATION_MODIFIER", 12, 24]]], ["The number of parameters is slightly above 30 million, the forward pass memory consumption depends on the image resolution.Affine RegistrationThe proposed network is trained in a relatively unusual way.", [["slightly", "OBSERVATION_MODIFIER", 28, 36]]], ["However, the optimizer is being updated only after a gradient of a given number of images (the real batch size) was already backpropagated.", [["images", "TEST", 83, 89]]], ["This approach makes its possible to use any real batch size during training but it requires an architectural change.", [["any real batch size during training", "TREATMENT", 40, 75], ["an architectural change", "PROBLEM", 92, 115], ["size", "OBSERVATION_MODIFIER", 55, 59], ["architectural change", "OBSERVATION", 95, 115]]], ["Since all the image pairs have a different resolution, they are divided into a different number of patches during unfolding.", [["different", "OBSERVATION_MODIFIER", 33, 42], ["resolution", "OBSERVATION_MODIFIER", 43, 53], ["different", "OBSERVATION_MODIFIER", 79, 88], ["number", "OBSERVATION_MODIFIER", 89, 95], ["patches", "OBSERVATION_MODIFIER", 99, 106], ["unfolding", "OBSERVATION_MODIFIER", 114, 123]]], ["As a result, it is incorrect to use the batch normalization layers because during inference they are unable to automatically choose the correct normalization parameters and strong overfitting is observed.", [["the batch normalization layers", "TREATMENT", 36, 66], ["strong overfitting", "PROBLEM", 173, 191], ["strong", "OBSERVATION_MODIFIER", 173, 179], ["overfitting", "OBSERVATION", 180, 191]]], ["Therefore, we replaced all the batch normalization layers by a group normalization [24] , which solved the problem.", [["layers", "OBSERVATION_MODIFIER", 51, 57]]], ["This is not the case because the batch size dimension after unfolding is sufficiently large to utilize the GPU correctly.", [["size", "OBSERVATION_MODIFIER", 39, 43], ["large", "OBSERVATION_MODIFIER", 86, 91]]], ["The network was trained using an Adam optimizer, with a learning rate equal to 10 \u22124 and a decaying scheduler after each epoch.", [["an Adam optimizer", "TREATMENT", 30, 47]]], ["The global negative NCC was used as the cost function.", [["NCC", "GENE_OR_GENE_PRODUCT", 20, 23], ["global negative NCC", "PROTEIN", 4, 23], ["global", "OBSERVATION_MODIFIER", 4, 10], ["negative NCC", "OBSERVATION", 11, 23]]], ["No difference was observed between the global NCC and the patch-based NCC.", [["NCC", "ANATOMY", 70, 73], ["NCC", "PROTEIN", 70, 73], ["difference", "OBSERVATION_MODIFIER", 3, 13]]], ["Moreover, the results provided by NCC were better than MIND or NGF since the latter two are not scale-resistant and would require additional constraints.", [["NCC", "GENE_OR_GENE_PRODUCT", 34, 37], ["NGF", "GENE_OR_GENE_PRODUCT", 63, 66], ["NCC", "PROTEIN", 34, 37], ["MIND", "PROTEIN", 55, 59], ["NGF", "PROTEIN", 63, 66], ["NGF", "TREATMENT", 63, 66]]], ["The dataset was augmented by random affine transformations applied both to the source and the target, including translating, scaling, rotating and shearing the images.", [["random affine transformations", "TREATMENT", 29, 58], ["shearing the images", "TEST", 147, 166]]], ["The network was trained using only the training dataset consisting of 230 image pairs.", [["the training dataset", "TREATMENT", 35, 55]]], ["The evaluation dataset consisting of 251 image pairs was used as a validation set.", [["The evaluation dataset", "TEST", 0, 22]]], ["However, no decision was made based on the validation results.", [["the validation", "TEST", 39, 53]]], ["The network state after the last epoch was used for testing.", [["testing", "TEST", 52, 59]]], ["Thanks to the augmentation, no overfitting was observed.", [["overfitting", "PROBLEM", 31, 42], ["no", "UNCERTAINTY", 28, 30], ["overfitting", "OBSERVATION", 31, 42]]], ["Moreover, the loss on the validation set was lower than on the training set.", [["the loss", "PROBLEM", 10, 18], ["the validation set", "TEST", 22, 40], ["loss", "OBSERVATION_MODIFIER", 14, 18]]], ["No information about the landmarks from both the training and the validation set was used during the training.", [["the training", "TREATMENT", 97, 109]]], ["The data set is open and can be freely downloaded, so results are fully reproducible.", [["The data", "TEST", 0, 8]]], ["For a more detailed data set description, including the tissue types, the procedure of the tissue staining and other important information, we refer to [3] .ResultsWe evaluated the proposed algorithm using the target registration error between landmarks provided by the challenge organizers, normalized by the image diagonal, defined as:Resultswhere T RE denotes the target registration error, w is the image width and h is the image height.", [["tissue", "ANATOMY", 56, 62], ["tissue", "ANATOMY", 91, 97], ["tissue", "TISSUE", 56, 62], ["tissue", "TISSUE", 91, 97], ["the procedure", "TREATMENT", 70, 83], ["the tissue staining", "TEST", 87, 106]]], ["We compare the proposed method to the most popular computer vision descriptors (SURF [25] and SIFT [26] ) as well as the intensitybased, iterative affine registration [27] .", [["iterative affine registration", "TREATMENT", 137, 166]]], ["All the methods were applied to the dataset after the preprocessing and the parameters were tuned to optimize the results.", [["All the methods", "TREATMENT", 0, 15], ["the preprocessing", "TEST", 50, 67]]], ["Unfortunately, we could not compare to initial alignment methods used by other challenge participants because the submission system reports only the final results after nonrigid registration.", [["participants", "SPECIES", 89, 101]]], ["The cumulative histogram of the target registration error for the available landmarks is shown in Fig. 2 .", [["The cumulative histogram", "TEST", 0, 24]]], ["In Table 1 we summarize the rTRE for the evaluation set using the evaluation platform provided by the challenge organizers.", [["rTRE", "DNA", 28, 32], ["the evaluation", "TEST", 37, 51], ["the evaluation platform", "TEST", 62, 85]]], ["As the success ratio, we define cases that are registered in a manner that can we followed by a converging, generic, nonrigid registration algorithm like B-Splines free form deformations or Demons.", [["deformations", "DISEASE", 174, 186], ["nonrigid registration algorithm", "TEST", 117, 148], ["Demons", "PROBLEM", 190, 196]]], ["The cumulative histogram of the target registration error for the proposed and compared methods.", [["The cumulative histogram", "TEST", 0, 24]]], ["We experimentally verified that the preprocessing does not deteriorate the results for the feature-based approach and significantly improves the results for the iterative registration.", [["the iterative registration", "TEST", 157, 183]]], ["An exemplary failure visualization of the evaluated methods.", [["An exemplary failure visualization", "TEST", 0, 34], ["exemplary", "OBSERVATION_MODIFIER", 3, 12], ["failure", "OBSERVATION", 13, 20]]], ["Please note that the calculated transformations were applied to the images before the preprocessing.", [["the calculated transformations", "TREATMENT", 17, 47], ["the images", "TEST", 64, 74], ["the preprocessing", "TEST", 82, 99]]], ["It is visible that the feature-based approach failed and the iterative affine registration was unable to converge correctly.Discussion and ConclusionThe proposed method works well for more than 98% of the ANHIR image pairs.", [["ANHIR image pairs", "DNA", 205, 222], ["the iterative affine registration", "TEST", 57, 90]]], ["The registration time is significantly lower than using the iterative or feature-based approach.", [["The registration time", "TEST", 0, 21], ["significantly", "OBSERVATION_MODIFIER", 25, 38], ["lower", "OBSERVATION_MODIFIER", 39, 44]]], ["This step could be significantly lowered by proposing a different data format, which already includes the resampled version of the images.", [["the images", "TEST", 127, 137], ["significantly", "OBSERVATION_MODIFIER", 19, 32], ["lowered", "OBSERVATION", 33, 40]]], ["It can be noticed that both the iterative affine registration and the featurebased alignment provide slightly better results when they can converge correctly.", [["the iterative affine registration", "TEST", 28, 61], ["affine registration", "OBSERVATION", 42, 61]]], ["However, the registration accuracy achieved by the proposed method is sufficient for the following nonrigid registration for which the gap between the proposed method and the iterative alignment is not that important.", [["the registration accuracy", "TEST", 9, 34], ["nonrigid registration", "TEST", 99, 120]]], ["The proposed method is significantly faster and more robust, resulting in a higher success ratio, which in practice is more important than the slightly lower target registration error.", [["a higher success ratio", "PROBLEM", 74, 96], ["the slightly lower target registration error", "PROBLEM", 139, 183], ["significantly", "OBSERVATION_MODIFIER", 23, 36], ["faster", "OBSERVATION_MODIFIER", 37, 43], ["higher", "OBSERVATION_MODIFIER", 76, 82], ["slightly", "OBSERVATION_MODIFIER", 143, 151], ["lower", "OBSERVATION_MODIFIER", 152, 157], ["target registration", "OBSERVATION", 158, 177]]], ["The feature-based methods often fail and without a proper detection of the failures they cannot be used in a fully automatic algorithm.", [["the failures", "PROBLEM", 71, 83], ["failures", "OBSERVATION", 75, 83]]], ["On the other hand, the proposed method does not suffer from this problem.Discussion and ConclusionTo conclude, we propose a method for an automatic, robust and fast initial affine registration of histology images based on a deep learning approach.", [["histology images", "TEST", 196, 212], ["a deep learning approach", "TREATMENT", 222, 246]]], ["The method works well for images with different aspect ratios, resolutions, generalizes well for the evaluation set and requires a relatively low number of the network parameters.", [["images", "TEST", 26, 32], ["the evaluation", "TEST", 97, 111]]], ["The next step involves a deep network to perform the non-rigid registration, using the highest resolution provided by the challenge organizers.", [["the non-rigid registration", "TEST", 49, 75]]], ["We think it is possible to solve this problem efficiently, even though a single image can take up to 1 GB of the GPU memory.", [["a single image", "TEST", 71, 85]]]], "PMC7440146": [["IntroductionCoronavirus disease 2019 (COVID-19) is a novel disease entity caused by SARS-CoV-2 virus that recently spread throughout the world.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["SARS-CoV-2 virus", "ORGANISM", 84, 100], ["CoV-2 virus", "SPECIES", 89, 100], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["SARS-CoV-2 virus", "SPECIES", 84, 100], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["a novel disease entity", "PROBLEM", 51, 73], ["SARS", "PROBLEM", 84, 88], ["CoV-2 virus", "PROBLEM", 89, 100], ["disease", "OBSERVATION", 59, 66]]], ["The disease appears to be mild in the majority of patients, however, about 15% of affected individuals can develop a severe disease with respiratory insufficiency, that may require mechanical ventilation and intensive care (Guan et al., 2020).", [["respiratory", "ANATOMY", 137, 148], ["respiratory insufficiency", "DISEASE", 137, 162], ["patients", "ORGANISM", 50, 58], ["individuals", "ORGANISM", 91, 102], ["patients", "SPECIES", 50, 58], ["The disease", "PROBLEM", 0, 11], ["affected individuals", "PROBLEM", 82, 102], ["a severe disease", "PROBLEM", 115, 131], ["respiratory insufficiency", "PROBLEM", 137, 162], ["mechanical ventilation", "TREATMENT", 181, 203], ["disease", "OBSERVATION", 4, 11], ["appears to be", "UNCERTAINTY", 12, 25], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["majority", "OBSERVATION_MODIFIER", 38, 46], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["disease", "OBSERVATION", 124, 131], ["respiratory insufficiency", "OBSERVATION", 137, 162]]], ["Whether people with MS are at increased risk of COVID-19 infection, or at higher risk of more severe infection, is unknown (Thakolwiboon et al., 2020 May 18, Willis and Robertson, 2020).", [["MS", "DISEASE", 20, 22], ["infection", "DISEASE", 57, 66], ["infection", "DISEASE", 101, 110], ["people", "ORGANISM", 8, 14], ["COVID-19", "ORGANISM", 48, 56], ["people", "SPECIES", 8, 14], ["MS", "PROBLEM", 20, 22], ["COVID-19 infection", "PROBLEM", 48, 66], ["more severe infection", "PROBLEM", 89, 110], ["infection", "OBSERVATION", 57, 66], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["infection", "OBSERVATION", 101, 110]]], ["Although, immunosuppression is thought to increase risk of severe infections compared with the general population.", [["infections", "DISEASE", 66, 76], ["immunosuppression", "TREATMENT", 10, 27], ["severe infections", "PROBLEM", 59, 76], ["immunosuppression", "OBSERVATION", 10, 27], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["infections", "OBSERVATION", 66, 76]]], ["MSIF (Multiple Sclerosis International Federation) guidelines recommend that MS patients should take extra care to minimize their exposure to the virus and use alternatives to face-to-face medical appointments (4).", [["MSIF", "CHEMICAL", 0, 4], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["extra care", "TREATMENT", 101, 111]]], ["Patients are seen virtually using telemedicine or phone calls and they were advised to take all preventive measures to reduce COVID-19 transmission (social-distancing, frequent hand-washing, respiratory hygiene) and also were recommended to avoid contact with the hospital and other medical institutions as much as possible (Repovic, 2019 Jun 1).", [["hand", "ANATOMY", 177, 181], ["respiratory", "ANATOMY", 191, 202], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 126, 131], ["respiratory hygiene", "TREATMENT", 191, 210]]], ["Oral corticosteroids (oCS) may be preferable to intravenous corticosteroids in some patients with MS relapse (Burton et al., 2012).", [["Oral", "ANATOMY", 0, 4], ["intravenous", "ANATOMY", 48, 59], ["corticosteroids", "CHEMICAL", 5, 20], ["oCS", "CHEMICAL", 22, 25], ["MS", "DISEASE", 98, 100], ["corticosteroids", "CHEMICAL", 5, 20], ["Oral corticosteroids", "SIMPLE_CHEMICAL", 0, 20], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 59], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Oral corticosteroids (oCS)", "TREATMENT", 0, 26], ["intravenous corticosteroids", "TREATMENT", 48, 75], ["MS relapse", "PROBLEM", 98, 108], ["corticosteroids", "OBSERVATION", 5, 20]]], ["This administration route may relieve pressure on the hospitals that may be affected due to the pandemic and reduces the risk of COVID-19 transmission in these patients.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 129, 137], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["This administration route", "TREATMENT", 0, 25], ["pressure", "PROBLEM", 38, 46], ["the pandemic", "PROBLEM", 92, 104], ["COVID", "TEST", 129, 134]]], ["In Argentina, there are no recommendations regarding relapses treatment during the COVID-19 pandemic.", [["relapses treatment", "TREATMENT", 53, 71], ["the COVID", "TEST", 79, 88], ["pandemic", "PROBLEM", 92, 100], ["no", "UNCERTAINTY", 24, 26]]], ["Therefore, patients are still hospitalized and receiving intravenous methylprednisolone (IVMP).", [["intravenous", "ANATOMY", 57, 68], ["methylprednisolone", "CHEMICAL", 69, 87], ["IVMP", "CHEMICAL", 89, 93], ["methylprednisolone", "CHEMICAL", 69, 87], ["IVMP", "CHEMICAL", 89, 93], ["patients", "ORGANISM", 11, 19], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 68], ["methylprednisolone", "SIMPLE_CHEMICAL", 69, 87], ["IVMP", "SIMPLE_CHEMICAL", 89, 93], ["patients", "SPECIES", 11, 19], ["intravenous methylprednisolone (IVMP)", "TREATMENT", 57, 94]]], ["The objective of this study is to make a descriptive review of the available literature about the efficacy of high doses oral corticosteroids for MS relapses treatment.", [["oral", "ANATOMY", 121, 125], ["MS", "DISEASE", 146, 148], ["oral", "ORGANISM_SUBDIVISION", 121, 125], ["this study", "TEST", 17, 27], ["high doses oral corticosteroids", "TREATMENT", 110, 141], ["MS relapses treatment", "TREATMENT", 146, 167]]], ["In addition, we propose an algorithm of management and treatment during this pandemic context.MethodsWe searched for the following terms in PubMed and Scientific Electronic Library online (Scielo): \u201cMultiple Sclerosis\u201d, \u201cMS\u201d, \u201crelapse treatment\u201d, \u201coral corticosteroids\u201d, \u201chigh dose oral corticosteroids\u201d, \u201ccorticosteroids\u201d, \u201coral methylprednisolone\u201d, \u201coral prednisone\u201d, \u201cintravenous corticosteroids\u201d, \u201cIVMP\u201d, \u201coMP\u201d.", [["oral", "ANATOMY", 248, 252], ["oral", "ANATOMY", 282, 286], ["oral", "ANATOMY", 325, 329], ["oral", "ANATOMY", 352, 356], ["intravenous", "ANATOMY", 371, 382], ["Sclerosis", "DISEASE", 208, 217], ["methylprednisolone", "CHEMICAL", 330, 348], ["prednisone", "CHEMICAL", 357, 367], ["methylprednisolone", "CHEMICAL", 330, 348], ["prednisone", "CHEMICAL", 357, 367], ["oral", "ORGANISM_SUBDIVISION", 248, 252], ["oral", "ORGANISM_SUBDIVISION", 282, 286], ["oral", "ORGANISM_SUBDIVISION", 325, 329], ["methylprednisolone", "SIMPLE_CHEMICAL", 330, 348], ["oral", "ORGANISM_SUBDIVISION", 352, 356], ["prednisone", "SIMPLE_CHEMICAL", 357, 367], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 371, 382], ["an algorithm of management", "TREATMENT", 24, 50], ["treatment", "TREATMENT", 55, 64], ["Multiple Sclerosis\u201d", "PROBLEM", 199, 218], ["relapse treatment", "TREATMENT", 227, 244], ["oral corticosteroids", "TREATMENT", 248, 268], ["high dose oral corticosteroids", "TREATMENT", 272, 302], ["\u201ccorticosteroids", "TREATMENT", 305, 321], ["oral methylprednisolone", "TREATMENT", 325, 348], ["oral prednisone", "TREATMENT", 352, 367], ["\u201cintravenous corticosteroids", "TREATMENT", 370, 398], ["Multiple", "OBSERVATION_MODIFIER", 199, 207], ["Sclerosis", "OBSERVATION", 208, 217]]], ["Duplicate records, reviews, comments, nonrandomized trials or unrelated to topic were excluded.", [["nonrandomized trials", "TREATMENT", 38, 58]]], ["Studies were selected when they met the following entry criteria: randomized controlled trials, blinded or unblinded, comparing the use of high dose oCS and IVMP for MS relapses treatment.", [["oCS", "CHEMICAL", 149, 152], ["IVMP", "CHEMICAL", 157, 161], ["MS", "DISEASE", 166, 168], ["IVMP", "SIMPLE_CHEMICAL", 157, 161], ["randomized controlled trials", "TREATMENT", 66, 94], ["high dose oCS", "TREATMENT", 139, 152], ["IVMP", "TREATMENT", 157, 161], ["MS relapses treatment", "TREATMENT", 166, 187]]], ["Five articles were selected and following variables were described: number of patients, dose and route administration of the treatment, outcomes, comparative efficacy and safety and/or tolerability.Result", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["the treatment", "TREATMENT", 121, 134]]]], "PMC4308519": [["IntroductionIn September 2012, a novel human coronavirus, Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), was isolated from a Saudi Arabian patient suffering with a SARS-like disease characterized by fever, cough and shortness of breath.", [["human coronavirus", "DISEASE", 39, 56], ["Middle East respiratory syndrome (MERS) coronavirus", "DISEASE", 58, 109], ["SARS-like disease", "DISEASE", 181, 198], ["fever", "DISEASE", 216, 221], ["cough", "DISEASE", 223, 228], ["shortness of breath", "DISEASE", 233, 252], ["human", "ORGANISM", 39, 44], ["Middle East respiratory syndrome (MERS) coronavirus", "ORGANISM", 58, 109], ["MERS-CoV", "ORGANISM", 111, 119], ["patient", "ORGANISM", 156, 163], ["human", "SPECIES", 39, 44], ["coronavirus", "SPECIES", 45, 56], ["patient", "SPECIES", 156, 163], ["human coronavirus", "SPECIES", 39, 56], ["Middle East respiratory syndrome (MERS) coronavirus", "SPECIES", 58, 109], ["MERS-CoV", "SPECIES", 111, 119], ["a novel human coronavirus", "PROBLEM", 31, 56], ["Middle East respiratory syndrome", "PROBLEM", 58, 90], ["coronavirus", "PROBLEM", 98, 109], ["a SARS-like disease", "PROBLEM", 179, 198], ["fever", "PROBLEM", 216, 221], ["cough", "PROBLEM", 223, 228], ["shortness of breath", "PROBLEM", 233, 252], ["respiratory syndrome", "OBSERVATION", 70, 90], ["fever", "OBSERVATION", 216, 221]]], ["The patient later died of respiratory and renal failure [1].", [["respiratory", "ANATOMY", 26, 37], ["renal", "ANATOMY", 42, 47], ["respiratory and renal failure", "DISEASE", 26, 55], ["patient", "ORGANISM", 4, 11], ["renal", "ORGAN", 42, 47], ["patient", "SPECIES", 4, 11], ["respiratory and renal failure", "PROBLEM", 26, 55], ["renal", "ANATOMY", 42, 47], ["failure", "OBSERVATION", 48, 55]]], ["Most people diagnosed with MERS-CoV infection have developed severe acute respiratory illness.", [["respiratory", "ANATOMY", 74, 85], ["MERS-CoV infection", "DISEASE", 27, 45], ["acute respiratory illness", "DISEASE", 68, 93], ["people", "ORGANISM", 5, 11], ["MERS-CoV", "ORGANISM", 27, 35], ["people", "SPECIES", 5, 11], ["MERS-CoV", "SPECIES", 27, 35], ["MERS", "PROBLEM", 27, 31], ["CoV infection", "PROBLEM", 32, 45], ["severe acute respiratory illness", "PROBLEM", 61, 93], ["CoV", "ANATOMY", 32, 35], ["infection", "OBSERVATION", 36, 45], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory illness", "OBSERVATION", 74, 93]]], ["As of November 7, 2014, 909 laboratory-confirmed cases of MERS-CoV infection have been reported to the World Health Organization, including at least 331 related deaths (http://www.who.int/csr/don/07-november-2014-mers).", [["MERS-CoV infection", "DISEASE", 58, 76], ["deaths", "DISEASE", 161, 167], ["MERS-CoV", "ORGANISM", 58, 66], ["MERS-CoV", "SPECIES", 58, 66], ["MERS", "PROBLEM", 58, 62], ["CoV infection", "PROBLEM", 63, 76], ["infection", "OBSERVATION", 67, 76]]], ["The outbreak of MERS-CoV poses a serious threat to global public health and highlights an urgent need for the development of effective therapeutic and prophylactic agents to treat and prevent MERS-CoV infection [2], [3].IntroductionTherapeutic modalities based on monoclonal antibodies (mAbs) have shown clinical success in the treatment of many diseases [4], [5], [6], [7], [8].", [["MERS-CoV", "DISEASE", 16, 24], ["MERS-CoV infection", "DISEASE", 192, 210], ["MERS-CoV", "ORGANISM", 16, 24], ["MERS-CoV", "ORGANISM", 192, 200], ["[5], [6], [7]", "SIMPLE_CHEMICAL", 360, 373], ["[8]", "SIMPLE_CHEMICAL", 375, 378], ["monoclonal antibodies", "PROTEIN", 264, 285], ["mAbs", "PROTEIN", 287, 291], ["MERS-CoV", "SPECIES", 16, 24], ["MERS-CoV", "SPECIES", 192, 200], ["prophylactic agents", "TREATMENT", 151, 170], ["MERS", "PROBLEM", 192, 196], ["CoV infection", "PROBLEM", 197, 210], ["Therapeutic modalities", "TREATMENT", 232, 254], ["monoclonal antibodies", "TEST", 264, 285], ["many diseases", "PROBLEM", 341, 354]]], ["The therapeutic potential of antibodies targeting coronaviruses was well recognized during the SARS outbreak [8], [9], [10], [11], [12], [13], [14].", [["SARS", "DISEASE", 95, 99], ["coronaviruses", "ORGANISM", 50, 63], ["[9]", "SIMPLE_CHEMICAL", 114, 117], ["[10]", "SIMPLE_CHEMICAL", 119, 123], ["[11]", "SIMPLE_CHEMICAL", 125, 129], ["[12]", "SIMPLE_CHEMICAL", 131, 135], ["[13]", "SIMPLE_CHEMICAL", 137, 141], ["antibodies", "PROTEIN", 29, 39], ["antibodies targeting coronaviruses", "PROBLEM", 29, 63], ["the SARS outbreak", "TEST", 91, 108]]], ["In this review, we summarize the recent progress in identifying human neutralizing mAbs against MERS-CoV, describe their mechanisms of action, and analyze their potential for the therapy and prophylaxis of MERS.", [["human", "ORGANISM", 64, 69], ["MERS-CoV", "ORGANISM", 96, 104], ["human neutralizing mAbs", "PROTEIN", 64, 87], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["MERS-CoV", "SPECIES", 96, 104], ["human neutralizing mAbs", "TREATMENT", 64, 87], ["the therapy", "TREATMENT", 175, 186], ["prophylaxis", "TREATMENT", 191, 202], ["MERS", "PROBLEM", 206, 210]]], ["We also discuss future directions towards developing a strategy for the rapid development of antibody-based antivirals to combat emerging viruses and diseases in an outbreak setting.From SARS to MERS: the threat of novel coronavirusesCoronaviruses are a large family of viruses that typically infect the respiratory and gastrointestinal tract of mammals.", [["respiratory", "ANATOMY", 304, 315], ["gastrointestinal tract", "ANATOMY", 320, 342], ["SARS", "DISEASE", 187, 191], ["respiratory and gastrointestinal tract", "DISEASE", 304, 342], ["coronaviruses", "ORGANISM", 221, 234], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 320, 342], ["a strategy", "TREATMENT", 53, 63], ["antibody-based antivirals", "TREATMENT", 93, 118], ["emerging viruses", "PROBLEM", 129, 145], ["diseases", "PROBLEM", 150, 158], ["novel coronavirusesCoronaviruses", "PROBLEM", 215, 247], ["viruses", "PROBLEM", 270, 277], ["coronaviruses", "OBSERVATION", 221, 234], ["viruses", "OBSERVATION", 270, 277], ["gastrointestinal tract", "ANATOMY", 320, 342]]], ["Based on observation under electron microscopy, they are named for solar corona-like surface projections created by viral spike (S) glycoproteins.", [["surface", "ANATOMY", 85, 92], ["viral spike (S) glycoproteins", "GENE_OR_GENE_PRODUCT", 116, 145], ["viral spike (S) glycoproteins", "PROTEIN", 116, 145], ["electron microscopy", "TEST", 27, 46], ["solar corona-like surface projections", "TREATMENT", 67, 104], ["viral spike (S) glycoproteins", "PROBLEM", 116, 145], ["viral spike", "OBSERVATION", 116, 127]]], ["The first two coronaviruses infecting human, HCoV-229E and HCoV-OC43, were identified in the 1960s from the nasal cavities of patients presenting with the common cold [15], [16], [17].", [["HCoV-229E", "ANATOMY", 45, 54], ["HCoV-OC43", "ANATOMY", 59, 68], ["nasal cavities", "ANATOMY", 108, 122], ["coronaviruses", "ORGANISM", 14, 27], ["human", "ORGANISM", 38, 43], ["HCoV-229E", "CELL", 45, 54], ["HCoV-OC43", "CELL", 59, 68], ["nasal cavities", "MULTI-TISSUE_STRUCTURE", 108, 122], ["patients", "ORGANISM", 126, 134], ["[16], [17]", "SIMPLE_CHEMICAL", 173, 183], ["human", "SPECIES", 38, 43], ["patients", "SPECIES", 126, 134], ["human", "SPECIES", 38, 43], ["HCoV-229E", "SPECIES", 45, 54], ["HCoV", "SPECIES", 59, 63], ["HCoV", "TEST", 45, 49], ["HCoV", "TEST", 59, 63], ["nasal cavities", "ANATOMY", 108, 122]]], ["They were found to cause only mild to moderate upper respiratory tract illnesses [18], [19]; as a result, coronaviruses were considered relatively harmless to humans.", [["upper respiratory tract", "ANATOMY", 47, 70], ["upper respiratory tract illnesses", "DISEASE", 47, 80], ["coronaviruses", "ORGANISM", 106, 119], ["humans", "ORGANISM", 159, 165], ["humans", "SPECIES", 159, 165], ["humans", "SPECIES", 159, 165], ["mild to moderate upper respiratory tract illnesses", "PROBLEM", 30, 80], ["coronaviruses", "PROBLEM", 106, 119], ["mild", "OBSERVATION_MODIFIER", 30, 34], ["moderate", "OBSERVATION_MODIFIER", 38, 46], ["upper", "ANATOMY_MODIFIER", 47, 52], ["respiratory tract", "ANATOMY", 53, 70]]], ["However, during the winter of 2002\u20132003, clinicians recognized a new, deadly coronavirus strain able to infect both the upper and lower respiratory tract and cause severe acute respiratory syndrome (SARS) [20], [21].", [["lower respiratory tract", "ANATOMY", 130, 153], ["acute respiratory syndrome", "DISEASE", 171, 197], ["SARS", "DISEASE", 199, 203], ["coronavirus", "ORGANISM", 77, 88], ["upper", "ORGANISM_SUBDIVISION", 120, 125], ["lower", "ORGANISM_SUBDIVISION", 130, 135], ["respiratory tract", "ORGANISM_SUBDIVISION", 136, 153], ["deadly coronavirus strain", "PROBLEM", 70, 95], ["severe acute respiratory syndrome", "PROBLEM", 164, 197], ["upper", "ANATOMY_MODIFIER", 120, 125], ["lower", "ANATOMY_MODIFIER", 130, 135], ["respiratory tract", "ANATOMY", 136, 153], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["respiratory syndrome", "OBSERVATION", 177, 197]]], ["This coronavirus, subsequently named SARS-CoV, rapidly spread around the world and caused a worldwide outbreak with 8096 confirmed cases, including 774 deaths from 2002 to 2003 (http://www.who.int/csr/sars/country/table2004_04_21).From SARS to MERS: the threat of novel coronavirusesThe SARS epidemic was contained in 2003, and no known cases of SARS-CoV infection have been reported since 2004.", [["coronavirus", "DISEASE", 5, 16], ["SARS-CoV", "DISEASE", 37, 45], ["deaths", "DISEASE", 152, 158], ["SARS", "DISEASE", 236, 240], ["MERS", "DISEASE", 244, 248], ["coronaviruses", "DISEASE", 270, 283], ["SARS", "DISEASE", 287, 291], ["SARS-CoV infection", "DISEASE", 346, 364], ["coronavirus", "ORGANISM", 5, 16], ["SARS-CoV", "ORGANISM", 37, 45], ["coronaviruses", "ORGANISM", 270, 283], ["SARS-CoV", "ORGANISM", 346, 354], ["SARS-CoV", "SPECIES", 37, 45], ["SARS-CoV", "SPECIES", 346, 354], ["This coronavirus", "PROBLEM", 0, 16], ["SARS", "PROBLEM", 37, 41], ["novel coronaviruses", "PROBLEM", 264, 283], ["The SARS epidemic", "PROBLEM", 283, 300], ["SARS", "PROBLEM", 346, 350], ["CoV infection", "PROBLEM", 351, 364], ["coronaviruses", "OBSERVATION", 270, 283], ["infection", "OBSERVATION", 355, 364]]], ["Two more human coronaviruses, NL63 and HKU1, were discovered from 2004 to 2005 [22], [23].", [["human", "ORGANISM", 9, 14], ["coronaviruses", "ORGANISM", 15, 28], ["NL63", "GENE_OR_GENE_PRODUCT", 30, 34], ["HKU1", "GENE_OR_GENE_PRODUCT", 39, 43], ["human", "SPECIES", 9, 14], ["human coronaviruses", "SPECIES", 9, 28]]], ["These coronaviruses, like HCoV-229E and HCoV-OC43, are only common cold viruses which circulate worldwide and generally cause relatively mild respiratory symptoms [22], [23], [24].", [["respiratory", "ANATOMY", 142, 153], ["coronaviruses", "ORGANISM", 6, 19], ["HCoV-229E", "ORGANISM", 26, 35], ["HCoV-OC43", "ORGANISM", 40, 49], ["HCoV-229E", "SPECIES", 26, 35], ["HCoV-OC43", "SPECIES", 40, 49], ["These coronaviruses", "TEST", 0, 19], ["HCoV", "TEST", 26, 30], ["HCoV", "TEST", 40, 44], ["common cold viruses", "PROBLEM", 60, 79], ["relatively mild respiratory symptoms", "PROBLEM", 126, 162], ["common cold", "OBSERVATION_MODIFIER", 60, 71], ["viruses", "OBSERVATION", 72, 79], ["mild", "OBSERVATION_MODIFIER", 137, 141]]], ["However, the threat of coronaviruses has not disappeared.", [["coronaviruses", "DISEASE", 23, 36], ["coronaviruses", "ORGANISM", 23, 36], ["coronaviruses", "PROBLEM", 23, 36], ["coronaviruses", "OBSERVATION", 23, 36], ["not disappeared", "UNCERTAINTY", 41, 56]]], ["In 2012, a novel coronavirus, MERS-CoV, was identified, and its human infection results in a higher mortality rate (\u223c36%) than that of SARS-CoV (\u223c10%) [1].", [["coronavirus", "DISEASE", 17, 28], ["infection", "DISEASE", 70, 79], ["SARS", "DISEASE", 135, 139], ["coronavirus", "ORGANISM", 17, 28], ["MERS-CoV", "ORGANISM", 30, 38], ["human", "ORGANISM", 64, 69], ["SARS-CoV", "ORGANISM", 135, 143], ["coronavirus", "SPECIES", 17, 28], ["human", "SPECIES", 64, 69], ["MERS-CoV", "SPECIES", 30, 38], ["human", "SPECIES", 64, 69], ["SARS-CoV", "SPECIES", 135, 143], ["a novel coronavirus", "PROBLEM", 9, 28], ["its human infection", "PROBLEM", 60, 79], ["a higher mortality rate", "TEST", 91, 114], ["SARS", "TEST", 135, 139], ["CoV", "TEST", 140, 143]]], ["Similar to SARS-CoV, MERS-CoV can cause atypical pneumonia, acute respiratory distress syndrome, and, potentially, renal failure in infected individuals [25].", [["respiratory", "ANATOMY", 66, 77], ["renal", "ANATOMY", 115, 120], ["SARS", "DISEASE", 11, 15], ["pneumonia", "DISEASE", 49, 58], ["acute respiratory distress syndrome", "DISEASE", 60, 95], ["renal failure", "DISEASE", 115, 128], ["SARS-CoV", "ORGANISM", 11, 19], ["MERS-CoV", "ORGANISM", 21, 29], ["renal", "ORGAN", 115, 120], ["SARS-CoV", "SPECIES", 11, 19], ["MERS-CoV", "SPECIES", 21, 29], ["SARS", "PROBLEM", 11, 15], ["atypical pneumonia", "PROBLEM", 40, 58], ["acute respiratory distress syndrome", "PROBLEM", 60, 95], ["renal failure", "PROBLEM", 115, 128], ["infected individuals", "PROBLEM", 132, 152], ["atypical", "OBSERVATION_MODIFIER", 40, 48], ["pneumonia", "OBSERVATION", 49, 58], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory distress syndrome", "OBSERVATION", 66, 95], ["renal", "ANATOMY", 115, 120], ["failure", "OBSERVATION", 121, 128], ["infected", "OBSERVATION_MODIFIER", 132, 140]]], ["MERS-CoV cases have been reported in more than twenty countries, including Saudi Arabia, Qatar, Egypt, the United Arab Emirates, France, the United Kingdom, and the United States, and it has been shown to spread between people who are in close contact [2], [3].From SARS to MERS: the threat of novel coronavirusesDespite sharing several clinical and epidemiological features in common with SARS-CoV, the two coronaviruses can still be distinguished.", [["SARS", "DISEASE", 266, 270], ["MERS", "DISEASE", 274, 278], ["SARS-CoV", "DISEASE", 390, 398], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["people", "ORGANISM", 220, 226], ["coronaviruses", "ORGANISM", 300, 313], ["SARS-CoV", "ORGANISM", 390, 398], ["coronaviruses", "ORGANISM", 408, 421], ["people", "SPECIES", 220, 226], ["MERS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 390, 398], ["novel coronaviruses", "PROBLEM", 294, 313], ["SARS-CoV", "PROBLEM", 390, 398], ["the two coronaviruses", "PROBLEM", 400, 421]]], ["MERS-CoV is a lineage C betacoronavirus, while SARS-CoV is a lineage B betacoronavirus [1].", [["SARS-CoV", "DISEASE", 47, 55], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS-CoV", "ORGANISM", 47, 55], ["MERS-CoV", "PROTEIN", 0, 8], ["C betacoronavirus", "SPECIES", 22, 39], ["SARS-CoV", "SPECIES", 47, 55], ["B betacoronavirus", "SPECIES", 69, 86], ["MERS-CoV", "PROBLEM", 0, 8], ["a lineage C betacoronavirus", "PROBLEM", 12, 39], ["SARS", "PROBLEM", 47, 51]]], ["MERS-CoV is phylogenetically distinct from any human coronavirus, including SARS-CoV, but it is more related to the bat coronaviruses HKU4 and HKU5 [26], [27].", [["coronavirus", "DISEASE", 53, 64], ["SARS-CoV", "DISEASE", 76, 84], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 47, 52], ["coronavirus", "ORGANISM", 53, 64], ["SARS-CoV", "ORGANISM", 76, 84], ["bat coronaviruses", "ORGANISM", 116, 133], ["HKU4", "GENE_OR_GENE_PRODUCT", 134, 138], ["MERS-CoV", "DNA", 0, 8], ["human", "SPECIES", 47, 52], ["coronavirus", "SPECIES", 53, 64], ["MERS-CoV", "SPECIES", 0, 8], ["human coronavirus", "SPECIES", 47, 64], ["SARS-CoV", "SPECIES", 76, 84], ["bat coronaviruses", "SPECIES", 116, 133], ["any human coronavirus", "PROBLEM", 43, 64], ["SARS-CoV", "PROBLEM", 76, 84], ["HKU5", "TEST", 143, 147], ["phylogenetically distinct", "OBSERVATION_MODIFIER", 12, 37], ["coronavirus", "OBSERVATION", 53, 64]]], ["Importantly, MERS-CoV uses dipeptidyl peptidase-4 (DPP4, also named CD26) as the receptor on the surface of human cells, while SARS-CoV uses angiotensin-converting enzyme 2 (ACE2) as the cellular receptor [28].", [["surface", "ANATOMY", 97, 104], ["cells", "ANATOMY", 114, 119], ["cellular", "ANATOMY", 187, 195], ["angiotensin", "CHEMICAL", 141, 152], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["dipeptidyl peptidase-4", "GENE_OR_GENE_PRODUCT", 27, 49], ["DPP4", "GENE_OR_GENE_PRODUCT", 51, 55], ["CD26", "GENE_OR_GENE_PRODUCT", 68, 72], ["surface", "CELLULAR_COMPONENT", 97, 104], ["human", "ORGANISM", 108, 113], ["cells", "CELL", 114, 119], ["SARS-CoV", "ORGANISM", 127, 135], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 141, 172], ["ACE2", "GENE_OR_GENE_PRODUCT", 174, 178], ["cellular", "CELL", 187, 195], ["MERS-CoV", "PROTEIN", 13, 21], ["dipeptidyl peptidase-4", "PROTEIN", 27, 49], ["DPP4", "PROTEIN", 51, 55], ["CD26", "PROTEIN", 68, 72], ["human cells", "CELL_TYPE", 108, 119], ["angiotensin-converting enzyme 2", "PROTEIN", 141, 172], ["ACE2", "PROTEIN", 174, 178], ["human", "SPECIES", 108, 113], ["MERS-CoV", "SPECIES", 13, 21], ["human", "SPECIES", 108, 113], ["SARS-CoV", "SPECIES", 127, 135], ["dipeptidyl peptidase", "TREATMENT", 27, 47], ["DPP4", "TREATMENT", 51, 55], ["SARS", "PROBLEM", 127, 131], ["angiotensin", "TREATMENT", 141, 152]]], ["The differences in receptor binding by MERS-CoV and SARS-CoV may be a reflection of their ability and preference to infect cells.", [["cells", "ANATOMY", 123, 128], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 39, 47], ["SARS-CoV", "ORGANISM", 52, 60], ["cells", "CELL", 123, 128], ["MERS", "PROTEIN", 39, 43], ["MERS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 52, 60], ["The differences in receptor binding", "PROBLEM", 0, 35], ["SARS", "PROBLEM", 52, 56], ["CoV", "PROBLEM", 57, 60], ["infect cells", "PROBLEM", 116, 128]]], ["DPP4 is widely expressed on nonciliated bronchial epithelium and the epithelial cells in kidney, small intestine, liver, parotid gland, and even testis and prostate [2].", [["bronchial epithelium", "ANATOMY", 40, 60], ["epithelial cells", "ANATOMY", 69, 85], ["kidney", "ANATOMY", 89, 95], ["small intestine", "ANATOMY", 97, 112], ["liver", "ANATOMY", 114, 119], ["parotid gland", "ANATOMY", 121, 134], ["testis", "ANATOMY", 145, 151], ["prostate", "ANATOMY", 156, 164], ["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["bronchial epithelium", "TISSUE", 40, 60], ["epithelial cells", "CELL", 69, 85], ["kidney", "ORGAN", 89, 95], ["small intestine", "ORGAN", 97, 112], ["liver", "ORGAN", 114, 119], ["parotid gland", "ORGAN", 121, 134], ["testis", "ORGAN", 145, 151], ["prostate", "ORGAN", 156, 164], ["DPP4", "PROTEIN", 0, 4], ["epithelial cells", "CELL_TYPE", 69, 85], ["DPP4", "TREATMENT", 0, 4], ["nonciliated bronchial epithelium", "PROBLEM", 28, 60], ["the epithelial cells in kidney, small intestine, liver, parotid gland", "PROBLEM", 65, 134], ["nonciliated", "ANATOMY_MODIFIER", 28, 39], ["bronchial", "ANATOMY", 40, 49], ["epithelium", "ANATOMY_MODIFIER", 50, 60], ["epithelial cells", "OBSERVATION", 69, 85], ["kidney", "ANATOMY", 89, 95], ["small intestine", "ANATOMY", 97, 112], ["liver", "ANATOMY", 114, 119], ["parotid gland", "ANATOMY", 121, 134], ["prostate", "ANATOMY", 156, 164]]], ["Its wide distribution may explain the diversity of clinical manifestations in MERS-CoV infections.From SARS to MERS: the threat of novel coronavirusesThe emergence of novel coronavirus MERS-CoV, which comes only a decade after the appearance of the first highly pathogenic coronavirus, SARS-CoV, suggests that coronaviruses may represent a continuous and long-term threat to human health.", [["MERS-CoV infections", "DISEASE", 78, 97], ["SARS", "DISEASE", 103, 107], ["MERS", "DISEASE", 111, 115], ["coronaviruses", "DISEASE", 137, 150], ["coronavirus", "DISEASE", 273, 284], ["SARS", "DISEASE", 286, 290], ["MERS-CoV", "ORGANISM", 78, 86], ["coronaviruses", "ORGANISM", 137, 150], ["coronavirus MERS-CoV", "ORGANISM", 173, 193], ["coronavirus", "ORGANISM", 273, 284], ["SARS-CoV", "ORGANISM", 286, 294], ["coronaviruses", "ORGANISM", 310, 323], ["human", "ORGANISM", 375, 380], ["human", "SPECIES", 375, 380], ["MERS-CoV", "SPECIES", 78, 86], ["coronavirus MERS-CoV", "SPECIES", 173, 193], ["SARS-CoV", "SPECIES", 286, 294], ["human", "SPECIES", 375, 380], ["clinical manifestations", "PROBLEM", 51, 74], ["CoV infections", "PROBLEM", 83, 97], ["novel coronaviruses", "PROBLEM", 131, 150], ["novel coronavirus MERS", "PROBLEM", 167, 189], ["pathogenic coronavirus", "PROBLEM", 262, 284], ["SARS-CoV", "PROBLEM", 286, 294], ["coronaviruses", "PROBLEM", 310, 323], ["wide", "OBSERVATION_MODIFIER", 4, 8], ["may explain", "UNCERTAINTY", 22, 33], ["diversity", "OBSERVATION_MODIFIER", 38, 47], ["CoV infections", "OBSERVATION", 83, 97], ["coronaviruses", "OBSERVATION", 137, 150], ["coronavirus", "OBSERVATION", 273, 284], ["coronaviruses", "OBSERVATION", 310, 323]]], ["Both SARS-CoV and MERS-CoV are believed to have originated from bats [29], [30].", [["SARS-CoV", "ORGANISM", 5, 13], ["MERS-CoV", "ORGANISM", 18, 26], ["SARS-CoV and MERS-CoV", "DNA", 5, 26], ["SARS-CoV", "SPECIES", 5, 13], ["MERS-CoV", "SPECIES", 18, 26], ["SARS", "OBSERVATION", 5, 9], ["CoV", "OBSERVATION_MODIFIER", 10, 13]]], ["Since MERS-CoV-specific antibodies and RNA fragments have been detected in camels from Saudi Arabia, Egypt, Tunisia, Nigeria, and Kenya, dromedary camels in the Middle East and Africa are considered to be an intermediate transmitter of MERS-CoV from bats to humans [31], [32], [33], [34].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 6, 14], ["dromedary camels", "ORGANISM", 137, 153], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 236, 244], ["humans", "ORGANISM", 258, 264], ["[32]", "SIMPLE_CHEMICAL", 271, 275], ["MERS-CoV-specific antibodies", "PROTEIN", 6, 34], ["RNA fragments", "DNA", 39, 52], ["humans", "SPECIES", 258, 264], ["MERS-CoV", "SPECIES", 6, 14], ["MERS-CoV", "SPECIES", 236, 244], ["humans", "SPECIES", 258, 264], ["CoV", "TEST", 11, 14], ["specific antibodies", "TEST", 15, 34], ["RNA fragments", "PROBLEM", 39, 52], ["RNA fragments", "OBSERVATION", 39, 52], ["Middle", "ANATOMY_MODIFIER", 161, 167]]], ["Importantly, Yang et al. recently examined the cross-species transmissibility of bat coronavirus HKU4, which is genetically related to MERS-CoV, and found that HKU4 also uses DPP4 as the cellular receptor, but prefers bat DPP4 over human DPP4, while MERS-CoV prefers human DPP4 over bat DPP4 [35].", [["cellular", "ANATOMY", 187, 195], ["bat coronavirus", "ORGANISM", 81, 96], ["HKU4", "GENE_OR_GENE_PRODUCT", 97, 101], ["MERS-CoV", "ORGANISM", 135, 143], ["HKU4", "GENE_OR_GENE_PRODUCT", 160, 164], ["DPP4", "GENE_OR_GENE_PRODUCT", 175, 179], ["cellular", "CELL", 187, 195], ["DPP4", "GENE_OR_GENE_PRODUCT", 222, 226], ["human", "ORGANISM", 232, 237], ["DPP4", "GENE_OR_GENE_PRODUCT", 238, 242], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 250, 258], ["human", "ORGANISM", 267, 272], ["DPP4", "GENE_OR_GENE_PRODUCT", 273, 277], ["DPP4", "GENE_OR_GENE_PRODUCT", 287, 291], ["HKU4", "PROTEIN", 160, 164], ["DPP4", "PROTEIN", 175, 179], ["cellular receptor", "PROTEIN", 187, 204], ["DPP4", "PROTEIN", 222, 226], ["human DPP4", "PROTEIN", 232, 242], ["MERS-CoV", "PROTEIN", 250, 258], ["human DPP4", "PROTEIN", 267, 277], ["DPP4", "PROTEIN", 287, 291], ["bat coronavirus", "SPECIES", 81, 96], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 267, 272], ["bat coronavirus", "SPECIES", 81, 96], ["MERS-CoV", "SPECIES", 135, 143], ["human", "SPECIES", 232, 237], ["MERS-CoV", "SPECIES", 250, 258], ["human", "SPECIES", 267, 272], ["bat coronavirus HKU4", "PROBLEM", 81, 101], ["DPP4", "TREATMENT", 175, 179], ["bat DPP4 over human DPP4", "TREATMENT", 218, 242]]], ["These results suggest that MERS-CoV has adapted to human DPP4 to gain entry into host cells.", [["cells", "ANATOMY", 86, 91], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 27, 35], ["human", "ORGANISM", 51, 56], ["DPP4", "GENE_OR_GENE_PRODUCT", 57, 61], ["cells", "CELL", 86, 91], ["MERS-CoV", "PROTEIN", 27, 35], ["human DPP4", "PROTEIN", 51, 61], ["host cells", "CELL_TYPE", 81, 91], ["human", "SPECIES", 51, 56], ["MERS-CoV", "SPECIES", 27, 35], ["human", "SPECIES", 51, 56], ["CoV", "PROBLEM", 32, 35], ["human DPP4", "TREATMENT", 51, 61]]], ["Since bats are the natural host for a wide range of coronaviruses, the risks posed by the cross-species transmission of these zoonotic coronaviruses for human infections must never be underestimated.MAbs for treatment of viral infectionsAlthough the emergence of highly pathogenic MERS-CoV highlights an urgent need for potent therapeutic and prophylactic agents, no approved antiviral treatments for any human coronavirus infections are currently available.", [["coronaviruses", "DISEASE", 52, 65], ["zoonotic coronaviruses", "DISEASE", 126, 148], ["infections", "DISEASE", 159, 169], ["viral infections", "DISEASE", 221, 237], ["coronavirus infections", "DISEASE", 411, 433], ["coronaviruses", "ORGANISM", 52, 65], ["zoonotic coronaviruses", "ORGANISM", 126, 148], ["human", "ORGANISM", 153, 158], ["MERS-CoV", "ORGANISM", 281, 289], ["human", "ORGANISM", 405, 410], ["coronavirus", "ORGANISM", 411, 422], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 405, 410], ["human", "SPECIES", 153, 158], ["MERS-CoV", "SPECIES", 281, 289], ["human coronavirus", "SPECIES", 405, 422], ["coronaviruses", "PROBLEM", 52, 65], ["these zoonotic coronaviruses", "PROBLEM", 120, 148], ["human infections", "PROBLEM", 153, 169], ["viral infections", "PROBLEM", 221, 237], ["prophylactic agents", "TREATMENT", 343, 362], ["antiviral treatments", "TREATMENT", 376, 396], ["any human coronavirus infections", "PROBLEM", 401, 433], ["zoonotic coronaviruses", "OBSERVATION", 126, 148], ["viral", "OBSERVATION_MODIFIER", 221, 226], ["infections", "OBSERVATION", 227, 237]]], ["Recently, tremendous efforts have been made in the search for an effective anti-MERS-CoV agent, and a number of antiviral agents have been identified.", [["anti-MERS-CoV", "GENE_OR_GENE_PRODUCT", 75, 88], ["anti-MERS-CoV", "SPECIES", 75, 88], ["an effective anti-MERS", "TREATMENT", 62, 84], ["CoV agent", "TREATMENT", 85, 94], ["antiviral agents", "TREATMENT", 112, 128]]], ["For example, some compounds with inhibitory activities in the low micromolar range on MERS-CoV replication in cell cultures have been identified from the libraries of FDA-approved drugs [36], [37].", [["cell cultures", "ANATOMY", 110, 123], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 86, 94], ["cell cultures", "CELL", 110, 123], ["[37]", "SIMPLE_CHEMICAL", 192, 196], ["cell cultures", "CELL_LINE", 110, 123], ["some compounds", "PROBLEM", 13, 27], ["inhibitory activities", "TEST", 33, 54], ["CoV replication", "TREATMENT", 91, 106], ["cell cultures", "TEST", 110, 123], ["some", "OBSERVATION_MODIFIER", 13, 17], ["compounds", "OBSERVATION_MODIFIER", 18, 27], ["low micromolar", "OBSERVATION_MODIFIER", 62, 76]]], ["Falzarano et al. also reported that rhesus macaques treated with a cocktail of IFN-\u03b12b with ribavirin, a nucleoside analog, exhibited reduced MERS-CoV replication and an improved clinical outcome [38].", [["IFN-\u03b12b", "CHEMICAL", 79, 86], ["ribavirin", "CHEMICAL", 92, 101], ["nucleoside", "CHEMICAL", 105, 115], ["ribavirin", "CHEMICAL", 92, 101], ["nucleoside", "CHEMICAL", 105, 115], ["rhesus", "ORGANISM", 36, 42], ["macaques", "ORGANISM", 43, 51], ["IFN-\u03b12b", "GENE_OR_GENE_PRODUCT", 79, 86], ["ribavirin", "SIMPLE_CHEMICAL", 92, 101], ["nucleoside", "SIMPLE_CHEMICAL", 105, 115], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 142, 150], ["IFN", "PROTEIN", 79, 82], ["rhesus macaques", "SPECIES", 36, 51], ["rhesus macaques", "SPECIES", 36, 51], ["MERS-CoV", "SPECIES", 142, 150], ["IFN", "TREATMENT", 79, 82], ["ribavirin", "TREATMENT", 92, 101], ["a nucleoside analog", "TREATMENT", 103, 122], ["reduced MERS", "PROBLEM", 134, 146], ["CoV replication", "TREATMENT", 147, 162]]], ["Interestingly, Lu et al. also found that HR2P, a synthesized peptide derived from the HR2 domain of MERS-CoV spike protein, could specifically bind to the HR1 domain of the viral spike protein and block viral fusion core formation, resulting in the inhibition of MERS-CoV replication and its spike protein-mediated cell\u2013cell fusion [39].", [["cell\u2013cell", "ANATOMY", 315, 324], ["HR2P", "CHEMICAL", 41, 45], ["HR2P", "SIMPLE_CHEMICAL", 41, 45], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 100, 108], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 263, 271], ["cell\u2013cell", "CELL", 315, 324], ["HR2P", "PROTEIN", 41, 45], ["HR2 domain", "PROTEIN", 86, 96], ["MERS-CoV spike protein", "PROTEIN", 100, 122], ["HR1 domain", "PROTEIN", 155, 165], ["viral spike protein", "PROTEIN", 173, 192], ["spike protein", "PROTEIN", 292, 305], ["MERS-CoV", "SPECIES", 263, 271], ["a synthesized peptide", "PROBLEM", 47, 68], ["MERS", "PROBLEM", 100, 104], ["CoV spike protein", "PROBLEM", 105, 122], ["the viral spike protein", "PROBLEM", 169, 192], ["block viral fusion core formation", "PROBLEM", 197, 230], ["MERS", "PROBLEM", 263, 267], ["CoV replication", "TREATMENT", 268, 283], ["its spike protein-mediated cell\u2013cell fusion", "TREATMENT", 288, 331], ["viral spike", "OBSERVATION", 173, 184], ["viral fusion", "OBSERVATION", 203, 215]]], ["HR2P is being optimized to further improve its inhibitory activity, and these HR2P analogs have the potential to be further developed as effective viral fusion inhibitors for treatment of MERS-CoV.MAbs for treatment of viral infectionsMAbs are enjoying significant clinical success, and they have been used for the effective treatment of a number of diseases, in particular, cancer and immune disorders [4], [5], [6].", [["cancer", "ANATOMY", 375, 381], ["HR2P", "CHEMICAL", 0, 4], ["viral infections", "DISEASE", 219, 235], ["cancer", "DISEASE", 375, 381], ["immune disorders", "DISEASE", 386, 402], ["HR2P", "CHEMICAL", 78, 82], ["HR2P", "SIMPLE_CHEMICAL", 0, 4], ["HR2P analogs", "SIMPLE_CHEMICAL", 78, 90], ["MERS-CoV", "ORGANISM", 188, 196], ["cancer", "CANCER", 375, 381], ["[5]", "SIMPLE_CHEMICAL", 408, 411], ["[6]", "SIMPLE_CHEMICAL", 413, 416], ["MERS-CoV", "SPECIES", 188, 196], ["HR2P", "TEST", 0, 4], ["effective viral fusion inhibitors", "TREATMENT", 137, 170], ["MERS", "PROBLEM", 188, 192], ["CoV", "PROBLEM", 193, 196], ["viral infections", "PROBLEM", 219, 235], ["the effective treatment", "TREATMENT", 311, 334], ["diseases", "PROBLEM", 350, 358], ["immune disorders", "PROBLEM", 386, 402], ["viral", "OBSERVATION_MODIFIER", 219, 224], ["infections", "OBSERVATION", 225, 235], ["diseases", "OBSERVATION", 350, 358]]], ["Although Synagis (palivizumab), a humanized mAb against respiratory syncytial virus, is still the only mAb approved by the FDA for clinical use against a viral disease [40], a number of antiviral mAbs have been developed in recent years, and some are now in clinical development [41], [42], [43], [44], [45].", [["Synagis", "CHEMICAL", 9, 16], ["palivizumab", "CHEMICAL", 18, 29], ["respiratory syncytial virus", "DISEASE", 56, 83], ["viral disease", "DISEASE", 154, 167], ["Synagis", "SIMPLE_CHEMICAL", 9, 16], ["palivizumab", "SIMPLE_CHEMICAL", 18, 29], ["respiratory syncytial virus", "ORGANISM", 56, 83], ["[42], [43], [44]", "SIMPLE_CHEMICAL", 285, 301], ["humanized mAb", "PROTEIN", 34, 47], ["mAb", "PROTEIN", 103, 106], ["antiviral mAbs", "PROTEIN", 186, 200], ["respiratory syncytial virus", "SPECIES", 56, 83], ["respiratory syncytial virus", "SPECIES", 56, 83], ["Synagis (palivizumab)", "TREATMENT", 9, 30], ["a humanized mAb", "TREATMENT", 32, 47], ["respiratory syncytial virus", "PROBLEM", 56, 83], ["a viral disease", "PROBLEM", 152, 167], ["antiviral mAbs", "TREATMENT", 186, 200], ["antiviral mAbs", "OBSERVATION", 186, 200]]], ["Recently, for example, a human mAb, m102.4 [41], made history by being the first mAb administered on a compassionate basis to humans exposed to Hendra virus based on its efficacy in vitro and in vivo[42], [43].", [["human", "ORGANISM", 25, 30], ["humans", "ORGANISM", 126, 132], ["Hendra virus", "ORGANISM", 144, 156], ["human mAb", "PROTEIN", 25, 34], ["mAb", "PROTEIN", 81, 84], ["human", "SPECIES", 25, 30], ["humans", "SPECIES", 126, 132], ["human", "SPECIES", 25, 30], ["humans", "SPECIES", 126, 132], ["Hendra virus", "SPECIES", 144, 156], ["a human mAb", "TEST", 23, 34], ["the first mAb", "TREATMENT", 71, 84], ["Hendra virus", "PROBLEM", 144, 156]]], ["More recently, ZMapp, a cocktail of three mAbs, which showed promising results when administered to rhesus monkeys infected with Ebola virus [46], has been administered to several Ebola patients.", [["Ebola virus", "DISEASE", 129, 140], ["Ebola", "DISEASE", 180, 185], ["ZMapp", "SIMPLE_CHEMICAL", 15, 20], ["rhesus", "ORGANISM", 100, 106], ["monkeys", "ORGANISM", 107, 114], ["Ebola virus", "ORGANISM", 129, 140], ["Ebola", "ORGANISM", 180, 185], ["patients", "ORGANISM", 186, 194], ["mAbs", "PROTEIN", 42, 46], ["rhesus monkeys", "SPECIES", 100, 114], ["Ebola virus", "SPECIES", 129, 140], ["patients", "SPECIES", 186, 194], ["rhesus monkeys", "SPECIES", 100, 114], ["Ebola virus", "SPECIES", 129, 140], ["Ebola virus", "PROBLEM", 129, 140]]], ["Broadly protective antibodies against HIV-1, or influenza A viruses, are also being tested in clinical trials [44], [45].MAbs for treatment of viral infectionsDuring the SARS outbreak, neutralizing antibodies were detected in SARS patients, as well as animals infected with the virus [47], [48], [49].", [["influenza A viruses", "DISEASE", 48, 67], ["viral infections", "DISEASE", 143, 159], ["SARS", "DISEASE", 170, 174], ["SARS", "DISEASE", 226, 230], ["HIV-1", "ORGANISM", 38, 43], ["influenza A viruses", "ORGANISM", 48, 67], ["patients", "ORGANISM", 231, 239], ["neutralizing antibodies", "PROTEIN", 185, 208], ["HIV-1", "SPECIES", 38, 43], ["influenza A viruses", "SPECIES", 48, 67], ["patients", "SPECIES", 231, 239], ["HIV-1", "SPECIES", 38, 43], ["influenza A viruses", "SPECIES", 48, 67], ["Broadly protective antibodies", "TEST", 0, 29], ["HIV", "PROBLEM", 38, 41], ["influenza A viruses", "PROBLEM", 48, 67], ["viral infections", "PROBLEM", 143, 159], ["the SARS outbreak", "PROBLEM", 166, 183], ["neutralizing antibodies", "TEST", 185, 208], ["the virus", "PROBLEM", 274, 283], ["viral", "OBSERVATION_MODIFIER", 143, 148], ["infections", "OBSERVATION", 149, 159]]], ["The antibodies also protected uninfected animals from SARS-CoV infection.", [["SARS-CoV infection", "DISEASE", 54, 72], ["SARS-CoV", "ORGANISM", 54, 62], ["antibodies", "PROTEIN", 4, 14], ["SARS-CoV", "SPECIES", 54, 62], ["The antibodies", "TEST", 0, 14], ["SARS", "PROBLEM", 54, 58], ["CoV infection", "PROBLEM", 59, 72], ["CoV", "OBSERVATION_MODIFIER", 59, 62], ["infection", "OBSERVATION", 63, 72]]], ["Specifically, passive transfer of immune serum to na\u00efve mice prevented virus replication in the lower respiratory tract following intranasal virus challenge [50].", [["immune serum", "ANATOMY", 34, 46], ["lower respiratory tract", "ANATOMY", 96, 119], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["mice", "ORGANISM", 56, 60], ["lower", "ORGANISM_SUBDIVISION", 96, 101], ["respiratory tract", "ORGANISM_SUBDIVISION", 102, 119], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 56, 60], ["immune serum to na\u00efve mice", "TREATMENT", 34, 60], ["virus replication", "TREATMENT", 71, 88], ["intranasal virus challenge", "TREATMENT", 130, 156], ["lower", "ANATOMY_MODIFIER", 96, 101], ["respiratory tract", "ANATOMY", 102, 119]]], ["Thus, a vast effort has been devoted to developing mAbs that can neutralize the virus and have the potential for treatment and prevention of SARS-CoV infection [9], [10], [11], [13], [14].", [["SARS-CoV infection", "DISEASE", 141, 159], ["SARS-CoV", "ORGANISM", 141, 149], ["[10], [11], [13]", "SIMPLE_CHEMICAL", 165, 181], ["[14]", "SIMPLE_CHEMICAL", 183, 187], ["mAbs", "PROTEIN", 51, 55], ["SARS-CoV", "SPECIES", 141, 149], ["mAbs", "TREATMENT", 51, 55], ["the virus", "PROBLEM", 76, 85], ["treatment", "TREATMENT", 113, 122], ["SARS", "PROBLEM", 141, 145], ["CoV infection", "PROBLEM", 146, 159]]], ["The generation and mechanism of neutralization of these mAbs have been thoroughly reviewed elsewhere [8].", [["mAbs", "GENE_OR_GENE_PRODUCT", 56, 60], ["mAbs", "PROTEIN", 56, 60], ["these mAbs", "TREATMENT", 50, 60]]], ["In general, neutralizing antibodies against SARS-CoV can be isolated from the memory B-cell repertoire of patients who have recovered from SARS-CoV infection, generated from transgenic mice with human immunoglobulin genes immunized with recombinant SARS-CoV S glycoprotein, or identified from non-immune human antibody libraries constructed from the B lymphocytes of healthy donors.", [["B-cell", "ANATOMY", 85, 91], ["B lymphocytes", "ANATOMY", 350, 363], ["SARS-CoV infection", "DISEASE", 139, 157], ["SARS-CoV", "ORGANISM", 44, 52], ["B-cell", "CELL", 85, 91], ["patients", "ORGANISM", 106, 114], ["SARS-CoV", "ORGANISM", 139, 147], ["mice", "ORGANISM", 185, 189], ["human", "ORGANISM", 195, 200], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 201, 215], ["SARS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 249, 272], ["human", "ORGANISM", 304, 309], ["B lymphocytes", "CELL", 350, 363], ["donors", "ORGANISM", 375, 381], ["neutralizing antibodies", "PROTEIN", 12, 35], ["human immunoglobulin genes", "DNA", 195, 221], ["recombinant SARS-CoV S glycoprotein", "PROTEIN", 237, 272], ["non-immune human antibody libraries", "DNA", 293, 328], ["B lymphocytes", "CELL_TYPE", 350, 363], ["patients", "SPECIES", 106, 114], ["mice", "SPECIES", 185, 189], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 304, 309], ["SARS-CoV", "SPECIES", 44, 52], ["SARS-CoV", "SPECIES", 139, 147], ["mice", "SPECIES", 185, 189], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 304, 309], ["neutralizing antibodies", "TEST", 12, 35], ["SARS", "PROBLEM", 44, 48], ["CoV", "PROBLEM", 49, 52], ["SARS", "PROBLEM", 139, 143], ["CoV infection", "PROBLEM", 144, 157], ["human immunoglobulin genes", "TREATMENT", 195, 221], ["recombinant SARS-CoV S glycoprotein", "PROBLEM", 237, 272], ["non-immune human antibody libraries", "TREATMENT", 293, 328], ["CoV infection", "OBSERVATION", 144, 157]]], ["The prophylactic and therapeutic efficacies of these human mAbs have been demonstrated in mice or ferret models of SARS-CoV infection [10], [13], [14].", [["SARS-CoV infection", "DISEASE", 115, 133], ["human", "ORGANISM", 53, 58], ["mAbs", "GENE_OR_GENE_PRODUCT", 59, 63], ["mice", "ORGANISM", 90, 94], ["ferret", "ORGANISM", 98, 104], ["SARS-CoV", "ORGANISM", 115, 123], ["[13]", "SIMPLE_CHEMICAL", 140, 144], ["[14]", "SIMPLE_CHEMICAL", 146, 150], ["human mAbs", "PROTEIN", 53, 63], ["human", "SPECIES", 53, 58], ["mice", "SPECIES", 90, 94], ["ferret", "SPECIES", 98, 104], ["human", "SPECIES", 53, 58], ["mice", "SPECIES", 90, 94], ["ferret", "SPECIES", 98, 104], ["SARS-CoV", "SPECIES", 115, 123], ["The prophylactic", "TREATMENT", 0, 16], ["these human mAbs", "TREATMENT", 47, 63], ["SARS", "PROBLEM", 115, 119], ["CoV infection", "PROBLEM", 120, 133]]], ["Most of the neutralizing antibodies target the receptor binding domain (RBD) of the SARS-CoV S glycoprotein, suggesting a possible mechanism of neutralization by preventing virus attachment to its receptor.", [["SARS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 84, 107], ["neutralizing antibodies", "PROTEIN", 12, 35], ["receptor binding domain", "PROTEIN", 47, 70], ["RBD", "PROTEIN", 72, 75], ["SARS-CoV S glycoprotein", "PROTEIN", 84, 107], ["SARS-CoV", "SPECIES", 84, 92], ["the neutralizing antibodies", "TEST", 8, 35], ["the SARS-CoV S glycoprotein", "PROBLEM", 80, 107], ["neutralization", "PROBLEM", 144, 158], ["virus attachment", "PROBLEM", 173, 189], ["neutralization", "OBSERVATION", 144, 158], ["virus", "OBSERVATION", 173, 178]]], ["Some antibodies recognize epitopes on the S2 domain of S glycoprotein, suggesting that other mechanisms could also be involved in the inhibition of SARS-CoV infection, including steric hindrance that indirectly prevents virus attachment, or antibody Fc-mediated effector functions, for example, antibody-dependent cellular cytotoxicity (ADCC).Human mAbs against MERS-CoV: development and efficacy evaluationSince the SARS epidemic was contained in July 2003, the clinical development of the above-mentioned antibodies targeting SARS-CoV has not been pursued.", [["cellular", "ANATOMY", 314, 322], ["SARS-CoV infection", "DISEASE", 148, 166], ["SARS", "DISEASE", 417, 421], ["SARS", "DISEASE", 528, 532], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 55, 69], ["SARS-CoV", "ORGANISM", 148, 156], ["antibody Fc", "GENE_OR_GENE_PRODUCT", 241, 252], ["cellular", "CELL", 314, 322], ["Human", "ORGANISM", 343, 348], ["MERS-CoV", "ORGANISM", 362, 370], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 528, 536], ["antibodies", "PROTEIN", 5, 15], ["epitopes", "PROTEIN", 26, 34], ["S2 domain", "PROTEIN", 42, 51], ["S glycoprotein", "PROTEIN", 55, 69], ["antibody Fc", "PROTEIN", 241, 252], ["Human mAbs", "PROTEIN", 343, 353], ["antibodies", "PROTEIN", 507, 517], ["Human", "SPECIES", 343, 348], ["SARS-CoV", "SPECIES", 148, 156], ["Human", "SPECIES", 343, 348], ["MERS-CoV", "SPECIES", 362, 370], ["SARS-CoV", "SPECIES", 528, 536], ["Some antibodies", "PROBLEM", 0, 15], ["SARS", "PROBLEM", 148, 152], ["CoV infection", "PROBLEM", 153, 166], ["steric hindrance", "PROBLEM", 178, 194], ["virus attachment", "PROBLEM", 220, 236], ["antibody Fc", "TEST", 241, 252], ["antibody", "TEST", 295, 303], ["dependent cellular cytotoxicity", "PROBLEM", 304, 335], ["efficacy evaluation", "TEST", 388, 407], ["the SARS epidemic", "PROBLEM", 413, 430], ["infection", "OBSERVATION", 157, 166], ["cellular cytotoxicity", "OBSERVATION", 314, 335]]], ["Fortunately, a wealth of knowledge has been accumulated through the experience of managing the SARS outbreak, and the therapeutic potential of coronavirus-targeting antibodies has been well recognized.", [["SARS", "DISEASE", 95, 99], ["coronavirus", "ORGANISM", 143, 154], ["coronavirus-targeting antibodies", "PROTEIN", 143, 175], ["the SARS outbreak", "PROBLEM", 91, 108], ["coronavirus", "PROBLEM", 143, 154], ["targeting antibodies", "PROBLEM", 155, 175], ["coronavirus", "OBSERVATION", 143, 154]]], ["When the novel coronavirus MERS-CoV emerged in Saudi Arabia in 2012, this body of knowledge allowed the development of an effective response to the threat of MERS at an unprecedented pace.Human mAbs against MERS-CoV: development and efficacy evaluationFirst, it has been found that the RBD of MERS-CoV S1 glycoprotein is capable of inducing significant neutralizing antibody responses in mice [51], [52], [53].", [["MERS", "DISEASE", 158, 162], ["coronavirus MERS-CoV", "ORGANISM", 15, 35], ["Human", "ORGANISM", 188, 193], ["MERS-CoV", "ORGANISM", 207, 215], ["MERS-CoV S1 glycoprotein", "GENE_OR_GENE_PRODUCT", 293, 317], ["mice", "ORGANISM", 388, 392], ["Human mAbs", "PROTEIN", 188, 198], ["RBD", "PROTEIN", 286, 289], ["MERS-CoV S1 glycoprotein", "PROTEIN", 293, 317], ["coronavirus", "SPECIES", 15, 26], ["Human", "SPECIES", 188, 193], ["mice", "SPECIES", 388, 392], ["coronavirus MERS-CoV", "SPECIES", 15, 35], ["Human", "SPECIES", 188, 193], ["MERS-CoV", "SPECIES", 207, 215], ["MERS-CoV", "SPECIES", 293, 301], ["mice", "SPECIES", 388, 392], ["the RBD of MERS", "PROBLEM", 282, 297], ["CoV S1 glycoprotein", "TREATMENT", 298, 317], ["significant neutralizing antibody responses", "PROBLEM", 341, 384]]], ["Thus, neutralizing mouse mAbs could be developed to block MERS-CoV entry into human cells.", [["cells", "ANATOMY", 84, 89], ["mouse", "ORGANISM", 19, 24], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["human", "ORGANISM", 78, 83], ["cells", "CELL", 84, 89], ["neutralizing mouse mAbs", "PROTEIN", 6, 29], ["human cells", "CELL_TYPE", 78, 89], ["mouse", "SPECIES", 19, 24], ["human", "SPECIES", 78, 83], ["mouse", "SPECIES", 19, 24], ["human", "SPECIES", 78, 83], ["neutralizing mouse mAbs", "TREATMENT", 6, 29]]], ["For example, Du et al. generated some neutralizing mAbs by immunizing mice with recombinant MERS-CoV S1 fused to IgG1 Fc [53].", [["mAbs", "GENE_OR_GENE_PRODUCT", 51, 55], ["mice", "ORGANISM", 70, 74], ["MERS-CoV S1", "GENE_OR_GENE_PRODUCT", 92, 103], ["IgG1", "GENE_OR_GENE_PRODUCT", 113, 117], ["neutralizing mAbs", "PROTEIN", 38, 55], ["recombinant MERS-CoV S1", "PROTEIN", 80, 103], ["IgG1 Fc", "PROTEIN", 113, 120], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 70, 74], ["MERS-CoV", "SPECIES", 92, 100], ["some neutralizing mAbs", "TREATMENT", 33, 55], ["neutralizing mAbs", "OBSERVATION", 38, 55]]], ["Anti-MERS-CoV mAbs were identified by screening positive clones from hybridoma cell lines and testing their inhibition of MERS-CoV pseudovirus entry mediated by S protein, as well as neutralization against live MERS-CoV infection, in DPP4-expressing Vero E6 cells.", [["clones", "ANATOMY", 57, 63], ["hybridoma cell lines", "ANATOMY", 69, 89], ["cells", "ANATOMY", 258, 263], ["infection", "DISEASE", 220, 229], ["Anti-MERS-CoV mAbs", "GENE_OR_GENE_PRODUCT", 0, 18], ["hybridoma cell lines", "CELL", 69, 89], ["MERS-CoV pseudovirus", "ORGANISM", 122, 142], ["S protein", "GENE_OR_GENE_PRODUCT", 161, 170], ["MERS-CoV", "ORGANISM", 211, 219], ["DPP4", "GENE_OR_GENE_PRODUCT", 234, 238], ["Vero E6 cells", "CELL", 250, 263], ["Anti-MERS-CoV mAbs", "PROTEIN", 0, 18], ["positive clones", "CELL_LINE", 48, 63], ["hybridoma cell lines", "CELL_LINE", 69, 89], ["S protein", "PROTEIN", 161, 170], ["DPP4-expressing Vero E6 cells", "CELL_LINE", 234, 263], ["MERS-CoV pseudovirus", "SPECIES", 122, 142], ["MERS-CoV", "SPECIES", 211, 219], ["Vero E6", "SPECIES", 250, 257], ["Anti-MERS-CoV mAbs", "TREATMENT", 0, 18], ["screening positive clones", "PROBLEM", 38, 63], ["hybridoma cell lines", "TREATMENT", 69, 89], ["testing", "TEST", 94, 101], ["MERS", "PROBLEM", 122, 126], ["neutralization", "TREATMENT", 183, 197], ["live MERS", "PROBLEM", 206, 215], ["CoV infection", "PROBLEM", 216, 229], ["DPP4", "TEST", 234, 238], ["hybridoma cell lines", "OBSERVATION", 69, 89], ["infection", "OBSERVATION", 220, 229], ["E6 cells", "OBSERVATION", 255, 263]]], ["Mersmab1, the most potent anti-MERS-CoV mAb, was selected on the basis of its efficacy in blocking the entry of MERS-CoV pseudoviruses into DPP4-expressing Huh-7 cells and inhibiting the formation of MERS-CoV-induced CPE during MERS-CoV infection of permissive Vero E6 cells and Calu-3 cells.", [["Huh-7 cells", "ANATOMY", 156, 167], ["Vero E6 cells", "ANATOMY", 261, 274], ["Calu-3 cells", "ANATOMY", 279, 291], ["Mersmab1", "CHEMICAL", 0, 8], ["infection", "DISEASE", 237, 246], ["Mersmab1", "GENE_OR_GENE_PRODUCT", 0, 8], ["anti-MERS-CoV mAb", "GENE_OR_GENE_PRODUCT", 26, 43], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 112, 120], ["DPP4", "GENE_OR_GENE_PRODUCT", 140, 144], ["Huh-7 cells", "CELL", 156, 167], ["MERS-CoV", "ORGANISM", 200, 208], ["MERS-CoV", "ORGANISM", 228, 236], ["Vero E6 cells", "CELL", 261, 274], ["Calu-3 cells", "CELL", 279, 291], ["Mersmab1", "PROTEIN", 0, 8], ["anti-MERS-CoV mAb", "PROTEIN", 26, 43], ["MERS", "PROTEIN", 112, 116], ["DPP4-expressing Huh-7 cells", "CELL_LINE", 140, 167], ["permissive Vero E6 cells", "CELL_LINE", 250, 274], ["Calu-3 cells", "CELL_LINE", 279, 291], ["MERS-CoV", "SPECIES", 112, 120], ["MERS-CoV", "SPECIES", 200, 208], ["MERS-CoV", "SPECIES", 228, 236], ["Vero E6", "SPECIES", 261, 268], ["CoV pseudoviruses", "TEST", 117, 134], ["DPP4", "TEST", 140, 144], ["Huh", "TEST", 156, 159], ["MERS", "PROBLEM", 200, 204], ["CoV", "TEST", 205, 208], ["CPE", "PROBLEM", 217, 220], ["CoV infection", "PROBLEM", 233, 246], ["permissive Vero E6 cells", "PROBLEM", 250, 274], ["Calu", "TEST", 279, 283], ["Vero E6 cells", "OBSERVATION", 261, 274]]], ["Thus, mouse mAbs, such as Mersmab1, can be humanized for development as potent therapeutic and prophylactic agents against MERS-CoV infections.Human mAbs against MERS-CoV: development and efficacy evaluationIn April 2014, three studies conducted by separate laboratories around the world reported the development of fully human neutralizing mAbs against MERS-CoV [54], [55], [56].", [["Mersmab1", "CHEMICAL", 26, 34], ["MERS-CoV infections", "DISEASE", 123, 142], ["mouse", "ORGANISM", 6, 11], ["mAbs", "GENE_OR_GENE_PRODUCT", 12, 16], ["Mersmab1", "GENE_OR_GENE_PRODUCT", 26, 34], ["MERS-CoV", "ORGANISM", 123, 131], ["Human", "ORGANISM", 143, 148], ["MERS-CoV", "ORGANISM", 162, 170], ["human", "ORGANISM", 322, 327], ["MERS-CoV", "ORGANISM", 354, 362], ["mouse mAbs", "PROTEIN", 6, 16], ["Mersmab1", "PROTEIN", 26, 34], ["Human mAbs", "PROTEIN", 143, 153], ["human neutralizing mAbs", "PROTEIN", 322, 345], ["mouse", "SPECIES", 6, 11], ["Human", "SPECIES", 143, 148], ["human", "SPECIES", 322, 327], ["mouse", "SPECIES", 6, 11], ["MERS-CoV", "SPECIES", 123, 131], ["Human", "SPECIES", 143, 148], ["MERS-CoV", "SPECIES", 162, 170], ["human", "SPECIES", 322, 327], ["MERS-CoV", "SPECIES", 354, 362], ["mouse mAbs", "TREATMENT", 6, 16], ["prophylactic agents", "TREATMENT", 95, 114], ["MERS", "PROBLEM", 123, 127], ["CoV infections", "PROBLEM", 128, 142], ["fully human neutralizing mAbs", "TREATMENT", 316, 345], ["infections", "OBSERVATION", 132, 142]]], ["It is noteworthy that all these mAbs target the RBD of the MERS-CoV S1 glycoprotein and that they were all identified from non-immune human antibody libraries.", [["mAbs", "GENE_OR_GENE_PRODUCT", 32, 36], ["MERS-CoV S1", "GENE_OR_GENE_PRODUCT", 59, 70], ["human", "ORGANISM", 134, 139], ["mAbs", "PROTEIN", 32, 36], ["RBD", "PROTEIN", 48, 51], ["MERS-CoV S1 glycoprotein", "PROTEIN", 59, 83], ["non-immune human antibody libraries", "DNA", 123, 158], ["human", "SPECIES", 134, 139], ["MERS-CoV", "SPECIES", 59, 67], ["human", "SPECIES", 134, 139], ["non-immune human antibody libraries", "PROBLEM", 123, 158]]], ["Specifically, among these antibodies, three highly potent mAbs (m336, m337, m338) were identified from a very large phage-displayed antibody Fab library that we recently generated by using B cells from the blood of 40 healthy donors [54].", [["B cells", "ANATOMY", 189, 196], ["blood", "ANATOMY", 206, 211], ["B cells", "CELL", 189, 196], ["blood", "ORGANISM_SUBSTANCE", 206, 211], ["donors", "ORGANISM", 226, 232], ["antibodies", "PROTEIN", 26, 36], ["mAbs", "PROTEIN", 58, 62], ["m336", "PROTEIN", 64, 68], ["m337", "PROTEIN", 70, 74], ["B cells", "CELL_TYPE", 189, 196], ["these antibodies", "TEST", 20, 36], ["a very large phage", "PROBLEM", 103, 121]]], ["This library was panned against recombinant MERS-CoV RBD to enrich for high affinity binders.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 44, 52], ["recombinant MERS-CoV RBD", "PROTEIN", 32, 56], ["MERS-CoV", "SPECIES", 44, 52], ["recombinant MERS", "PROBLEM", 32, 48], ["CoV RBD", "PROBLEM", 49, 56], ["high affinity binders", "TREATMENT", 71, 92]]], ["The three identified mAbs, all derived from the VH gene 1\u201369, which has been the source of many other antiviral antibodies, exhibited exceptionally potent activity and neutralized pseudotyped MERS-CoV with 50% inhibitory concentration (IC50), ranging from 0.005 to 0.017 \u03bcg/ml.", [["mAbs", "GENE_OR_GENE_PRODUCT", 21, 25], ["VH", "GENE_OR_GENE_PRODUCT", 48, 50], ["1\u201369", "GENE_OR_GENE_PRODUCT", 56, 60], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 192, 200], ["mAbs", "PROTEIN", 21, 25], ["VH gene 1\u201369", "DNA", 48, 60], ["antiviral antibodies", "PROTEIN", 102, 122], ["MERS-CoV", "SPECIES", 192, 200], ["many other antiviral antibodies", "PROBLEM", 91, 122], ["neutralized pseudotyped MERS", "TREATMENT", 168, 196], ["IC50", "TEST", 236, 240], ["mAbs", "OBSERVATION", 21, 25], ["antiviral antibodies", "OBSERVATION", 102, 122]]], ["Notably, the most potent mAb, m336, inhibited >90% MERS-CoV pseudovirus infection (IC90) in DPP4-expressing Huh-7 cells at a concentration of 0.039 \u03bcg/ml.", [["Huh-7 cells", "ANATOMY", 108, 119], ["infection", "DISEASE", 72, 81], ["MERS-CoV pseudovirus", "ORGANISM", 51, 71], ["DPP4", "GENE_OR_GENE_PRODUCT", 92, 96], ["Huh-7 cells", "CELL", 108, 119], ["mAb", "PROTEIN", 25, 28], ["DPP4", "PROTEIN", 92, 96], ["Huh-7 cells", "CELL_LINE", 108, 119], ["MERS-CoV pseudovirus", "SPECIES", 51, 71], ["CoV pseudovirus infection", "PROBLEM", 56, 81], ["DPP4", "TEST", 92, 96], ["Huh", "TEST", 108, 111], ["most potent", "OBSERVATION_MODIFIER", 13, 24]]], ["Similarly, m336 showed the most potent live MERS-CoV neutralizing activity in inhibiting the formation of MERS-CoV-induced CPE during live MERS-CoV infection of permissive Vero E6 cells, with an IC50 of 0.07 \u03bcg/ml.", [["Vero E6 cells", "ANATOMY", 172, 185], ["m336", "CHEMICAL", 11, 15], ["CPE", "CHEMICAL", 123, 126], ["infection", "DISEASE", 148, 157], ["m336", "SIMPLE_CHEMICAL", 11, 15], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 44, 52], ["MERS-CoV", "ORGANISM", 106, 114], ["MERS-CoV", "ORGANISM", 139, 147], ["Vero E6 cells", "CELL", 172, 185], ["permissive Vero E6 cells", "CELL_LINE", 161, 185], ["MERS-CoV", "SPECIES", 106, 114], ["MERS-CoV", "SPECIES", 139, 147], ["Vero E6", "SPECIES", 172, 179], ["CoV neutralizing activity", "PROBLEM", 49, 74], ["MERS", "PROBLEM", 106, 110], ["CoV", "PROBLEM", 111, 114], ["CPE", "PROBLEM", 123, 126], ["live MERS", "PROBLEM", 134, 143], ["CoV infection", "PROBLEM", 144, 157], ["permissive Vero E6 cells", "PROBLEM", 161, 185], ["an IC50", "TEST", 192, 199], ["most potent", "OBSERVATION_MODIFIER", 27, 38], ["CoV", "OBSERVATION_MODIFIER", 49, 52], ["neutralizing activity", "OBSERVATION", 53, 74], ["Vero E6 cells", "OBSERVATION", 172, 185]]], ["Jiang et al. also identified two potent RBD-specific neutralizing mAbs, MERS-4 and MERS-27, by using a non-immune yeast-displayed scFv library to screen against the recombinant MERS-CoV RBD [55].", [["MERS-4", "GENE_OR_GENE_PRODUCT", 72, 78], ["MERS-27", "CELL", 83, 90], ["MERS-CoV", "ORGANISM", 177, 185], ["RBD", "PROTEIN", 40, 43], ["neutralizing mAbs", "PROTEIN", 53, 70], ["MERS-4", "PROTEIN", 72, 78], ["MERS-27", "PROTEIN", 83, 90], ["recombinant MERS-CoV RBD", "PROTEIN", 165, 189], ["yeast", "SPECIES", 114, 119], ["yeast", "SPECIES", 114, 119], ["MERS-CoV", "SPECIES", 177, 185], ["two potent RBD", "PROBLEM", 29, 43], ["specific neutralizing mAbs", "TEST", 44, 70], ["MERS", "TEST", 72, 76], ["MERS", "TEST", 83, 87], ["a non-immune yeast", "PROBLEM", 101, 119], ["potent", "OBSERVATION_MODIFIER", 33, 39], ["RBD", "OBSERVATION", 40, 43]]], ["The most potent mAb, MERS-4, neutralized the pseudotyped MERS-CoV infection in DPP4-expressing Huh-7 cells with an IC50 of 0.056 \u03bcg/ml and inhibited the formation of MERS-CoV-induced CPE during live MERS-CoV infection of permissive Vero E6 cells with an IC50 of 0.5 \u03bcg/ml.", [["Huh-7 cells", "ANATOMY", 95, 106], ["Vero E6 cells", "ANATOMY", 232, 245], ["infection", "DISEASE", 66, 75], ["CPE", "CHEMICAL", 183, 186], ["MERS-4", "GENE_OR_GENE_PRODUCT", 21, 27], ["pseudotyped", "ORGANISM", 45, 56], ["MERS-CoV", "ORGANISM", 57, 65], ["DPP4", "GENE_OR_GENE_PRODUCT", 79, 83], ["Huh-7 cells", "CELL", 95, 106], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 166, 174], ["MERS-CoV", "ORGANISM", 199, 207], ["Vero E6 cells", "CELL", 232, 245], ["MERS-4", "PROTEIN", 21, 27], ["DPP4-expressing Huh-7 cells", "CELL_LINE", 79, 106], ["permissive Vero E6 cells", "CELL_LINE", 221, 245], ["MERS-CoV", "SPECIES", 57, 65], ["Huh-7", "SPECIES", 95, 100], ["MERS-CoV", "SPECIES", 166, 174], ["MERS-CoV", "SPECIES", 199, 207], ["Vero E6", "SPECIES", 232, 239], ["MERS", "TEST", 21, 25], ["the pseudotyped MERS", "PROBLEM", 41, 61], ["CoV infection", "PROBLEM", 62, 75], ["DPP4", "TEST", 79, 83], ["Huh", "TEST", 95, 98], ["an IC50", "TEST", 112, 119], ["MERS", "PROBLEM", 166, 170], ["CoV", "PROBLEM", 171, 174], ["induced CPE", "PROBLEM", 175, 186], ["live MERS", "PROBLEM", 194, 203], ["CoV infection", "PROBLEM", 204, 217], ["permissive Vero E6 cells", "TREATMENT", 221, 245], ["an IC50", "TEST", 251, 258], ["most potent", "OBSERVATION_MODIFIER", 4, 15], ["pseudotyped", "OBSERVATION", 45, 56], ["CoV infection", "OBSERVATION", 62, 75]]], ["Tang et al. also identified neutralizing mAbs by using a non-immune phage-displayed scFv library [56].", [["neutralizing mAbs", "PROTEIN", 28, 45], ["neutralizing mAbs", "TREATMENT", 28, 45], ["a non-immune phage", "TREATMENT", 55, 73], ["neutralizing mAbs", "OBSERVATION", 28, 45]]], ["The panning was performed by sequentially using MERS-CoV spike-containing paramagnetic proteoliposomes and MERS-CoV S glycoprotein-expressing 293T cells as antigens.", [["293T cells", "ANATOMY", 142, 152], ["MERS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 107, 130], ["293T cells", "CELL", 142, 152], ["MERS-CoV spike-containing paramagnetic proteoliposomes", "PROTEIN", 48, 102], ["MERS-CoV S glycoprotein", "PROTEIN", 107, 130], ["expressing 293T cells", "CELL_LINE", 131, 152], ["The panning", "TEST", 0, 11], ["MERS", "TEST", 48, 52], ["CoV spike", "TEST", 53, 62], ["paramagnetic proteoliposomes", "TREATMENT", 74, 102], ["MERS", "TEST", 107, 111], ["CoV S glycoprotein", "TREATMENT", 112, 130]]], ["A panel of 7 anti-S1 scFvs was identified and expressed in both scFv-Fc and IgG1 formats, and their neutralizing activity against pseudotyped MERS-CoV in DPP4-expressing 293T cells, as well as live MERS-CoV infection in Vero cells, was measured.", [["293T cells", "ANATOMY", 170, 180], ["Vero cells", "ANATOMY", 220, 230], ["infection", "DISEASE", 207, 216], ["anti-S1 scFvs", "GENE_OR_GENE_PRODUCT", 13, 26], ["scFv-Fc", "GENE_OR_GENE_PRODUCT", 64, 71], ["IgG1", "GENE_OR_GENE_PRODUCT", 76, 80], ["pseudotyped", "ORGANISM", 130, 141], ["MERS-CoV", "ORGANISM", 142, 150], ["DPP4", "GENE_OR_GENE_PRODUCT", 154, 158], ["293T cells", "CELL", 170, 180], ["MERS-CoV", "ORGANISM", 198, 206], ["Vero cells", "CELL", 220, 230], ["7 anti-S1 scFvs", "PROTEIN", 11, 26], ["scFv-Fc", "PROTEIN", 64, 71], ["IgG1", "PROTEIN", 76, 80], ["DPP4-expressing 293T cells", "CELL_LINE", 154, 180], ["Vero cells", "CELL_LINE", 220, 230], ["MERS-CoV", "SPECIES", 142, 150], ["MERS-CoV", "SPECIES", 198, 206], ["A panel", "TEST", 0, 7], ["IgG1 formats", "TEST", 76, 88], ["pseudotyped MERS", "PROBLEM", 130, 146], ["DPP4", "TEST", 154, 158], ["CoV infection in Vero cells", "PROBLEM", 203, 230], ["293T cells", "OBSERVATION", 170, 180], ["CoV", "OBSERVATION_MODIFIER", 203, 206], ["infection", "OBSERVATION", 207, 216], ["Vero cells", "OBSERVATION", 220, 230]]], ["The most potent antibody, 3B11, neutralized live MERS-CoV in the plaque reduction neutralization tests with an IC50 of 1.83 \u03bcg/ml and 3.50 \u03bcg/ml in the scFv-Fc and IgG format, respectively.Human mAbs against MERS-CoV: development and efficacy evaluationAlthough all the above-mentioned human mAbs exhibited potent neutralizing activity against MERS-CoV infection in vitro, the evaluation of their efficacy in animal models of infection is still necessary before any of them can be further developed as therapeutic or prophylactic agents.", [["plaque", "ANATOMY", 65, 71], ["MERS-CoV infection", "DISEASE", 344, 362], ["infection", "DISEASE", 426, 435], ["3B11", "SIMPLE_CHEMICAL", 26, 30], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 49, 57], ["plaque", "PATHOLOGICAL_FORMATION", 65, 71], ["scFv-Fc", "GENE_OR_GENE_PRODUCT", 152, 159], ["IgG", "GENE_OR_GENE_PRODUCT", 164, 167], ["Human", "ORGANISM", 189, 194], ["MERS-CoV", "ORGANISM", 208, 216], ["human", "ORGANISM", 286, 291], ["mAbs", "GENE_OR_GENE_PRODUCT", 292, 296], ["MERS-CoV", "ORGANISM", 344, 352], ["3B11", "PROTEIN", 26, 30], ["scFv-Fc", "PROTEIN", 152, 159], ["IgG", "PROTEIN", 164, 167], ["Human mAbs", "PROTEIN", 189, 199], ["human mAbs", "PROTEIN", 286, 296], ["Human", "SPECIES", 189, 194], ["human", "SPECIES", 286, 291], ["MERS-CoV", "SPECIES", 49, 57], ["Human", "SPECIES", 189, 194], ["MERS-CoV", "SPECIES", 208, 216], ["human", "SPECIES", 286, 291], ["MERS-CoV", "SPECIES", 344, 352], ["The most potent antibody", "TEST", 0, 24], ["neutralization tests", "TEST", 82, 102], ["an IC50", "TEST", 108, 115], ["the scFv-Fc", "TEST", 148, 159], ["IgG format", "TEST", 164, 174], ["efficacy evaluation", "TEST", 234, 253], ["human mAbs", "TREATMENT", 286, 296], ["MERS", "PROBLEM", 344, 348], ["CoV infection", "PROBLEM", 349, 362], ["the evaluation", "TEST", 373, 387], ["infection", "PROBLEM", 426, 435], ["prophylactic agents", "TREATMENT", 517, 536], ["most potent", "OBSERVATION_MODIFIER", 4, 15], ["plaque", "OBSERVATION", 65, 71], ["infection", "OBSERVATION", 353, 362], ["infection", "OBSERVATION", 426, 435]]], ["However, unlike SARS-CoV, which can effectively infect and replicate in several cell types in human and animals, including mice and rhesus macaques, MERS-CoV cannot infect small laboratory animals, e.g., mice, hamsters or ferrets, while only causing mild to moderate symptoms in rhesus macaques, thus effectively stalling further research efforts [57], [58], [59].", [["cell", "ANATOMY", 80, 84], ["SARS-CoV", "ORGANISM", 16, 24], ["cell", "CELL", 80, 84], ["human", "ORGANISM", 94, 99], ["mice", "ORGANISM", 123, 127], ["rhesus macaques", "ORGANISM", 132, 147], ["MERS-CoV", "ORGANISM", 149, 157], ["mice", "ORGANISM", 204, 208], ["hamsters", "ORGANISM", 210, 218], ["ferrets", "ORGANISM", 222, 229], ["rhesus", "ORGANISM", 279, 285], ["macaques", "ORGANISM", 286, 294], ["human", "SPECIES", 94, 99], ["mice", "SPECIES", 123, 127], ["rhesus macaques", "SPECIES", 132, 147], ["mice", "SPECIES", 204, 208], ["hamsters", "SPECIES", 210, 218], ["ferrets", "SPECIES", 222, 229], ["rhesus macaques", "SPECIES", 279, 294], ["SARS-CoV", "SPECIES", 16, 24], ["human", "SPECIES", 94, 99], ["mice", "SPECIES", 123, 127], ["rhesus macaques", "SPECIES", 132, 147], ["MERS-CoV", "SPECIES", 149, 157], ["mice", "SPECIES", 204, 208], ["hamsters", "SPECIES", 210, 218], ["ferrets", "SPECIES", 222, 229], ["rhesus macaques", "SPECIES", 279, 294], ["unlike SARS-CoV", "PROBLEM", 9, 24], ["mild to moderate symptoms in rhesus macaques", "PROBLEM", 250, 294], ["SARS", "OBSERVATION", 16, 20], ["several cell", "OBSERVATION_MODIFIER", 72, 84], ["mild", "OBSERVATION_MODIFIER", 250, 254], ["moderate", "OBSERVATION_MODIFIER", 258, 266], ["symptoms", "OBSERVATION", 267, 275]]], ["Variations in DPP4 among animal species are considered to determine susceptibility to MERS-CoV infection [59].", [["MERS-CoV infection", "DISEASE", 86, 104], ["DPP4", "GENE_OR_GENE_PRODUCT", 14, 18], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 86, 94], ["DPP4", "PROTEIN", 14, 18], ["MERS-CoV", "SPECIES", 86, 94], ["Variations in DPP4 among animal species", "PROBLEM", 0, 39], ["CoV infection", "PROBLEM", 91, 104]]], ["Thus, Zhao et al. developed a mouse model for MERS by using an adenovirus expressing the human DPP4 to sensitize mice for infection [60].", [["infection", "DISEASE", 122, 131], ["mouse", "ORGANISM", 30, 35], ["MERS", "CANCER", 46, 50], ["adenovirus", "ORGANISM", 63, 73], ["human", "ORGANISM", 89, 94], ["DPP4", "GENE_OR_GENE_PRODUCT", 95, 99], ["mice", "ORGANISM", 113, 117], ["human DPP4", "PROTEIN", 89, 99], ["mouse", "SPECIES", 30, 35], ["human", "SPECIES", 89, 94], ["mice", "SPECIES", 113, 117], ["mouse", "SPECIES", 30, 35], ["adenovirus", "SPECIES", 63, 73], ["human", "SPECIES", 89, 94], ["mice", "SPECIES", 113, 117], ["an adenovirus", "TREATMENT", 60, 73], ["the human DPP4", "TREATMENT", 85, 99], ["infection", "PROBLEM", 122, 131]]], ["With prior transduction of adenoviral human DPP4-expressing vectors, mice became more susceptible to MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 101, 119], ["adenoviral", "ORGANISM", 27, 37], ["human", "ORGANISM", 38, 43], ["DPP4", "GENE_OR_GENE_PRODUCT", 44, 48], ["mice", "ORGANISM", 69, 73], ["MERS-CoV", "ORGANISM", 101, 109], ["adenoviral human DPP4-expressing vectors", "DNA", 27, 67], ["human", "SPECIES", 38, 43], ["mice", "SPECIES", 69, 73], ["human", "SPECIES", 38, 43], ["mice", "SPECIES", 69, 73], ["MERS-CoV", "SPECIES", 101, 109], ["adenoviral human DPP4", "TREATMENT", 27, 48], ["MERS", "PROBLEM", 101, 105], ["CoV infection", "PROBLEM", 106, 119], ["CoV", "OBSERVATION_MODIFIER", 106, 109], ["infection", "OBSERVATION", 110, 119]]], ["This method could be used for rapid evaluation of an anti-MERS vaccine and an antiviral therapy.", [["This method", "TREATMENT", 0, 11], ["rapid evaluation", "TEST", 30, 46], ["an anti-MERS vaccine", "TREATMENT", 50, 70], ["an antiviral therapy", "TREATMENT", 75, 95], ["antiviral therapy", "OBSERVATION", 78, 95]]], ["However, whether the infected mice treated by this inhaled-adenovirus method underwent the same disease progression and immune response as typically observed in human remains unknown.", [["mice", "ORGANISM", 30, 34], ["adenovirus", "ORGANISM", 59, 69], ["human", "ORGANISM", 161, 166], ["mice", "SPECIES", 30, 34], ["human", "SPECIES", 161, 166], ["mice", "SPECIES", 30, 34], ["human", "SPECIES", 161, 166], ["the infected mice", "PROBLEM", 17, 34], ["this inhaled-adenovirus method", "TREATMENT", 46, 76], ["the same disease progression", "PROBLEM", 87, 115], ["immune response", "PROBLEM", 120, 135], ["infected", "OBSERVATION_MODIFIER", 21, 29]]], ["A better model could be a transgenic mouse model with the human DPP4 gene integrated into the genome.", [["mouse", "ORGANISM", 37, 42], ["human", "ORGANISM", 58, 63], ["DPP4", "GENE_OR_GENE_PRODUCT", 64, 68], ["human DPP4 gene", "DNA", 58, 73], ["mouse", "SPECIES", 37, 42], ["human", "SPECIES", 58, 63], ["mouse", "SPECIES", 37, 42], ["human", "SPECIES", 58, 63], ["a transgenic mouse model", "TREATMENT", 24, 48], ["the human DPP4 gene", "TREATMENT", 54, 73]]], ["Recently, Falzarano et al. found that MERS-CoV infection in marmosets closely mimics the severe pneumonia experienced by people infected with MERS-CoV [59].", [["infection", "DISEASE", 47, 56], ["pneumonia", "DISEASE", 96, 105], ["MERS-CoV", "ORGANISM", 38, 46], ["marmosets", "ORGANISM", 60, 69], ["people", "ORGANISM", 121, 127], ["MERS-CoV", "ORGANISM", 142, 150], ["people", "SPECIES", 121, 127], ["MERS-CoV", "SPECIES", 38, 46], ["MERS-CoV", "SPECIES", 142, 150], ["CoV infection", "PROBLEM", 43, 56], ["the severe pneumonia", "PROBLEM", 85, 105], ["CoV", "OBSERVATION_MODIFIER", 43, 46], ["infection", "OBSERVATION", 47, 56], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["pneumonia", "OBSERVATION", 96, 105]]], ["Most of the animals infected with MERS-CoV developed a progressive severe pneumonia leading to euthanasia of some animals.", [["pneumonia", "DISEASE", 74, 83], ["animals", "ORGANISM", 12, 19], ["MERS-CoV", "ORGANISM", 34, 42], ["MERS-CoV", "SPECIES", 34, 42], ["a progressive severe pneumonia", "PROBLEM", 53, 83], ["euthanasia of some animals", "PROBLEM", 95, 121], ["infected", "OBSERVATION", 20, 28], ["progressive", "OBSERVATION_MODIFIER", 55, 66], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["pneumonia", "OBSERVATION", 74, 83], ["euthanasia", "OBSERVATION", 95, 105]]], ["Extensive lesions were evident, and high viral loads were detected in the lungs of all marmosets.", [["lesions", "ANATOMY", 10, 17], ["lungs", "ANATOMY", 74, 79], ["lesions", "PATHOLOGICAL_FORMATION", 10, 17], ["lungs", "ORGAN", 74, 79], ["marmosets", "ORGANISM", 87, 96], ["Extensive lesions", "PROBLEM", 0, 17], ["high viral loads", "PROBLEM", 36, 52], ["lesions", "OBSERVATION", 10, 17], ["high", "OBSERVATION_MODIFIER", 36, 40], ["viral loads", "OBSERVATION", 41, 52], ["lungs", "ANATOMY", 74, 79], ["all marmosets", "ANATOMY", 83, 96]]], ["Marmoset DPP4 has an amino acid sequence identical to that of human DPP4 in the MERS-CoV S glycoprotein binding region, resulting in the observed susceptibility to MERS-CoV infection.", [["amino acid", "CHEMICAL", 21, 31], ["MERS-CoV infection", "DISEASE", 164, 182], ["amino acid", "CHEMICAL", 21, 31], ["DPP4", "GENE_OR_GENE_PRODUCT", 9, 13], ["amino acid", "AMINO_ACID", 21, 31], ["human", "ORGANISM", 62, 67], ["DPP4", "GENE_OR_GENE_PRODUCT", 68, 72], ["MERS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 80, 103], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 164, 172], ["DPP4", "PROTEIN", 9, 13], ["human DPP4", "PROTEIN", 62, 72], ["MERS-CoV S glycoprotein binding region", "DNA", 80, 118], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["MERS-CoV", "SPECIES", 80, 88], ["MERS-CoV", "SPECIES", 164, 172], ["Marmoset DPP4", "TREATMENT", 0, 13], ["an amino acid sequence", "TEST", 18, 40], ["human DPP4", "TEST", 62, 72], ["CoV S glycoprotein binding region", "TREATMENT", 85, 118], ["CoV infection", "PROBLEM", 169, 182], ["CoV", "OBSERVATION_MODIFIER", 169, 172], ["infection", "OBSERVATION", 173, 182]]], ["These results suggest that the marmoset model is an important advance in the ability to assess the efficacy of intervention strategies against MERS, in turn allowing the preclinical evaluation of neutralizing mAbs for treatment of MERS-CoV infection.Human mAbs against MERS-CoV: mechanisms of virus neutralizationTo realize the preventive or therapeutic potential of neutralizing mAbs in the clinical setting, it is also necessary to investigate the mechanisms by which the antibodies modulate the biological behaviors of MERS-CoV.", [["MERS", "DISEASE", 143, 147], ["MERS-CoV infection", "DISEASE", 231, 249], ["marmoset", "ORGANISM", 31, 39], ["MERS-CoV", "ORGANISM", 231, 239], ["Human", "ORGANISM", 250, 255], ["MERS-CoV", "ORGANISM", 269, 277], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 522, 530], ["neutralizing mAbs", "PROTEIN", 196, 213], ["Human mAbs", "PROTEIN", 250, 260], ["neutralizing mAbs", "PROTEIN", 367, 384], ["antibodies", "PROTEIN", 474, 484], ["Human", "SPECIES", 250, 255], ["MERS-CoV", "SPECIES", 231, 239], ["Human", "SPECIES", 250, 255], ["MERS-CoV", "SPECIES", 269, 277], ["MERS-CoV", "SPECIES", 522, 530], ["intervention strategies", "TREATMENT", 111, 134], ["MERS", "PROBLEM", 143, 147], ["the preclinical evaluation", "TEST", 166, 192], ["neutralizing mAbs", "TREATMENT", 196, 213], ["treatment", "TREATMENT", 218, 227], ["MERS", "PROBLEM", 231, 235], ["CoV infection", "PROBLEM", 236, 249], ["virus neutralization", "PROBLEM", 293, 313], ["neutralizing mAbs", "TREATMENT", 367, 384], ["the antibodies", "TEST", 470, 484], ["CoV", "OBSERVATION_MODIFIER", 236, 239], ["infection", "OBSERVATION", 240, 249], ["neutralizing mAbs", "OBSERVATION", 367, 384]]], ["In order to explore the mechanism of action of human mAbs m336, m337, and m338, we first defined the MERS-CoV epitopes recognized by these mAbs [54].", [["human", "ORGANISM", 47, 52], ["mAbs", "GENE_OR_GENE_PRODUCT", 53, 57], ["m336", "GENE_OR_GENE_PRODUCT", 58, 62], ["m337", "GENE_OR_GENE_PRODUCT", 64, 68], ["m338", "GENE_OR_GENE_PRODUCT", 74, 78], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 101, 109], ["human mAbs m336", "PROTEIN", 47, 62], ["m337", "PROTEIN", 64, 68], ["m338", "PROTEIN", 74, 78], ["MERS-CoV epitopes", "PROTEIN", 101, 118], ["mAbs", "PROTEIN", 139, 143], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["CoV epitopes", "TREATMENT", 106, 118]]], ["The binding of mAbs to fragments of the S glycoprotein was measured, and, as expected, the mAbs only bound to the S fragments containing the RBD, specifically residues 377 to 588.", [["mAbs", "GENE_OR_GENE_PRODUCT", 15, 19], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 40, 54], ["mAbs", "PROTEIN", 15, 19], ["S glycoprotein", "PROTEIN", 40, 54], ["mAbs", "PROTEIN", 91, 95], ["S fragments", "DNA", 114, 125], ["RBD", "PROTEIN", 141, 144], ["residues 377 to 588", "PROTEIN", 159, 178], ["the S glycoprotein", "TEST", 36, 54], ["S glycoprotein", "OBSERVATION_MODIFIER", 40, 54], ["RBD", "OBSERVATION", 141, 144]]], ["We further analyzed the mAbs binding to a series of alanine mutants of the RBD and found that the three mAbs had overlapping, but distinct, binding sites.", [["alanine", "CHEMICAL", 52, 59], ["alanine", "CHEMICAL", 52, 59], ["alanine", "AMINO_ACID", 52, 59], ["mAbs", "GENE_OR_GENE_PRODUCT", 104, 108], ["mAbs", "PROTEIN", 24, 28], ["alanine mutants", "PROTEIN", 52, 67], ["RBD", "PROTEIN", 75, 78], ["mAbs", "PROTEIN", 104, 108], ["binding sites", "PROTEIN", 140, 153], ["the mAbs binding", "PROBLEM", 20, 36], ["alanine mutants", "TREATMENT", 52, 67], ["the RBD", "PROBLEM", 71, 78], ["distinct", "OBSERVATION_MODIFIER", 130, 138], ["binding sites", "OBSERVATION", 140, 153]]], ["For example, residues 510 and 553 were important for binding of all three mAbs.", [["mAbs", "PROTEIN", 74, 78]]], ["Residues 536 and 539, on the other hand, were uniquely bound by m336, which turned out to be the most potent neutralizer among the three mAbs, suggesting that these residues may be crucial for m336 interaction and, hence, important for vaccine development.", [["m336", "GENE_OR_GENE_PRODUCT", 64, 68], ["m336", "GENE_OR_GENE_PRODUCT", 193, 197], ["mAbs", "PROTEIN", 137, 141], ["m336", "PROTEIN", 193, 197], ["vaccine development", "TREATMENT", 236, 255]]], ["We next found that the three mAbs competed with each other for binding the MERS-CoV RBD and also competed with RBD for binding to a soluble version of DPP4.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 75, 83], ["DPP4", "GENE_OR_GENE_PRODUCT", 151, 155], ["mAbs", "PROTEIN", 29, 33], ["MERS-CoV RBD", "PROTEIN", 75, 87], ["RBD", "PROTEIN", 111, 114], ["DPP4", "PROTEIN", 151, 155], ["MERS-CoV", "SPECIES", 75, 83], ["the three mAbs", "TREATMENT", 19, 33], ["CoV RBD", "PROBLEM", 80, 87], ["RBD", "PROBLEM", 111, 114], ["a soluble version of DPP4", "TREATMENT", 130, 155]]], ["Consistent with the neutralization results, m336 was slightly more potent than m337 and m338 in blocking the binding of RBD to DPP4.", [["m337", "CHEMICAL", 79, 83], ["m338", "CHEMICAL", 88, 92], ["m337", "SIMPLE_CHEMICAL", 79, 83], ["m338", "SIMPLE_CHEMICAL", 88, 92], ["RBD", "GENE_OR_GENE_PRODUCT", 120, 123], ["DPP4", "GENE_OR_GENE_PRODUCT", 127, 131], ["RBD", "PROTEIN", 120, 123], ["DPP4", "PROTEIN", 127, 131], ["DPP4", "TEST", 127, 131], ["more potent", "OBSERVATION_MODIFIER", 62, 73]]], ["The IC50s of m336, m337, and m338 were 0.034, 0.044, and 0.041 \u03bcg/ml, respectively, values which were in a range similar to the neutralizing activity of the mAbs against pseudotyped MERS-CoV in DPP4-expressing Huh-7 cells (0.005\u20130.017 \u03bcg/ml).", [["Huh-7 cells", "ANATOMY", 210, 221], ["m336, m337, and m338", "CHEMICAL", 13, 33], ["m336", "GENE_OR_GENE_PRODUCT", 13, 17], ["m337", "GENE_OR_GENE_PRODUCT", 19, 23], ["m338", "GENE_OR_GENE_PRODUCT", 29, 33], ["pseudotyped", "ORGANISM", 170, 181], ["MERS-CoV", "ORGANISM", 182, 190], ["DPP4", "GENE_OR_GENE_PRODUCT", 194, 198], ["Huh-7 cells", "CELL", 210, 221], ["mAbs", "PROTEIN", 157, 161], ["DPP4", "PROTEIN", 194, 198], ["Huh-7 cells", "CELL_LINE", 210, 221], ["MERS-CoV", "SPECIES", 182, 190], ["The IC50s", "TEST", 0, 9], ["the mAbs", "TEST", 153, 161], ["pseudotyped MERS", "TEST", 170, 186], ["CoV", "TEST", 187, 190], ["DPP4", "TEST", 194, 198], ["Huh", "TEST", 210, 213]]], ["These results support the idea that the mAbs have overlapping epitopes and neutralize MERS-CoV by competing with the receptor binding.", [["mAbs", "GENE_OR_GENE_PRODUCT", 40, 44], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 86, 94], ["mAbs", "PROTEIN", 40, 44], ["epitopes", "PROTEIN", 62, 70], ["MERS-CoV", "PROTEIN", 86, 94], ["MERS-CoV", "SPECIES", 86, 94], ["the mAbs", "TREATMENT", 36, 44], ["overlapping epitopes", "PROBLEM", 50, 70]]], ["Using the mutagenesis data and the MERS-CoV RBD crystal structure, we generated three-dimensional molecular docking models of the mAbs interacting with the RBD [54].", [["mAbs", "PROTEIN", 130, 134], ["RBD", "PROTEIN", 156, 159], ["the mutagenesis data", "TEST", 6, 26], ["the mAbs", "TREATMENT", 126, 134]]], ["Good superimposition of DPP4 with the mAbs-RBD structures confirmed that the competition with MERS-CoV for receptor binding is an important mechanism of action of the mAbs in neutralizing MERS-CoV cell entry.", [["cell", "ANATOMY", 197, 201], ["DPP4", "GENE_OR_GENE_PRODUCT", 24, 28], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 94, 102], ["MERS-CoV cell", "CELL", 188, 201], ["DPP4", "PROTEIN", 24, 28], ["mAbs", "PROTEIN", 38, 42], ["RBD", "PROTEIN", 43, 46], ["MERS", "PROTEIN", 94, 98], ["mAbs", "PROTEIN", 167, 171], ["MERS", "PROTEIN", 188, 192], ["MERS-CoV", "SPECIES", 188, 196], ["DPP4", "TEST", 24, 28], ["the mAbs", "TEST", 34, 42], ["receptor binding", "PROBLEM", 107, 123], ["the mAbs", "TREATMENT", 163, 171]]], ["The extensive overlapping between the mAb epitopes and the receptor binding sites on RBD explains the exceptional neutralizing potency of these mAbs.", [["mAbs", "GENE_OR_GENE_PRODUCT", 144, 148], ["mAb epitopes", "PROTEIN", 38, 50], ["receptor binding sites", "PROTEIN", 59, 81], ["RBD", "PROTEIN", 85, 88], ["mAbs", "PROTEIN", 144, 148], ["the mAb epitopes", "TREATMENT", 34, 50], ["the receptor binding sites", "PROBLEM", 55, 81], ["RBD", "PROBLEM", 85, 88], ["extensive", "OBSERVATION_MODIFIER", 4, 13], ["overlapping", "OBSERVATION_MODIFIER", 14, 25], ["mAb epitopes", "OBSERVATION", 38, 50]]], ["Similarly, Jiang et al. also found that the neutralizing mAbs MERS-4 and MERS-27 could inhibit the binding of soluble RBD to DPP4-expressing Huh7 cells [55].", [["Huh7 cells", "ANATOMY", 141, 151], ["MERS-27", "CHEMICAL", 73, 80], ["MERS-4", "GENE_OR_GENE_PRODUCT", 62, 68], ["MERS-27", "SIMPLE_CHEMICAL", 73, 80], ["RBD", "GENE_OR_GENE_PRODUCT", 118, 121], ["DPP4", "GENE_OR_GENE_PRODUCT", 125, 129], ["Huh7 cells", "CELL", 141, 151], ["neutralizing mAbs MERS-4", "PROTEIN", 44, 68], ["MERS-27", "PROTEIN", 73, 80], ["RBD", "PROTEIN", 118, 121], ["DPP4", "PROTEIN", 125, 129], ["Huh7 cells", "CELL_LINE", 141, 151], ["the neutralizing mAbs MERS", "TEST", 40, 66], ["soluble RBD", "PROBLEM", 110, 121], ["DPP4", "TEST", 125, 129], ["Huh7 cells", "TEST", 141, 151]]], ["From the binding competition assays, Tang et al. found that 2B11 and six other mAbs could recognize at least three different epitopes on MERS-CoV RBD and that the antibodies could block DPP4 binding to MERS-CoV RBD and inhibit the attachment of pseudovirus to DPP4-expressing cells [56].", [["cells", "ANATOMY", 276, 281], ["2B11", "SIMPLE_CHEMICAL", 60, 64], ["mAbs", "GENE_OR_GENE_PRODUCT", 79, 83], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 137, 145], ["DPP4", "GENE_OR_GENE_PRODUCT", 186, 190], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 202, 210], ["pseudovirus", "ORGANISM", 245, 256], ["DPP4", "GENE_OR_GENE_PRODUCT", 260, 264], ["cells", "CELL", 276, 281], ["2B11", "PROTEIN", 60, 64], ["mAbs", "PROTEIN", 79, 83], ["epitopes", "PROTEIN", 125, 133], ["MERS-CoV RBD", "PROTEIN", 137, 149], ["antibodies", "PROTEIN", 163, 173], ["DPP4", "PROTEIN", 186, 190], ["MERS-CoV RBD", "PROTEIN", 202, 214], ["DPP4", "PROTEIN", 260, 264], ["MERS-CoV", "SPECIES", 137, 145], ["MERS-CoV", "SPECIES", 202, 210], ["CoV RBD", "PROBLEM", 142, 149], ["the antibodies", "PROBLEM", 159, 173], ["CoV RBD", "PROBLEM", 207, 214], ["DPP4", "TEST", 260, 264]]], ["DPP4 could also block the antibodies from RBD binding.", [["RBD", "DISEASE", 42, 45], ["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["RBD", "GENE_OR_GENE_PRODUCT", 42, 45], ["DPP4", "PROTEIN", 0, 4], ["antibodies", "PROTEIN", 26, 36], ["RBD", "PROTEIN", 42, 45], ["DPP4", "TREATMENT", 0, 4], ["the antibodies from RBD binding", "PROBLEM", 22, 53]]], ["Taken together, these results suggest that the neutralizing mechanism of all the above-mentioned human mAbs, despite recognizing different epitopes on RBD, occurred through the blocking of MERS-CoV binding to its cellular receptor DPP4.", [["cellular", "ANATOMY", 213, 221], ["RBD", "DISEASE", 151, 154], ["human", "ORGANISM", 97, 102], ["mAbs", "GENE_OR_GENE_PRODUCT", 103, 107], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 189, 197], ["cellular", "CELL", 213, 221], ["DPP4", "GENE_OR_GENE_PRODUCT", 231, 235], ["human mAbs", "PROTEIN", 97, 107], ["epitopes", "PROTEIN", 139, 147], ["RBD", "PROTEIN", 151, 154], ["MERS", "PROTEIN", 189, 193], ["cellular receptor", "PROTEIN", 213, 230], ["DPP4", "PROTEIN", 231, 235], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["the neutralizing mechanism", "PROBLEM", 43, 69], ["human mAbs", "TREATMENT", 97, 107], ["different epitopes on RBD", "PROBLEM", 129, 154], ["CoV binding", "PROBLEM", 194, 205]]], ["Interestingly, Jiang et al. also demonstrated that the combination of MERS-4 and MERS-27, which were found to recognize different epitopes on RBD, resulted in a synergistic neutralizing effect against pseudotyped MERS-CoV [55].Future directionsEmerging viruses, e.g. SARS-like or MERS-like novel coronaviruses, are highly likely to continue posing a serious threat to human health in the near future.", [["MERS-27", "CHEMICAL", 81, 88], ["SARS", "DISEASE", 267, 271], ["MERS-4", "GENE_OR_GENE_PRODUCT", 70, 76], ["MERS-27", "GENE_OR_GENE_PRODUCT", 81, 88], ["MERS-CoV", "ORGANISM", 213, 221], ["MERS-like novel coronaviruses", "ORGANISM", 280, 309], ["human", "ORGANISM", 368, 373], ["MERS", "PROTEIN", 70, 74], ["MERS-27", "DNA", 81, 88], ["epitopes", "PROTEIN", 130, 138], ["RBD", "PROTEIN", 142, 145], ["human", "SPECIES", 368, 373], ["MERS-CoV", "SPECIES", 213, 221], ["human", "SPECIES", 368, 373], ["MERS", "TEST", 70, 74], ["MERS", "TEST", 81, 85], ["different epitopes on RBD", "PROBLEM", 120, 145], ["a synergistic neutralizing effect", "PROBLEM", 159, 192], ["pseudotyped MERS", "PROBLEM", 201, 217], ["Emerging viruses", "PROBLEM", 244, 260], ["SARS", "PROBLEM", 267, 271], ["novel coronaviruses", "PROBLEM", 290, 309], ["viruses", "OBSERVATION", 253, 260]]], ["Polyclonal human immunoglobulin has been used with various degrees of success for viral diseases for more than a century, and some are still in clinical use against, for example, hepatitis A, hepatitis B, cytomegalovirus, rabies, measles and vaccinia [7].", [["viral diseases", "DISEASE", 82, 96], ["hepatitis A, hepatitis B", "DISEASE", 179, 203], ["cytomegalovirus", "DISEASE", 205, 220], ["rabies", "DISEASE", 222, 228], ["measles", "DISEASE", 230, 237], ["human", "ORGANISM", 11, 16], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 17, 31], ["hepatitis A", "ORGANISM", 179, 190], ["hepatitis B", "ORGANISM", 192, 203], ["cytomegalovirus", "ORGANISM", 205, 220], ["rabies", "ORGANISM", 222, 228], ["vaccinia", "ORGANISM", 242, 250], ["Polyclonal human immunoglobulin", "PROTEIN", 0, 31], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["hepatitis A", "SPECIES", 179, 190], ["hepatitis B", "SPECIES", 192, 203], ["rabies", "SPECIES", 222, 228], ["Polyclonal human immunoglobulin", "TREATMENT", 0, 31], ["viral diseases", "PROBLEM", 82, 96], ["hepatitis A", "PROBLEM", 179, 190], ["hepatitis B", "PROBLEM", 192, 203], ["cytomegalovirus", "PROBLEM", 205, 220], ["rabies", "PROBLEM", 222, 228], ["measles", "PROBLEM", 230, 237], ["vaccinia", "PROBLEM", 242, 250], ["viral diseases", "OBSERVATION", 82, 96], ["hepatitis", "OBSERVATION", 179, 188]]], ["However, a number of toxicity-related problems have arisen, including a risk for allergic reactions, pathogen transmission, and lot-to-lot variation.", [["toxicity", "DISEASE", 21, 29], ["allergic reactions", "DISEASE", 81, 99], ["toxicity-related problems", "PROBLEM", 21, 46], ["allergic reactions", "PROBLEM", 81, 99], ["pathogen transmission", "TEST", 101, 122]]], ["In addition, only a very small portion of the total antibodies in a polyclonal preparation is typically neutralizing, while the remainder is not only ineffective, but could be immunogenic, or even toxic.", [["total antibodies", "PROTEIN", 46, 62], ["a very small portion of the total antibodies", "PROBLEM", 18, 62], ["a polyclonal preparation", "TREATMENT", 66, 90], ["immunogenic", "PROBLEM", 176, 187], ["very", "OBSERVATION_MODIFIER", 20, 24], ["small", "OBSERVATION_MODIFIER", 25, 30], ["portion", "OBSERVATION_MODIFIER", 31, 38], ["total", "OBSERVATION_MODIFIER", 46, 51], ["antibodies", "OBSERVATION", 52, 62], ["typically", "OBSERVATION_MODIFIER", 94, 103], ["neutralizing", "OBSERVATION", 104, 116], ["not only", "UNCERTAINTY", 141, 149]]], ["These limitations could be overcome by the use of human mAbs.", [["human", "ORGANISM", 50, 55], ["mAbs", "GENE_OR_GENE_PRODUCT", 56, 60], ["human mAbs", "PROTEIN", 50, 60], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["human mAbs", "TREATMENT", 50, 60]]], ["Nevertheless, a major obstacle comes from the difficulty of generating highly potent neutralizing mAbs in a relatively short amount of time.", [["neutralizing mAbs", "PROTEIN", 85, 102]]], ["In this review, we summarized the recent developments in human neutralizing mAbs against MERS-CoV which have been identified by different laboratories around the globe at an unprecedented pace.", [["human", "ORGANISM", 57, 62], ["MERS-CoV", "ORGANISM", 89, 97], ["human neutralizing mAbs", "PROTEIN", 57, 80], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["MERS-CoV", "SPECIES", 89, 97], ["human neutralizing mAbs", "TREATMENT", 57, 80], ["MERS", "PROBLEM", 89, 93], ["CoV", "PROBLEM", 94, 97], ["globe", "ANATOMY", 162, 167]]], ["Improvement in antibody identification techniques, combined with the recent advances in antibody production technologies, highlights the potential of human mAbs for application toward a strategy designed to combat future emerging viruses and diseases in an outbreak setting.Future directionsApart from the above limitations, the use of antiviral mAbs may produce escape mutants.", [["human", "ORGANISM", 150, 155], ["human mAbs", "PROTEIN", 150, 160], ["antiviral mAbs", "PROTEIN", 336, 350], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 150, 155], ["antibody identification techniques", "TEST", 15, 49], ["antibody production technologies", "TREATMENT", 88, 120], ["human mAbs", "TREATMENT", 150, 160], ["a strategy", "TREATMENT", 184, 194], ["emerging viruses", "PROBLEM", 221, 237], ["diseases", "PROBLEM", 242, 250], ["antiviral mAbs", "TREATMENT", 336, 350], ["escape mutants", "PROBLEM", 363, 377], ["escape mutants", "OBSERVATION", 363, 377]]], ["Although the mutation rates in SARS-CoV and MERS-CoV are only moderate compared to those in other RNA viruses, the frequency of the emergence of escape mutants should not be underestimated.", [["SARS", "DISEASE", 31, 35], ["SARS-CoV", "ORGANISM", 31, 39], ["MERS-CoV", "ORGANISM", 44, 52], ["SARS-CoV", "SPECIES", 31, 39], ["MERS-CoV", "SPECIES", 44, 52], ["the mutation rates", "TEST", 9, 27], ["SARS", "TEST", 31, 35], ["CoV", "PROBLEM", 49, 52], ["escape mutants", "PROBLEM", 145, 159], ["moderate", "OBSERVATION_MODIFIER", 62, 70], ["viruses", "OBSERVATION", 102, 109], ["escape mutants", "OBSERVATION", 145, 159], ["should not be", "UNCERTAINTY", 160, 173]]], ["A promising solution may lie in the use of \u201cmAb cocktails\u201d in which two or more mAbs targeting different epitopes are mixed.", [["mAbs", "PROTEIN", 80, 84], ["epitopes", "PROTEIN", 105, 113], ["A promising solution", "TREATMENT", 0, 20], ["\u201cmAb cocktails", "TREATMENT", 43, 57]]], ["Such mAb cocktails would not only provide more potent antiviral activity than a single mAb by additive and/or synergistic effects [61], but also prevent escape variants for many viruses, including SARS-CoV [13].", [["SARS", "DISEASE", 197, 201], ["SARS-CoV", "ORGANISM", 197, 205], ["mAb", "PROTEIN", 87, 90], ["SARS-CoV", "SPECIES", 197, 205], ["Such mAb cocktails", "TREATMENT", 0, 18], ["a single mAb", "TREATMENT", 78, 90], ["escape variants", "PROBLEM", 153, 168], ["many viruses", "PROBLEM", 173, 185], ["viruses", "OBSERVATION", 178, 185]]], ["Interestingly, even though all recently developed human mAbs against MERS-CoV target the RBD of S glycoprotein [54], [55], [56], most of them recognize distinct epitopes, as discussed above.", [["human", "ORGANISM", 50, 55], ["mAbs", "GENE_OR_GENE_PRODUCT", 56, 60], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 69, 77], ["human mAbs", "PROTEIN", 50, 60], ["MERS-CoV", "PROTEIN", 69, 77], ["RBD", "PROTEIN", 89, 92], ["S glycoprotein", "PROTEIN", 96, 110], ["epitopes", "PROTEIN", 161, 169], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["MERS-CoV", "SPECIES", 69, 77], ["human mAbs", "TEST", 50, 60], ["MERS", "PROBLEM", 69, 73], ["distinct", "OBSERVATION_MODIFIER", 152, 160], ["epitopes", "OBSERVATION", 161, 169]]], ["Therefore, it might be expected that the emergence of resistant viruses to these RBD-specific mAbs, if any, would exert a toll on virus fitness because the escape mutants could have lower affinity for the cellular receptor DPP4.", [["cellular", "ANATOMY", 205, 213], ["RBD", "DISEASE", 81, 84], ["RBD", "GENE_OR_GENE_PRODUCT", 81, 84], ["mAbs", "GENE_OR_GENE_PRODUCT", 94, 98], ["cellular", "CELL", 205, 213], ["DPP4", "GENE_OR_GENE_PRODUCT", 223, 227], ["RBD", "PROTEIN", 81, 84], ["mAbs", "PROTEIN", 94, 98], ["cellular receptor", "PROTEIN", 205, 222], ["DPP4", "PROTEIN", 223, 227], ["resistant viruses", "PROBLEM", 54, 71], ["these RBD", "TEST", 75, 84], ["a toll on virus fitness", "PROBLEM", 120, 143], ["the escape mutants", "PROBLEM", 152, 170], ["the cellular receptor DPP4", "TREATMENT", 201, 227]]], ["Furthermore, Jiang et al. have demonstrated that the combination of two human mAbs, MERS-4 and MERS-27, resulted in a synergistic neutralizing effect against pseudotyped MERS-CoV [55].", [["MERS-27", "CHEMICAL", 95, 102], ["human", "ORGANISM", 72, 77], ["MERS-4", "GENE_OR_GENE_PRODUCT", 84, 90], ["MERS-27", "GENE_OR_GENE_PRODUCT", 95, 102], ["MERS-CoV", "ORGANISM", 170, 178], ["human mAbs", "PROTEIN", 72, 82], ["MERS", "PROTEIN", 84, 88], ["MERS-27", "PROTEIN", 95, 102], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["MERS-CoV", "SPECIES", 170, 178], ["two human mAbs", "TREATMENT", 68, 82], ["MERS", "TEST", 84, 88], ["a synergistic neutralizing effect", "TREATMENT", 116, 149]]], ["Thus, it would be interesting to test if other combinations of the available mAbs would give similar, or better, synergistic effects and if so, whether these mAb cocktails could neutralize mutant viruses emerging in the future.Future directionsHigh production cost is a substantial obstacle for the commercial development of antiviral human mAbs, especially mAbs against emerging viruses.", [["mAb", "GENE_OR_GENE_PRODUCT", 158, 161], ["mutant viruses", "ORGANISM", 189, 203], ["human", "ORGANISM", 335, 340], ["mAbs", "GENE_OR_GENE_PRODUCT", 358, 362], ["mAbs", "PROTEIN", 77, 81], ["antiviral human mAbs", "PROTEIN", 325, 345], ["mAbs", "PROTEIN", 358, 362], ["human", "SPECIES", 335, 340], ["human", "SPECIES", 335, 340], ["the available mAbs", "TREATMENT", 63, 81], ["these mAb cocktails", "TREATMENT", 152, 171], ["mutant viruses", "PROBLEM", 189, 203], ["High production cost", "PROBLEM", 244, 264], ["antiviral human mAbs", "TREATMENT", 325, 345], ["substantial", "OBSERVATION_MODIFIER", 270, 281], ["antiviral human mAbs", "OBSERVATION", 325, 345]]], ["One strategy to reduce the overall cost is to develop exceptionally potent neutralizing mAbs, resulting in a reduction in the dose required to achieve efficacy.", [["neutralizing mAbs", "PROTEIN", 75, 92], ["exceptionally potent neutralizing mAbs", "PROBLEM", 54, 92], ["a reduction", "TREATMENT", 107, 118], ["reduction", "OBSERVATION_MODIFIER", 109, 118]]], ["This could be achieved by developing human mAbs with ultra high binding affinity and then rationally designing the products to target the critical neutralization site, e.g., RBD.", [["RBD", "DISEASE", 174, 177], ["human", "ORGANISM", 37, 42], ["human mAbs", "PROTEIN", 37, 47], ["RBD", "PROTEIN", 174, 177], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["ultra high binding affinity", "TREATMENT", 53, 80], ["the products", "TREATMENT", 111, 123], ["RBD", "PROBLEM", 174, 177]]], ["For example, the exceptionally potent mAb m336 can bind to the MERS-CoV RBD with picomolar affinity, and the potency for virus neutralization (IC50) is also in the picomolar range, suggesting that a low dose of mAbs could be clinically effective.", [["m336", "CHEMICAL", 42, 46], ["mAb m336", "GENE_OR_GENE_PRODUCT", 38, 46], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 63, 71], ["mAb m336", "PROTEIN", 38, 46], ["MERS-CoV RBD", "PROTEIN", 63, 75], ["mAbs", "PROTEIN", 211, 215], ["MERS-CoV", "SPECIES", 63, 71], ["picomolar affinity", "TREATMENT", 81, 99], ["virus neutralization (IC50", "TREATMENT", 121, 147], ["a low dose of mAbs", "TREATMENT", 197, 215], ["picomolar affinity", "OBSERVATION", 81, 99], ["low dose", "OBSERVATION_MODIFIER", 199, 207]]], ["Furthermore, recent progress in antibody engineering enables the generation of more effective antibody-based therapeutics, e.g., bispecific antibodies, antibody-drug conjugates, or antibodies with improved effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) [5].", [["cell", "ANATOMY", 253, 257], ["cell", "CELL", 253, 257], ["bispecific antibodies", "PROTEIN", 129, 150], ["antibody", "PROTEIN", 152, 160], ["antibodies", "PROTEIN", 181, 191], ["antibody engineering", "TREATMENT", 32, 52], ["bispecific antibodies", "TEST", 129, 150], ["antibody", "TEST", 152, 160], ["drug conjugates", "TEST", 161, 176], ["antibodies", "PROBLEM", 181, 191], ["improved effector functions", "PROBLEM", 197, 224], ["antibody", "TEST", 234, 242]]], ["Notably, antibody fragments with a reduced size (12\u201350 kDa) could achieve enhanced tissue penetration, as well as a wider range of possible targets, and, importantly, require much lower production costs, providing the potential to overcome the fundamental limitations of full-size mAbs [62].", [["fragments", "ANATOMY", 18, 27], ["tissue", "ANATOMY", 83, 89], ["tissue", "TISSUE", 83, 89], ["antibody fragments", "PROTEIN", 9, 27], ["mAbs", "PROTEIN", 281, 285], ["antibody fragments", "PROBLEM", 9, 27], ["a reduced size", "PROBLEM", 33, 47], ["enhanced tissue penetration", "PROBLEM", 74, 101], ["antibody fragments", "OBSERVATION", 9, 27], ["reduced", "OBSERVATION_MODIFIER", 35, 42], ["size", "OBSERVATION_MODIFIER", 43, 47]]], ["However, compared to mAbs, antibody fragments, such as VH or Fab, display greatly reduced half-lives, and as such, they have limited clinical potential.", [["VH", "GENE_OR_GENE_PRODUCT", 55, 57], ["Fab", "GENE_OR_GENE_PRODUCT", 61, 64], ["mAbs", "PROTEIN", 21, 25], ["antibody fragments", "PROTEIN", 27, 45], ["VH", "PROTEIN", 55, 57], ["Fab", "PROTEIN", 61, 64], ["mAbs", "TEST", 21, 25], ["antibody fragments", "PROBLEM", 27, 45], ["antibody fragments", "OBSERVATION", 27, 45], ["greatly", "OBSERVATION_MODIFIER", 74, 81], ["reduced", "OBSERVATION_MODIFIER", 82, 89]]], ["We recently generated some novel IgG1 Fc-based antibody fragments, which have small size (14\u201327 kDa), good stability and solubility, and relatively long in vivo half-life [63], [64], [65], [66], [67].", [["fragments", "ANATOMY", 56, 65], ["IgG1 Fc", "GENE_OR_GENE_PRODUCT", 33, 40], ["IgG1 Fc", "PROTEIN", 33, 40], ["antibody fragments", "DNA", 47, 65], ["some novel IgG1 Fc", "TREATMENT", 22, 40], ["based antibody fragments", "PROBLEM", 41, 65], ["kDa", "TEST", 96, 99], ["IgG1 Fc", "OBSERVATION", 33, 40], ["antibody fragments", "OBSERVATION", 47, 65], ["small", "OBSERVATION_MODIFIER", 78, 83], ["size", "OBSERVATION_MODIFIER", 84, 88], ["good", "OBSERVATION_MODIFIER", 102, 106], ["stability", "OBSERVATION_MODIFIER", 107, 116]]], ["When fused to VH, the resulting novel antibody constructs can still be solubly expressed in Escherichia coli with high yields [64].", [["Escherichia coli", "ORGANISM", 92, 108], ["VH", "DNA", 14, 16], ["novel antibody constructs", "DNA", 32, 57], ["Escherichia coli", "SPECIES", 92, 108], ["Escherichia coli", "SPECIES", 92, 108], ["the resulting novel antibody constructs", "PROBLEM", 18, 57], ["Escherichia coli", "PROBLEM", 92, 108], ["Escherichia coli", "OBSERVATION", 92, 108]]], ["Therefore, these small, long-acting antibodies have the potential to be developed as commercially attractive prophylactic and therapeutic antivirals for a wide array of indications (Fig. 1).ConclusionsThe threat of emerging infectious diseases, such as SARS and MERS, emphasizes the need for a fast and versatile approach that allows us to rapidly identify effective antivirals to combat the viruses.", [["infectious diseases", "DISEASE", 224, 243], ["SARS", "DISEASE", 253, 257], ["long-acting antibodies", "PROTEIN", 24, 46], ["these small, long-acting antibodies", "PROBLEM", 11, 46], ["therapeutic antivirals", "TREATMENT", 126, 148], ["a wide array of indications (Fig", "TREATMENT", 153, 185], ["emerging infectious diseases", "PROBLEM", 215, 243], ["SARS", "PROBLEM", 253, 257], ["a fast and versatile approach", "TREATMENT", 292, 321], ["effective antivirals", "TREATMENT", 357, 377], ["the viruses", "PROBLEM", 388, 399], ["small", "OBSERVATION_MODIFIER", 17, 22], ["infectious", "OBSERVATION", 224, 234]]], ["We have reviewed here the recent success in identifying fully human neutralizing mAbs against MERS-CoV.", [["human", "ORGANISM", 62, 67], ["MERS-CoV", "ORGANISM", 94, 102], ["human neutralizing mAbs", "PROTEIN", 62, 85], ["MERS-CoV", "PROTEIN", 94, 102], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["MERS-CoV", "SPECIES", 94, 102], ["fully human neutralizing mAbs", "TREATMENT", 56, 85]]], ["The rapid identification of these antibodies suggests the possibility of using non-immune human antibody libraries and related methodologies for a quick response to these emerging viruses with pandemic potential.", [["human", "ORGANISM", 90, 95], ["antibodies", "PROTEIN", 34, 44], ["non-immune human antibody libraries", "DNA", 79, 114], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["these antibodies", "TEST", 28, 44], ["non-immune human antibody libraries", "PROBLEM", 79, 114], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["suggests the possibility of", "UNCERTAINTY", 45, 72]]], ["All the mAbs, despite being developed by different laboratories, target the RBD of MERS-CoV S glycoprotein and may have a similar mechanism of action, i.e., blocking the binding of MERS-CoV to its cellular receptor DPP4.", [["cellular", "ANATOMY", 197, 205], ["mAbs", "GENE_OR_GENE_PRODUCT", 8, 12], ["MERS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 83, 106], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 181, 189], ["cellular", "CELL", 197, 205], ["DPP4", "GENE_OR_GENE_PRODUCT", 215, 219], ["mAbs", "PROTEIN", 8, 12], ["RBD", "PROTEIN", 76, 79], ["MERS-CoV S glycoprotein", "PROTEIN", 83, 106], ["MERS", "PROTEIN", 181, 185], ["CoV", "PROTEIN", 186, 189], ["cellular receptor", "PROTEIN", 197, 214], ["DPP4", "PROTEIN", 215, 219], ["MERS-CoV", "SPECIES", 83, 91], ["mAbs", "OBSERVATION", 8, 12]]], ["Notably, some human mAbs have exhibited exceptionally potent neutralizing activity against MERS-CoV infection in vitro, whereas the evaluation of their efficacy in an effective animal infection model, like the marmoset MERS-CoV infection model, is yet to be performed.", [["infection", "DISEASE", 100, 109], ["infection", "DISEASE", 184, 193], ["infection", "DISEASE", 228, 237], ["human", "ORGANISM", 14, 19], ["mAbs", "GENE_OR_GENE_PRODUCT", 20, 24], ["MERS-CoV", "ORGANISM", 91, 99], ["marmoset", "ORGANISM", 210, 218], ["MERS-CoV", "ORGANISM", 219, 227], ["human mAbs", "PROTEIN", 14, 24], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["MERS-CoV", "SPECIES", 91, 99], ["marmoset MERS-CoV", "SPECIES", 210, 227], ["some human mAbs", "PROBLEM", 9, 24], ["MERS", "PROBLEM", 91, 95], ["CoV infection", "PROBLEM", 96, 109], ["the evaluation", "TEST", 128, 142], ["an effective animal infection model", "PROBLEM", 164, 199], ["the marmoset MERS", "PROBLEM", 206, 223], ["CoV infection model", "PROBLEM", 224, 243], ["infection", "OBSERVATION", 100, 109], ["infection", "OBSERVATION", 184, 193]]], ["Most mAbs recognize different epitopes on MERS-CoV RBD, suggesting that mAb cocktails may exhibit more potent anti-MERS activity based on additive and/or synergistic effects, also helping to prevent the occurrence of viral escape mutants.", [["mAbs", "GENE_OR_GENE_PRODUCT", 5, 9], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 42, 50], ["mAbs", "PROTEIN", 5, 9], ["epitopes", "PROTEIN", 30, 38], ["MERS-CoV RBD", "PROTEIN", 42, 54], ["MERS-CoV", "SPECIES", 42, 50], ["CoV RBD", "PROBLEM", 47, 54], ["mAb cocktails", "TREATMENT", 72, 85], ["viral escape mutants", "PROBLEM", 217, 237], ["viral escape", "OBSERVATION", 217, 229]]], ["We expect that recent advances in antibody engineering will foster the development of more effective and affordable therapeutic or prophylactic agents by improving effector functions, making antibody-drug conjugates, or generating small-sized and long-acting novel antibody constructs based on these human neutralizing mAbs.Conflict of interestThe authors declare no competing financial interest.", [["human", "ORGANISM", 300, 305], ["antibody constructs", "DNA", 265, 284], ["human neutralizing mAbs", "PROTEIN", 300, 323], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 300, 305], ["antibody engineering", "TREATMENT", 34, 54], ["prophylactic agents", "TREATMENT", 131, 150], ["antibody", "TEST", 191, 199], ["long-acting novel antibody constructs", "TREATMENT", 247, 284], ["these human neutralizing mAbs", "TREATMENT", 294, 323], ["small", "OBSERVATION_MODIFIER", 231, 236], ["sized", "OBSERVATION_MODIFIER", 237, 242]]]], "PMC7121445": [["IntroductionOne of the most common chief complaints in a primary care physician's office is sore throat.", [["sore throat", "DISEASE", 92, 103], ["throat", "ORGANISM_SUBDIVISION", 97, 103], ["sore throat", "PROBLEM", 92, 103], ["throat", "ANATOMY", 97, 103]]], ["Although a broad variety of differential diagnoses must be considered, ranging from infectious or inflammatory etiology to traumatic or neoplastic processes, the vast majority of these symptoms derive from either a viral or bacterial source.", [["neoplastic", "ANATOMY", 136, 146], ["traumatic or neoplastic processes", "PROBLEM", 123, 156], ["these symptoms", "PROBLEM", 179, 193], ["a viral or bacterial source", "PROBLEM", 213, 240], ["broad", "OBSERVATION_MODIFIER", 11, 16], ["infectious", "OBSERVATION_MODIFIER", 84, 94], ["inflammatory", "OBSERVATION_MODIFIER", 98, 110], ["traumatic", "OBSERVATION_MODIFIER", 123, 132], ["neoplastic", "OBSERVATION", 136, 146], ["viral", "OBSERVATION", 215, 220], ["bacterial", "OBSERVATION_MODIFIER", 224, 233]]], ["The physician must narrow the differential, decide which clinical and laboratory data may be helpful, select the most appropriate management plan for the patient's symptoms and disease process, and prevent further complications.", [["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["laboratory data", "TEST", 70, 85], ["the patient's symptoms", "PROBLEM", 150, 172], ["disease process", "PROBLEM", 177, 192], ["further complications", "PROBLEM", 206, 227]]], ["This chapter reviews the most common causes of pharyngitis, relevant available clinical information, appropriate laboratory tests, recommended treatment guidelines, possible complications, and general strategies for evaluating patients with acute pharyngitis.IntroductionIn the 1990s, more than 6.7 million visits with a primary complaint of sore throat were made by adults to physicians' offices, emergency departments, or other primary care providers in the Unites States.2 Currently, acute pharyngitis accounts for approximately 2% of all primary healthcare visits for adults and 6% for children annually (more than 10 million visits).7,10 Of these cases, approximately 30% are idiopathic, 30 to 60% have a viral etiology, and 5 to 15% are caused by bacteria.8 Of the possible bacterial sources, Group A \u03b2-hemolytic streptococci (GABHS) is the most frequently isolated pathogen, causing acute pharyngitis in 5 to 15% of adults and 15 to 36% of children in the USA.4,10 Although this chapter reviews the broad range of causes of pharyngitis, the emphasis is on the diagnosis and treatment of GABHS, because this is the only common cause of sore throat that warrants antibiotic treatment.IntroductionIn recent years, fear of GABHS infection and its possible complications, and growing expectation of antibiotic prescriptions by patients has resulted in overuse of antibiotics for treatment of acute pharyngitis.", [["pharyngitis", "DISEASE", 47, 58], ["pharyngitis", "DISEASE", 247, 258], ["sore throat", "DISEASE", 342, 353], ["pharyngitis", "DISEASE", 493, 504], ["idiopathic", "DISEASE", 681, 691], ["GABHS", "DISEASE", 833, 838], ["pharyngitis", "DISEASE", 896, 907], ["pharyngitis", "DISEASE", 1031, 1042], ["GABHS", "DISEASE", 1094, 1099], ["sore throat", "DISEASE", 1142, 1153], ["GABHS infection", "DISEASE", 1226, 1241], ["pharyngitis", "DISEASE", 1400, 1411], ["patients", "ORGANISM", 227, 235], ["children", "ORGANISM", 590, 598], ["Group A \u03b2-hemolytic streptococci", "GENE_OR_GENE_PRODUCT", 799, 831], ["children", "ORGANISM", 947, 955], ["patients", "ORGANISM", 1329, 1337], ["patients", "SPECIES", 227, 235], ["children", "SPECIES", 590, 598], ["children", "SPECIES", 947, 955], ["patients", "SPECIES", 1329, 1337], ["pharyngitis", "PROBLEM", 47, 58], ["appropriate laboratory tests", "TEST", 101, 129], ["treatment guidelines", "TREATMENT", 143, 163], ["complications", "PROBLEM", 174, 187], ["acute pharyngitis", "PROBLEM", 241, 258], ["sore throat", "PROBLEM", 342, 353], ["acute pharyngitis", "PROBLEM", 487, 504], ["these cases", "TEST", 646, 657], ["idiopathic", "PROBLEM", 681, 691], ["bacteria", "PROBLEM", 753, 761], ["bacterial sources", "PROBLEM", 780, 797], ["Group A \u03b2-hemolytic streptococci (GABHS", "PROBLEM", 799, 838], ["acute pharyngitis", "PROBLEM", 890, 907], ["pharyngitis", "PROBLEM", 1031, 1042], ["treatment", "TREATMENT", 1081, 1090], ["GABHS", "PROBLEM", 1094, 1099], ["sore throat", "PROBLEM", 1142, 1153], ["antibiotic treatment", "TREATMENT", 1168, 1188], ["GABHS infection", "PROBLEM", 1226, 1241], ["complications", "PROBLEM", 1259, 1272], ["antibiotic prescriptions", "TREATMENT", 1301, 1325], ["antibiotics", "TREATMENT", 1365, 1376], ["treatment", "TREATMENT", 1381, 1390], ["acute pharyngitis", "PROBLEM", 1394, 1411], ["pharyngitis", "OBSERVATION", 47, 58], ["acute", "OBSERVATION_MODIFIER", 241, 246], ["pharyngitis", "OBSERVATION", 247, 258], ["acute", "OBSERVATION_MODIFIER", 487, 492], ["pharyngitis", "OBSERVATION", 493, 504], ["idiopathic", "OBSERVATION_MODIFIER", 681, 691], ["bacteria", "OBSERVATION", 753, 761], ["possible", "UNCERTAINTY", 771, 779], ["bacterial sources", "OBSERVATION", 780, 797], ["most frequently", "OBSERVATION_MODIFIER", 847, 862], ["pathogen", "OBSERVATION", 872, 880], ["acute", "OBSERVATION_MODIFIER", 890, 895], ["pharyngitis", "OBSERVATION", 896, 907], ["pharyngitis", "OBSERVATION", 1031, 1042], ["GABHS infection", "OBSERVATION", 1226, 1241], ["acute", "OBSERVATION_MODIFIER", 1394, 1399], ["pharyngitis", "OBSERVATION", 1400, 1411]]], ["Reportedly, 50 to 75% of all cases of pharyngitis are currently treated with antibiotic therapy, approximately 40% of which use broad-spectrum antibiotics or antibiotics that are not indicated.7,10,14 Spurred by efforts from the Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA), recent guidelines have been established to decrease the frequency of unnecessary antibiotic use, and to concentrate instead on clinical protocol and appropriate laboratory evaluation.PathophysiologyPharyngitis is an inflammation of the pharynx that can lead to a sore throat.", [["pharynx", "ANATOMY", 565, 572], ["pharyngitis", "DISEASE", 38, 49], ["Infectious Diseases", "DISEASE", 282, 301], ["Pharyngitis", "DISEASE", 527, 538], ["inflammation of the pharynx", "DISEASE", 545, 572], ["sore throat", "DISEASE", 592, 603], ["pharynx", "ORGAN", 565, 572], ["pharyngitis", "PROBLEM", 38, 49], ["antibiotic therapy", "TREATMENT", 77, 95], ["broad-spectrum antibiotics", "TREATMENT", 128, 154], ["antibiotics", "TREATMENT", 158, 169], ["Disease Control", "TREATMENT", 241, 256], ["unnecessary antibiotic use", "TREATMENT", 398, 424], ["clinical protocol", "TREATMENT", 456, 473], ["appropriate laboratory evaluation", "TEST", 478, 511], ["PathophysiologyPharyngitis", "PROBLEM", 512, 538], ["an inflammation of the pharynx", "PROBLEM", 542, 572], ["a sore throat", "PROBLEM", 590, 603], ["pharyngitis", "OBSERVATION", 38, 49], ["Infectious", "OBSERVATION_MODIFIER", 282, 292], ["Pharyngitis", "OBSERVATION", 527, 538], ["inflammation", "OBSERVATION", 545, 557], ["pharynx", "ANATOMY", 565, 572], ["sore", "OBSERVATION", 592, 596]]], ["Etiologic agents are passed through person-to-person contact, most likely via droplets of nasal secretions or saliva.", [["nasal secretions", "ANATOMY", 90, 106], ["nasal secretions", "ORGANISM_SUBSTANCE", 90, 106], ["saliva", "ORGANISM_SUBSTANCE", 110, 116], ["person", "SPECIES", 36, 42], ["nasal secretions", "PROBLEM", 90, 106], ["saliva", "PROBLEM", 110, 116], ["most likely", "UNCERTAINTY", 62, 73], ["nasal", "ANATOMY", 90, 95], ["secretions", "OBSERVATION", 96, 106]]], ["Symptoms often manifest after an incubation period ranging from 1 to 5 days, and occur most commonly in the winter or early spring.", [["Symptoms", "PROBLEM", 0, 8]]], ["Outbreaks of pharyngitis may occur in households or classrooms, and, infrequently, may be linked to food or animal sources.PathophysiologyThe most common bacterial cause of pharyngitis, GABHS, is also known as Streptococcus pyogenes and may exist as single, paired, or chained gram-positive cocci.", [["pharyngitis", "DISEASE", 13, 24], ["pharyngitis", "DISEASE", 173, 184], ["GABHS", "DISEASE", 186, 191], ["Streptococcus pyogenes", "DISEASE", 210, 232], ["Streptococcus pyogenes", "ORGANISM", 210, 232], ["Streptococcus pyogenes", "SPECIES", 210, 232], ["Streptococcus pyogenes", "SPECIES", 210, 232], ["pharyngitis", "PROBLEM", 13, 24], ["pharyngitis", "PROBLEM", 173, 184], ["GABHS", "PROBLEM", 186, 191], ["Streptococcus pyogenes", "PROBLEM", 210, 232], ["chained gram-positive cocci", "PROBLEM", 269, 296], ["pharyngitis", "OBSERVATION", 13, 24], ["most common", "OBSERVATION_MODIFIER", 142, 153], ["pharyngitis", "OBSERVATION", 173, 184], ["GABHS", "OBSERVATION", 186, 191], ["Streptococcus pyogenes", "OBSERVATION", 210, 232], ["positive cocci", "OBSERVATION", 282, 296]]], ["These bacteria possess protein M, a potent virulence factor that inhibits bacterial phagocytosis, as well as a hyaluronic acid capsule that enhances its ability to invade tissues.", [["tissues", "ANATOMY", 171, 178], ["hyaluronic acid", "CHEMICAL", 111, 126], ["protein M", "GENE_OR_GENE_PRODUCT", 23, 32], ["hyaluronic acid", "SIMPLE_CHEMICAL", 111, 126], ["tissues", "TISSUE", 171, 178], ["protein M", "PROTEIN", 23, 32], ["virulence factor", "PROTEIN", 43, 59], ["These bacteria", "TEST", 0, 14], ["protein M", "PROBLEM", 23, 32], ["a potent virulence factor", "PROBLEM", 34, 59], ["bacterial phagocytosis", "PROBLEM", 74, 96], ["a hyaluronic acid capsule", "TREATMENT", 109, 134], ["bacterial phagocytosis", "OBSERVATION", 74, 96]]], ["Multiple exotoxins and two hemolysins (Streptolysin S and Streptolysin O) further enhance the virulence of GABHS.", [["GABHS", "DISEASE", 107, 112], ["Streptolysin O", "CHEMICAL", 58, 72], ["hemolysins", "GENE_OR_GENE_PRODUCT", 27, 37], ["Streptolysin S", "GENE_OR_GENE_PRODUCT", 39, 53], ["Streptolysin O", "SIMPLE_CHEMICAL", 58, 72], ["Multiple exotoxins", "PROBLEM", 0, 18], ["two hemolysins", "TEST", 23, 37], ["Streptolysin S", "TREATMENT", 39, 53], ["GABHS", "PROBLEM", 107, 112], ["exotoxins", "OBSERVATION", 9, 18], ["GABHS", "OBSERVATION", 107, 112]]], ["Cocci may be detected on cultures (grown on blood agar), latex agglutination tests, or rapid tests using labeled monoclonal antibodies.PathophysiologyThe viruses and other nonstreptococcal bacteria that also can cause pharyngitis are discussed in greater detail below, in the \u201cDifferential Diagnosis\u201d section.History ::: Clinical PresentationPharyngitis can present with sudden onset of sore throat, fever, headache, tender anterior cervical lymphadenopathy or lymphadenitis, and, occasionally, abdominal pain, nausea, vomiting, fatigue, or rash.", [["cultures", "ANATOMY", 25, 33], ["blood", "ANATOMY", 44, 49], ["cervical", "ANATOMY", 433, 441], ["abdominal", "ANATOMY", 495, 504], ["pharyngitis", "DISEASE", 218, 229], ["Pharyngitis", "DISEASE", 342, 353], ["sore throat", "DISEASE", 387, 398], ["fever", "DISEASE", 400, 405], ["headache", "DISEASE", 407, 415], ["anterior cervical lymphadenopathy", "DISEASE", 424, 457], ["lymphadenitis", "DISEASE", 461, 474], ["abdominal pain", "DISEASE", 495, 509], ["nausea", "DISEASE", 511, 517], ["vomiting", "DISEASE", 519, 527], ["fatigue", "DISEASE", 529, 536], ["rash", "DISEASE", 541, 545], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["abdominal", "ORGANISM_SUBDIVISION", 495, 504], ["labeled monoclonal antibodies", "PROTEIN", 105, 134], ["Cocci", "PROBLEM", 0, 5], ["cultures", "TEST", 25, 33], ["blood agar", "TEST", 44, 54], ["latex agglutination tests", "TEST", 57, 82], ["rapid tests", "TEST", 87, 98], ["labeled monoclonal antibodies", "TEST", 105, 134], ["The viruses", "PROBLEM", 150, 161], ["other nonstreptococcal bacteria", "PROBLEM", 166, 197], ["pharyngitis", "PROBLEM", 218, 229], ["Pharyngitis", "PROBLEM", 342, 353], ["sore throat", "PROBLEM", 387, 398], ["fever", "PROBLEM", 400, 405], ["headache", "PROBLEM", 407, 415], ["tender anterior cervical lymphadenopathy", "PROBLEM", 417, 457], ["lymphadenitis", "PROBLEM", 461, 474], ["abdominal pain", "PROBLEM", 495, 509], ["nausea", "PROBLEM", 511, 517], ["vomiting", "PROBLEM", 519, 527], ["fatigue", "PROBLEM", 529, 536], ["rash", "PROBLEM", 541, 545], ["viruses", "OBSERVATION", 154, 161], ["pharyngitis", "OBSERVATION", 218, 229], ["sore throat", "ANATOMY", 387, 398], ["tender", "OBSERVATION_MODIFIER", 417, 423], ["anterior", "ANATOMY_MODIFIER", 424, 432], ["cervical", "ANATOMY", 433, 441], ["lymphadenopathy", "OBSERVATION", 442, 457], ["lymphadenitis", "OBSERVATION", 461, 474], ["abdominal", "ANATOMY", 495, 504], ["pain", "OBSERVATION", 505, 509]]], ["When GABHS is the etiologic agent, fevers are often > 38.5 \u00b0C (101.3 \u00b0F), tonsillar exudates are common, and patients may experience fevers, chills, and myalgias.8 Children may sometimes present with atypical symptoms such as abdominal pain and emesis, regardless of the cause of their pharyngitis.Physical Exam ::: Clinical PresentationOn examination, the typical findings of acute pharyngitis may include an erythematous and swollen pharynx, tonsillar hypertrophy and inflammation (with or without tonsillar exudates), fever, edematous uvula, petechial rash along the palate, and tender anterior cervical lymphadenopathy.", [["tonsillar exudates", "ANATOMY", 74, 92], ["abdominal", "ANATOMY", 226, 235], ["erythematous", "ANATOMY", 410, 422], ["pharynx", "ANATOMY", 435, 442], ["tonsillar", "ANATOMY", 444, 453], ["tonsillar exudates", "ANATOMY", 500, 518], ["edematous uvula", "ANATOMY", 528, 543], ["petechial", "ANATOMY", 545, 554], ["palate", "ANATOMY", 570, 576], ["cervical", "ANATOMY", 598, 606], ["GABHS", "DISEASE", 5, 10], ["fevers", "DISEASE", 35, 41], ["tonsillar exudates", "DISEASE", 74, 92], ["fevers", "DISEASE", 133, 139], ["chills", "DISEASE", 141, 147], ["myalgias", "DISEASE", 153, 161], ["abdominal pain", "DISEASE", 226, 240], ["emesis", "DISEASE", 245, 251], ["pharyngitis", "DISEASE", 286, 297], ["pharyngitis", "DISEASE", 383, 394], ["tonsillar hypertrophy", "DISEASE", 444, 465], ["inflammation", "DISEASE", 470, 482], ["tonsillar exudates", "DISEASE", 500, 518], ["fever", "DISEASE", 521, 526], ["edematous uvula", "DISEASE", 528, 543], ["rash along the palate", "DISEASE", 555, 576], ["cervical lymphadenopathy", "DISEASE", 598, 622], ["tonsillar exudates", "PATHOLOGICAL_FORMATION", 74, 92], ["patients", "ORGANISM", 109, 117], ["Children", "ORGANISM", 164, 172], ["abdominal", "ORGANISM_SUBDIVISION", 226, 235], ["pharynx", "ORGAN", 435, 442], ["tonsillar", "ORGAN", 444, 453], ["tonsillar exudates", "MULTI-TISSUE_STRUCTURE", 500, 518], ["uvula", "ORGAN", 538, 543], ["palate", "ORGAN", 570, 576], ["patients", "SPECIES", 109, 117], ["Children", "SPECIES", 164, 172], ["GABHS", "PROBLEM", 5, 10], ["fevers", "PROBLEM", 35, 41], ["tonsillar exudates", "PROBLEM", 74, 92], ["fevers", "PROBLEM", 133, 139], ["chills", "PROBLEM", 141, 147], ["myalgias", "PROBLEM", 153, 161], ["atypical symptoms", "PROBLEM", 200, 217], ["abdominal pain", "PROBLEM", 226, 240], ["emesis", "PROBLEM", 245, 251], ["their pharyngitis", "PROBLEM", 280, 297], ["Clinical PresentationOn examination", "TEST", 316, 351], ["acute pharyngitis", "PROBLEM", 377, 394], ["an erythematous and swollen pharynx", "PROBLEM", 407, 442], ["tonsillar hypertrophy", "PROBLEM", 444, 465], ["inflammation", "PROBLEM", 470, 482], ["tonsillar exudates", "PROBLEM", 500, 518], ["fever", "PROBLEM", 521, 526], ["edematous uvula", "PROBLEM", 528, 543], ["petechial rash along the palate", "PROBLEM", 545, 576], ["tender anterior cervical lymphadenopathy", "PROBLEM", 582, 622], ["tonsillar", "ANATOMY", 74, 83], ["exudates", "OBSERVATION", 84, 92], ["abdominal", "ANATOMY", 226, 235], ["pharyngitis", "OBSERVATION", 286, 297], ["acute", "OBSERVATION_MODIFIER", 377, 382], ["pharyngitis", "OBSERVATION", 383, 394], ["erythematous", "OBSERVATION", 410, 422], ["swollen", "OBSERVATION_MODIFIER", 427, 434], ["pharynx", "ANATOMY", 435, 442], ["tonsillar", "ANATOMY", 444, 453], ["hypertrophy", "OBSERVATION", 454, 465], ["inflammation", "OBSERVATION", 470, 482], ["without", "UNCERTAINTY", 492, 499], ["tonsillar", "ANATOMY", 500, 509], ["exudates", "OBSERVATION", 510, 518], ["fever", "OBSERVATION_MODIFIER", 521, 526], ["edematous", "OBSERVATION_MODIFIER", 528, 537], ["uvula", "ANATOMY", 538, 543], ["petechial", "OBSERVATION_MODIFIER", 545, 554], ["rash", "OBSERVATION", 555, 559], ["palate", "ANATOMY", 570, 576], ["tender", "OBSERVATION_MODIFIER", 582, 588], ["anterior", "ANATOMY_MODIFIER", 589, 597], ["cervical", "ANATOMY", 598, 606], ["lymphadenopathy", "OBSERVATION", 607, 622]]], ["Occasionally, a scarlatiniform rash may be present, often seen in association with a GABHS infection.Clinical Guidelines ::: Clinical PresentationGiven the above historical and physical findings, a number of clinical tools have been established to help determine whether GABHS is the likely causative pathogen.", [["rash", "DISEASE", 31, 35], ["GABHS infection", "DISEASE", 85, 100], ["GABHS", "DISEASE", 271, 276], ["a scarlatiniform rash", "PROBLEM", 14, 35], ["a GABHS infection", "PROBLEM", 83, 100], ["GABHS", "PROBLEM", 271, 276], ["causative pathogen", "PROBLEM", 291, 309], ["scarlatiniform", "OBSERVATION_MODIFIER", 16, 30], ["rash", "OBSERVATION", 31, 35], ["GABHS", "OBSERVATION", 85, 90]]], ["The most widely accepted of these tools is the Centor Clinical Prediction Rules for the diagnosis of GABHS in adults, which uses the presence (or absence) of four main criteria (see Table 2.1).4,12", [["GABHS", "DISEASE", 101, 106], ["4,12", "CHEMICAL", 193, 197], ["GABHS", "PROBLEM", 101, 106], ["most widely", "OBSERVATION_MODIFIER", 4, 15], ["GABHS", "OBSERVATION", 101, 106]]]], "1cf8303b7c30df31ae713dd76f45c0f17be40a2f": [["During infection outbreak in crisis like the COVID-19 pandemic, diagnostics are a crucial step to manage 2 the rate of infection, especially when clinical symptoms are difficult to distinguish from other respiratory 3 infections such as influenza.", [["infection", "DISEASE", 7, 16], ["infection", "DISEASE", 119, 128], ["respiratory 3 infections", "DISEASE", 204, 228], ["influenza", "DISEASE", 237, 246], ["infection outbreak in crisis", "PROBLEM", 7, 35], ["the COVID", "TEST", 41, 50], ["a crucial step", "TREATMENT", 80, 94], ["infection", "PROBLEM", 119, 128], ["clinical symptoms", "PROBLEM", 146, 163], ["other respiratory 3 infections", "PROBLEM", 198, 228], ["influenza", "PROBLEM", 237, 246], ["infection", "OBSERVATION", 7, 16], ["infection", "OBSERVATION", 119, 128], ["infections", "OBSERVATION", 218, 228]]], ["Public health measures decisions, such as a patient and contact tracing 4 requiring further quarantine and surveillance are intimately related to whether a suspected case has 5 been confirmed.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["contact tracing", "TEST", 56, 71], ["further quarantine", "TREATMENT", 84, 102], ["surveillance", "TREATMENT", 107, 119]]], ["Therefore, speed and accuracy of such tests are paramount, thus the development and 6 application of sensitive and reliable diagnostic tests are critical.", [["such tests", "TEST", 33, 43], ["reliable diagnostic tests", "TEST", 115, 140]]]], "d6f1e328c18e848995059090544eb89c96756c39": [["IntroductionThe current pandemics of COVID-19 disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone an accentuated exponential increase of cases all over the world.", [["COVID-19 disease", "DISEASE", 37, 53], ["acute respiratory syndrome coronavirus", "DISEASE", 75, 113], ["COVID-19", "ORGANISM", 37, 45], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 68, 115], ["SARS-CoV-2", "ORGANISM", 117, 127], ["COVID-19", "SPECIES", 37, 45], ["severe acute respiratory syndrome coronavirus", "SPECIES", 68, 113], ["SARS-CoV-2", "SPECIES", 117, 127], ["COVID-19 disease", "PROBLEM", 37, 53], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 64, 113], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory syndrome", "OBSERVATION", 81, 101], ["accentuated", "OBSERVATION_MODIFIER", 146, 157], ["exponential", "OBSERVATION_MODIFIER", 158, 169], ["increase", "OBSERVATION_MODIFIER", 170, 178]]], ["As in other transmissible diseases, the infected with SARS-CoV-2 may have in the incubation period mild forms or even no symptoms such that they can be not aware of the fact that are carrying the virus.", [["transmissible diseases", "DISEASE", 12, 34], ["SARS", "DISEASE", 54, 58], ["SARS-CoV-2", "ORGANISM", 54, 64], ["SARS-CoV", "SPECIES", 54, 62], ["other transmissible diseases", "PROBLEM", 6, 34], ["SARS", "PROBLEM", 54, 58], ["symptoms", "PROBLEM", 121, 129], ["the virus", "PROBLEM", 192, 201], ["infected", "OBSERVATION_MODIFIER", 40, 48]]], ["But, the particular and the worst aspect of COVID-19 disease is that the exposed, called here asymptomatic, are highly contagious and can transmit the disease (see [5] ).", [["COVID-19", "CANCER", 44, 52], ["COVID-19 disease", "PROBLEM", 44, 60], ["asymptomatic", "PROBLEM", 94, 106]]], ["Hence, the early identification of individuals infected with SARS-CoV-2 and the necessity of isolation of the people found infected is crucial for reducing the virus spread.", [["SARS", "DISEASE", 61, 65], ["individuals", "ORGANISM", 35, 46], ["SARS-CoV-2", "ORGANISM", 61, 71], ["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116], ["SARS-CoV", "SPECIES", 61, 69], ["individuals infected", "PROBLEM", 35, 55], ["SARS", "PROBLEM", 61, 65], ["CoV", "TEST", 66, 69], ["isolation", "TREATMENT", 93, 102], ["infected", "PROBLEM", 123, 131], ["the virus spread", "PROBLEM", 156, 172], ["infected", "OBSERVATION", 123, 131], ["virus", "OBSERVATION", 160, 165]]], ["Mathematical modeling can help to estimate some relevant parameters of this epidemic, which can allow the prediction of the disease evolution and the preparation of the necessary measures for the disease containment.IntroductionThe study of various aspects of the SARS-CoV-2 has led to an extremely rich article production since the debut of the pandemics.", [["SARS", "DISEASE", 264, 268], ["SARS-CoV-2", "ORGANISM", 264, 274], ["the disease evolution", "PROBLEM", 120, 141], ["the necessary measures", "TREATMENT", 165, 187], ["the disease containment", "TREATMENT", 192, 215], ["The study", "TEST", 228, 237], ["the SARS", "TEST", 260, 268], ["the pandemics", "PROBLEM", 342, 355], ["disease", "OBSERVATION", 124, 131]]], ["Mathematical modelling of various aspects of the disease has been addressed as well.", [["the disease", "PROBLEM", 45, 56], ["various", "OBSERVATION_MODIFIER", 26, 33], ["disease", "OBSERVATION", 49, 56]]], ["Many of them are based on the SIR model which describes the transmission of the disease through three stages of infection, susceptible, infected and recovered.", [["infection", "DISEASE", 112, 121], ["the disease", "PROBLEM", 76, 87], ["infection", "PROBLEM", 112, 121], ["disease", "OBSERVATION", 80, 87], ["three stages", "OBSERVATION_MODIFIER", 96, 108], ["infection", "OBSERVATION", 112, 121], ["susceptible", "OBSERVATION_MODIFIER", 123, 134], ["infected", "OBSERVATION_MODIFIER", 136, 144]]], ["However, taking into account the previous considerations, the SIR model cannot adequately characterize the COVID-19 disease.", [["the COVID-19 disease", "PROBLEM", 103, 123]]], ["Several more complex models have been also considered to illustrate the spread of this disease.", [["this disease", "PROBLEM", 82, 94], ["more complex", "OBSERVATION_MODIFIER", 8, 20], ["spread", "OBSERVATION_MODIFIER", 72, 78], ["disease", "OBSERVATION", 87, 94]]], ["We cite here a few studies: a SEIR (susceptible, exposed, infectious, removed) model considering risk perception and the cumulative number of cases has been developed in [9] ; a discrete-time SIR model including dead individuals was proposed in [1] , a control-oriented SIR model that puts into evidence the effects of delays and compares the outcomes of different containment policies was discussed in [6] .", [["dead individuals", "PROBLEM", 212, 228], ["infectious", "OBSERVATION", 58, 68]]], ["In [13] a mathematical method was developed to deduce the evolution over time of the new coronavirus infection and to establish the effect of isolation strategies from the accumulated data, such as the number of deaths and hospitalizations.", [["coronavirus infection", "DISEASE", 89, 110], ["deaths", "DISEASE", 212, 218], ["coronavirus", "ORGANISM", 89, 100], ["a mathematical method", "TEST", 8, 29], ["the new coronavirus infection", "PROBLEM", 81, 110], ["isolation strategies", "TREATMENT", 142, 162], ["new", "OBSERVATION_MODIFIER", 85, 88], ["coronavirus", "OBSERVATION_MODIFIER", 89, 100], ["infection", "OBSERVATION", 101, 110]]], ["This model, called SIDARTHE, involves many compartments, such as: susceptible, non-life-threatening cases, asymptomatic with minor and moderate infection, symptomatic, for each of them being separate classes of detected and undetected individuals, symptomatic with a severe situation, dead and recovered.", [["infection", "DISEASE", 144, 153], ["asymptomatic", "PROBLEM", 107, 119], ["minor and moderate infection", "PROBLEM", 125, 153], ["a severe situation", "PROBLEM", 265, 283], ["moderate", "OBSERVATION_MODIFIER", 135, 143], ["infection", "OBSERVATION", 144, 153], ["symptomatic", "OBSERVATION_MODIFIER", 155, 166]]], ["The model omits the probability rate of becoming susceptible again after having recovered from the infection.", [["infection", "DISEASE", 99, 108], ["the infection", "PROBLEM", 95, 108], ["infection", "OBSERVATION", 99, 108]]], ["The computations were based on data measured in Italy between the beginning of the outbreak and early April and were updated over time to reflect the progressive introduction of increased restrictions.IntroductionIn this paper we introduce a mathematical model for SARS-CoV-2 epidemic, involving five compartments considered to be essential to depict the feature of the epidemic.", [["SARS", "DISEASE", 265, 269], ["SARS-CoV", "SPECIES", 265, 273], ["increased restrictions", "TREATMENT", 178, 200], ["SARS", "PROBLEM", 265, 269], ["CoV", "TEST", 270, 273], ["progressive", "OBSERVATION_MODIFIER", 150, 161], ["increased", "OBSERVATION_MODIFIER", 178, 187], ["epidemic", "OBSERVATION", 370, 378]]], ["A first goal is to approach by an optimal control technique the identification of some parameters such as the average number of individuals infected in unit time by an infected symptomatic and the number of asymptomatic and symptomatic individuals still undetected at a moment of time.", [["an infected symptomatic", "PROBLEM", 165, 188], ["asymptomatic and symptomatic individuals", "PROBLEM", 207, 247], ["infected", "OBSERVATION_MODIFIER", 168, 176], ["symptomatic", "OBSERVATION", 177, 188]]], ["These parameters can be further used to calculate the reproduction rate and are relevant for predicting the evolution of the epidemic and for planning effective control policies.", [["planning effective control policies", "TREATMENT", 142, 177]]], ["These justifies the second objective in the paper which refers to the control of classes A and I, by finding optimal control coefficients related to actions as screening, testing, tracing, which may lead to the reduction of the infected population by moving it into the isolated compartment L.Mathematical modelWe introduce a mathematical model of SEIR type with five compartments, represented at time t by: susceptible S(t) (a healthy individual which can acquire the disease), infected asymptomatic A(t) (individuals who have acquired the disease, have no symptoms or only mild ones and have been not tested yet), infected with symptoms but not confirmed yet I(t), detected by tests and isolated (by hospitalization, quarantine, isolation) L(t) and recovered R(t).", [["screening", "TEST", 160, 169], ["testing", "TEST", 171, 178], ["tracing", "TEST", 180, 187], ["the infected population", "PROBLEM", 224, 247], ["the disease)", "PROBLEM", 465, 477], ["the disease", "PROBLEM", 537, 548], ["symptoms", "PROBLEM", 558, 566], ["mild ones", "PROBLEM", 575, 584], ["symptoms", "PROBLEM", 630, 638], ["infected", "OBSERVATION", 228, 236]]], ["As said before, the individuals in the infected classes A and I, meaning those not tested yet, and whose number is not known, can be in circulation and infect other people.", [["people", "ORGANISM", 165, 171], ["people", "SPECIES", 165, 171], ["infected", "OBSERVATION", 39, 47]]], ["The people tested and found infectious are supposed to be removed from circulation until healing and introduced in the class L. Since the identification of the parameters we propose here is considered to be performed on short intervals of time, we skip in this model the extinct (from any reason) and the newborns, because their number is negligible compared with the large number of people in the relevant compartments for this disease.", [["people", "ORGANISM", 4, 10], ["newborns", "ORGANISM", 305, 313], ["people", "ORGANISM", 384, 390], ["people", "SPECIES", 4, 10], ["people", "SPECIES", 384, 390], ["infectious", "PROBLEM", 28, 38], ["this disease", "PROBLEM", 424, 436], ["infectious", "OBSERVATION", 28, 38], ["circulation", "OBSERVATION_MODIFIER", 71, 82]]], ["Thus, we assume that both A and I are infectious and so the susceptible can be infected by the infective with symptoms with the rate \u03b2 I (t), as well as by the infective asymptomatic with a rate \u03b2 A (t).", [["A", "GENE_OR_GENE_PRODUCT", 26, 27], ["infectious", "PROBLEM", 38, 48], ["the infective with symptoms", "PROBLEM", 91, 118], ["infectious", "OBSERVATION", 38, 48], ["infective", "OBSERVATION_MODIFIER", 95, 104]]], ["We also assume that the infective A and I detected by various actions are quickly isolated, in order to help the disease containment.", [["the infective A", "PROBLEM", 20, 35], ["infective", "OBSERVATION", 24, 33], ["disease", "OBSERVATION", 113, 120]]], ["Then, the individuals A have three possibilities: can become symptomatic with the rate \u03c3, can be detected by testing and isolated with the rate l A or can recover with the rate \u00b5 A .", [["symptomatic", "PROBLEM", 61, 72]]], ["At their turn, the infected symptomatic can be detected by testing and isolated with the rate l I and can recover with the rate \u00b5 I .", [["the infected symptomatic", "PROBLEM", 15, 39], ["testing", "TEST", 59, 66], ["infected", "OBSERVATION_MODIFIER", 19, 27], ["symptomatic", "OBSERVATION", 28, 39]]], ["Of course, the model can be completed with other classes of population but in this paper we keep only this formulation.", [["this formulation", "TREATMENT", 102, 118]]], ["For the SIR model the form of the normalized system is described in the monograph [11] .", [["normalized", "OBSERVATION", 34, 44]]], ["There, \u03b2 I stands for the average number of individuals infected in unit time by an infective symptomatic.", [["\u03b2 I", "GENE_OR_GENE_PRODUCT", 7, 10], ["\u03b2 I", "PROTEIN", 7, 10], ["an infective symptomatic", "PROBLEM", 81, 105], ["infected", "OBSERVATION", 56, 64], ["infective", "OBSERVATION_MODIFIER", 84, 93], ["symptomatic", "OBSERVATION", 94, 105]]], ["This is given by the number of contacts an infective I has in the time unit, multiplied by the probability that a contact produces an infective, when one of the two individuals is susceptible and the other is infective symptomatic.", [["an infective", "PROBLEM", 131, 143], ["infective symptomatic", "PROBLEM", 209, 230], ["infective", "OBSERVATION", 43, 52], ["infective", "OBSERVATION", 134, 143], ["infective", "OBSERVATION", 209, 218]]], ["Thus, we can analogously characterize \u03b2 A as being the average number of individuals infected in unit time by an infective asymptomatic.", [["\u03b2 A", "GENE_OR_GENE_PRODUCT", 38, 41], ["\u03b2 A", "PROTEIN", 38, 41], ["an infective asymptomatic", "PROBLEM", 110, 135], ["infective", "OBSERVATION", 113, 122]]], ["The rates \u03b2 I , \u03b2 A and \u03be can vary in time.", [["\u03b2 I", "GENE_OR_GENE_PRODUCT", 10, 13], ["\u03b2 A", "GENE_OR_GENE_PRODUCT", 16, 19], ["\u03b2 I", "PROTEIN", 10, 13], ["\u03b2 A", "PROTEIN", 16, 19]]], ["For example, \u03be can be zero for some time and then begin to increase, and \u03b2 I and \u03b2 A may have a periodic increasing-decreasing behavior due to the particularities of the transmission, the medical or social measures that are imposed or the variation of the virus virulence.", [["\u03be", "GENE_OR_GENE_PRODUCT", 13, 14], ["\u03b2 I", "GENE_OR_GENE_PRODUCT", 73, 76], ["\u03b2 A", "GENE_OR_GENE_PRODUCT", 81, 84], ["\u03b2 I", "PROTEIN", 73, 76], ["\u03b2 A", "PROTEIN", 81, 84], ["a periodic increasing-decreasing behavior", "PROBLEM", 94, 135], ["the virus virulence", "PROBLEM", 252, 271]]], ["The removal rates \u00b5 I , \u00b5 A and also \u00b5 L are considered constant because they generally depend on the interaction between the pathogen agents and the immune system of an infected individual (see e.g. [11] ).", [["immune system", "ANATOMY", 150, 163], ["The removal rates", "TEST", 0, 17], ["the pathogen agents", "TREATMENT", 122, 141], ["infected", "OBSERVATION", 170, 178]]], ["The parameters \u03c4 I = 1/\u00b5 I , \u03c4 A = 1/\u00b5 A and \u03c4 L = 1/\u00b5 L are the average durations of the infection for an infective I, an infective A (which may follow a treatment or not) and an infective isolated L, respectively.", [["infection", "DISEASE", 90, 99], ["The parameters", "TEST", 0, 14], ["I", "TEST", 17, 18], ["A", "TEST", 39, 40], ["the infection", "PROBLEM", 86, 99], ["an infective I", "PROBLEM", 104, 118], ["an infective A", "PROBLEM", 120, 134], ["a treatment", "TREATMENT", 153, 164], ["an infective isolated L", "PROBLEM", 177, 200], ["infection", "OBSERVATION", 90, 99], ["infective", "OBSERVATION", 107, 116], ["infective", "OBSERVATION", 123, 132], ["infective", "OBSERVATION", 180, 189]]], ["The last one is supposed to receive a treatment.Mathematical modelThe rates l A and l I are related to the probability rate of detection, relative to asymptomatic and symptomatic cases, respectively.", [["a treatment", "TREATMENT", 36, 47]]], ["They may reflect for instance the number of tests performed over the population and they can be modified by enforcing sustained actions, as for example a massive testing campaign (see [12] ).", [["tests", "TEST", 44, 49], ["may reflect for", "UNCERTAINTY", 5, 20]]], ["The value l I may be larger than l A , because a symptomatic individual is more likely to be tested.", [["The value l I", "TEST", 0, 13], ["a symptomatic individual", "PROBLEM", 47, 71], ["may be", "UNCERTAINTY", 14, 20], ["larger", "OBSERVATION", 21, 27]]], ["We assume that l I and l A are constant.Mathematical modelThe values of the model parameters are used to compute the expression of the reproduction rate, denoted in this paper by R 0 , which represents the average number of secondary cases produced by one infected individual introduced into a population of susceptible individuals.", [["l I", "GENE_OR_GENE_PRODUCT", 15, 18], ["l A", "GENE_OR_GENE_PRODUCT", 23, 26], ["the reproduction rate", "TEST", 131, 152], ["susceptible individuals", "PROBLEM", 308, 331], ["l I", "OBSERVATION_MODIFIER", 15, 18], ["l", "ANATOMY_MODIFIER", 23, 24], ["constant", "OBSERVATION_MODIFIER", 31, 39], ["infected", "OBSERVATION", 256, 264]]], ["This is the crucial indicator in a transmissible disease.", [["a transmissible disease", "PROBLEM", 33, 56], ["transmissible disease", "OBSERVATION", 35, 56]]], ["Detailed approaches of the determination of the reproduction rate in particular models are found in the literature, see e.g., [11] , [7] and in the references indicated there.Mathematical modelThus, the mathematical model we propose here isMathematical model2)Mathematical modelfor a.a. t > 0, with the initial conditionsMathematical modelThe model is given here in a normalized form, that is the real number of individuals at time t in each class is divided to the total population N (t).Mathematical modelThe sum of the individuals in all compartments gives the total population N (t) at time t.", [["the reproduction rate", "TEST", 44, 65]]], ["By (1.1)-(1.5) we observe thatMathematical modelwhere the constant N is exactly the total population which, in this model, remains unchanged at all t.", [["unchanged", "OBSERVATION_MODIFIER", 131, 140]]], ["It is clear that if each term in these sums is nonnegative (as representing a fraction of population), then it is bounded by N. Moreover, since we work with fractions of population, N defined before equals 1.", [["clear", "OBSERVATION", 6, 11]]], ["We assume the following conditions for the coefficients of the system:Mathematical model\u03c3, \u00b5 A , \u00b5 I , \u00b5 L , l A , l I \u2265 0, and denoteMathematical modelAt the end, we make a few comments on some different interpretations of the model, according to some possible modifications of the coefficients.", [["Mathematical model\u03c3", "TEST", 70, 89], ["denoteMathematical model", "TREATMENT", 128, 152]]], ["Thus, if setting \u03be = 0, and interpreting \u00b5 A , \u00b5 I and \u00b5 L as the mortality of the individuals in the classes A, I, L, respectively, it follows that the class R turns out to correspond to the extinct population.Mathematical modelIf l A = l I = \u00b5 L = 0 the class of isolated individuals disappear and so all asymptomatic and symptomatic remain in circulation.", [["class R", "GENE_OR_GENE_PRODUCT", 153, 160], ["isolated individuals", "PROBLEM", 265, 285], ["symptomatic", "PROBLEM", 324, 335], ["symptomatic", "OBSERVATION_MODIFIER", 324, 335]]], ["Thus, the class L is relevant as a control class for the disease containment.", [["the disease containment", "PROBLEM", 53, 76]]], ["A larger isolation action can be modeled by larger coefficients l A and l I .Problem statementWe assume that two sets of measured values of the isolated and recovered people, at a time t = 0 and at a successive time t = T , are available.", [["people", "ORGANISM", 167, 173], ["people", "SPECIES", 167, 173], ["A larger isolation action", "TREATMENT", 0, 25], ["larger", "OBSERVATION_MODIFIER", 2, 8], ["isolation", "OBSERVATION", 9, 18]]], ["As specified before, the number of undetected infected and of the susceptible at these times is not known, so that a first objective is to estimate A 0 , I 0 , S 0 .", [["infected", "OBSERVATION", 46, 54]]], ["As far as the parameters \u03c3, \u00b5 A , \u00b5 I , \u00b5 L , l A , l I , \u03be can be estimated by observations, a direct estimate of the rates \u03b2 I and \u03b2 A is less obvious.", [["\u03b2 I", "GENE_OR_GENE_PRODUCT", 125, 128], ["\u03b2 A", "GENE_OR_GENE_PRODUCT", 133, 136], ["\u03c3", "PROTEIN", 25, 26], ["\u03b2 I", "PROTEIN", 125, 128], ["\u03b2 A", "PROTEIN", 133, 136], ["the parameters", "TEST", 10, 24], ["the rates", "TEST", 115, 124], ["l", "ANATOMY_MODIFIER", 46, 47]]], ["All these justify a study developed in the present paper, of identifying the rate \u03b2 I (t) and the number of the undetected infectious individuals A 0 , I 0 , relying on these available observations for the isolated and recovered people at times 0 and T. Simultaneously, the number of susceptible S 0 is identified, too, because relation (1.7) impliesProblem statement.", [["people", "ORGANISM", 229, 235], ["people", "SPECIES", 229, 235], ["a study", "TEST", 18, 25], ["infectious", "OBSERVATION", 123, 133]]], ["Thus, it is sufficient to identify only A 0 and I 0 .Problem statementOnce the information about the size of the populations A, I and S is available at time 0, a prediction about their values at a further time t can be done.Problem statementThe second objective is to control within a successive time interval the action of isolating more infected individuals by means of the controllers l A and l I .", [["infected", "OBSERVATION", 339, 347]]], ["More precisely, the target is to reduce the number of infected A and I by various actions which can lead to the isolation of those confirmed, by removing them from circulation and transferring in L. This action is supposed however to be led such that L should not exceed an upper bound L.Problem statementThese proposed objectives will be expressed by two minimization problems.", [["infected", "OBSERVATION", 54, 62]]], ["We introduce the cost functionalProblem statementand the minimization problem (P 0 ) below Minimize {J(\u03b2 I , A 0 , I 0 ); \u03b2 I (t) \u2265 0 a.e. t \u2208 (0, T ),Problem statementHere, \u03b1 0 , \u03b1 1 are positive constants which may give a larger or smaller weight to the terms they multiply.", [["\u03b1 0", "GENE_OR_GENE_PRODUCT", 174, 177], ["\u03b1 1", "GENE_OR_GENE_PRODUCT", 180, 183], ["\u03b1 1", "PROTEIN", 180, 183], ["the cost functionalProblem", "TREATMENT", 13, 39], ["the minimization problem", "TREATMENT", 53, 77], ["Minimize", "TEST", 91, 99], ["t", "TEST", 139, 140], ["\u2208", "TEST", 141, 142], ["positive constants", "PROBLEM", 188, 206], ["positive", "OBSERVATION", 188, 196]]], ["For the second objective we introduce the cost functionalProblem statementand formulate the optimal control problem Minimize J (l A , l I ); l A \u2208 [0, 1], l I \u2208 [0, 1], 0 \u2264 L(t) \u2264 L (P ) subject to (1.1)-(1.6), (1.7), where L is a fixed constant, L > L 0 .", [["the cost functionalProblem statementand", "TREATMENT", 38, 77], ["subject", "TEST", 187, 194], ["L", "TEST", 224, 225], ["L", "ANATOMY_MODIFIER", 247, 248]]], ["The upper bound L for L is justified by the fact that we try to catch in the class L as much as possible individuals from the classes A and I, but not the total population.", [["upper", "ANATOMY_MODIFIER", 4, 9]]], ["The aim is to detect, by enforcing the testing, at least a part of the population A 0 + I 0 in order to isolate it.", [["the testing", "TEST", 35, 46]]], ["We note that (P ) is an optimal control problem with the state constraint L(t) \u2208 [0, L] which will require a more elaborated treatment.", [["a more elaborated treatment", "TREATMENT", 107, 134]]], ["In fact, for such a problem, the maximum principle (the first order conditions of optimality) lead to a singular dual backward system.", [["a singular dual backward system", "TREATMENT", 102, 133]]], ["Problem (P 0 ) is much simpler, as we shall see, and this entitles us to begin our study by approaching first problem (P ) and dealing after then with problem (P 0 ).", [["our study", "TEST", 79, 88]]], ["Thus, we start to solve (P ) by assuming that the values of A, I, S at the time T are calculated after solving (P 0 ) and they become the known A 0 , I 0 , S 0 by resetting the time at 0.Problem statementWe approach problem (P ) by an optimal control technique.", [["an optimal control technique", "TREATMENT", 232, 260]]], ["In Section 2, after proving the existence and uniqueness of the solution to the state system (1.1)-(1.6), we show that there exists at least a solution (l * A , l * I ) to problem (P ) in Proposition 2.2.", [["the state system", "TEST", 76, 92]]], ["The convergence of a sequence of solutions to (P \u03b5 ) precisely to a certain chosen solution to (P ) is proved in Proposition 2.4 and the approximating optimality conditions are provided in Proposition 2.5.", [["a sequence of solutions", "TREATMENT", 19, 42]]], ["An investigation of the asymptotic stability of the system done in Section 4 finds the conditions under which the disease can evolve towards an asymptotic equilibrium state and allows the definition of the reproduction rate.", [["the disease", "PROBLEM", 110, 121], ["the reproduction rate", "TEST", 202, 223], ["disease", "OBSERVATION", 114, 121]]], ["Its solution will be sometimes denoted by X := (S, A, I, L, R).", [["Its solution", "TREATMENT", 0, 12]]], ["In system (1.1)-(1.5) we apply the Banach fixed point theorem, using the setProblem (P )Let us pick a \u2208 M and fix it in the systemProblem (P )where C 1 (T ) is a polynomial in T with coefficients consisting in sums of the constant systems parameters and the L \u221e -norms of the time dependent system parameters.", [["the Banach fixed point theorem", "TREATMENT", 31, 61]]], ["This shows that \u03a8 is a contraction for small T, that is we obtain a local solution.", [["\u03a8", "SIMPLE_CHEMICAL", 16, 17], ["\u03a8", "PROTEIN", 16, 17], ["a local solution", "TREATMENT", 66, 82]]], ["Since all solution components are bounded by N it follows that the solution is global (see e.g., [3] , p.", [["N", "CHEMICAL", 45, 46], ["all solution components", "TREATMENT", 6, 29]]], ["Let (l n A , l n I ) n be a sequence such that l n A \u2192 l A , l n I \u2192 l I as n \u2192 \u221e and let X n and X be the solutions to (1.1)-(1.6) corresponding to these data, respectively.", [["a sequence", "TEST", 26, 36], ["the solutions", "TEST", 103, 116], ["these data", "TEST", 149, 159]]], ["Since the solution X n \u2208 (W 1,\u221e (0, T )) 5 it follows that X n \u2192 X uniformly in [0, T ] and weak* in (W 1,\u221e (0, T )) 5 and by passing to the limit in (1.1)-(1.6) we deduce that X (t) = lim n\u2192\u221e (X n ) (t), whence it follows that X is the solution to (1.1)-(1.6).Problem (P )Proposition 2.2.", [["the solution", "TEST", 6, 18], ["lim n\u2192\u221e", "TEST", 185, 192]]], ["It is obvious that an admissible pair exists.", [["pair", "OBSERVATION", 33, 37]]], ["For example, for l A = l I = 0 we get L(t) \u2264 L 0 < L and J(l A , l I ) < \u221e.", [["example", "TEST", 4, 11]]], ["Let d := inf J(l A , l I ) \u2265 0.", [["J(l A , l I )", "TREATMENT", 13, 26]]], ["The minimizing sequence also satisfiesProblem (P )This implies that l n A \u2192 l * A and l n I \u2192 l * I as n \u2192 \u221e and l * A , l * I \u2208 [0, 1].", [["A", "TEST", 117, 118], ["\u2208", "TEST", 127, 128]]], ["By Proposition 2.1 this solution exists and belong to (W 1,\u221e (0, T )) 5 and each component belongs to [0, N ].", [["[0, N ]", "SIMPLE_CHEMICAL", 102, 109], ["this solution", "TREATMENT", 19, 32]]], ["Then, on a subsequence, X n \u2192 X * , (X n ) \u2192 (X * ) weak* in (L \u221e (0, T )) 5 .", [["weak", "TEST", 52, 56]]], ["Therefore, by Arzel\u00e0 theorem it follows that X n \u2192 X * uniformly in [0, T ], and so X n (0) \u2192 X * (0) = X 0 and X n (T ) \u2192 X * (T ).", [["T", "TEST", 72, 73], ["so", "TEST", 81, 83], ["\u2192", "TEST", 92, 93]]], ["Finally, by the weakly lower semicontinuity of the norms we get lim n\u2192\u221e J(l n A , l n I ) = J(l * A , l * I ) and so (l * A , l * I ) turns out to be optimal in (P ).The approximating problem (P \u03b5 )Let \u03b5 > 0 and let (l * A , l * I ) be optimal in (P ).", [["I", "TEST", 106, 107], ["so", "TEST", 114, 116], ["A", "TEST", 122, 123], ["turns out", "TEST", 134, 143]]], ["We introduce the adapted approximating cost functionalThe approximating problem (P \u03b5 )and study the following approximating problem (P \u03b5 ),The approximating problem (P \u03b5 )We observe that the state constraint in (P ) is replaced here by the penalization of the L 2 -norm of the positive part of (L(t) \u2212 L), where \u03b1 2 > 0.", [["positive", "OBSERVATION", 277, 285]]], ["The last two penalization terms in (2.6) ensure the convergence of the approximating solution to the chosen optimal controller (l * A , l * I ) in (P ).The approximating problem (P \u03b5 )Proof.", [["the approximating solution", "TREATMENT", 67, 93]]], ["First of all we see that there is at least an admissible triplet, let it be (l * * A , l * * I ) an optimal one in (P ) with the corresponding global state X * * , belonging to (W 1,\u221e (0, T )) 5 and L * * \u2264 L. Then, J \u03b5 (l * * A , l * * I ) < \u221e.", [["L.", "TEST", 207, 209], ["J", "TEST", 216, 217], ["A", "TEST", 227, 228], ["I", "TEST", 237, 238]]], ["Hence, the admissible set in (P \u03b5 ) is not empty and since J \u03b5 (l A , l I ) \u2265 0, there exists d \u03b5 := inf J \u03b5 (l A , l I ) \u2265 0.", [["the admissible set", "TEST", 7, 25], ["empty", "TEST", 43, 48], ["d", "TEST", 94, 95]]], ["We take a minimizing sequence (l n A,\u03b5 , l n I,\u03b5 ) with the corresponding solution X n \u03b5 to the state system in the class of global solutions, with the components in the interval [0, N ].", [["X n \u03b5", "PROTEIN", 83, 88], ["a minimizing sequence", "TEST", 8, 29]]], ["If (l * A,\u03b5 , l * I,\u03b5 ) is optimal, then J \u03b5 (l * A,\u03b5 , l * I,\u03b5 ) \u2264 J \u03b5 (l A , l I ), for all (l A , l I ) satisfying the constraints in (P \u03b5 ).", [["J \u03b5", "PROTEIN", 41, 44], ["optimal", "TEST", 27, 34]]], ["Thus, the left-hand side is bounded and we have l * A,\u03b5 \u2192 l * A , l * I,\u03b5 \u2192 l * I , as \u03b5 \u2192 0.", [["left-hand", "ANATOMY", 10, 19], ["I", "TEST", 80, 81], ["left", "ANATOMY_MODIFIER", 10, 14]]], ["By Proposition 2.1, we infer that X \u03b5 \u2192 X * weak* in (W 1,\u221e (0, T )) 5 and uniformly in [0, T ].", [["Proposition", "TEST", 3, 14]]], ["By (2.9) we can writeThe approximating problem (P \u03b5 )for all t \u2208 [0, T ], so that L * (t) \u2264 L, which ends the proof.The approximating optimality conditionsLet \u03bb > 0 and set the variationsThe approximating optimality conditionsis the solution to (1.1)-(1.6) corresponding to (l \u03bb A,\u03b5 , l \u03bb I,\u03b5 ), satisfying (1.7) and X * \u03b5 is the optimal state corresponding to (l * A,\u03b5 , l * I,\u03b5 ).", [["all t \u2208", "TEST", 57, 64]]], ["We introduce the linearized system for problem (P ) whereThe approximating optimality conditionsFirst, by the known results for linear systems we infer that (2.10) has a unique global solution x = (s, a, i, l, r) \u2208 (W 1,\u221e (0, T )) 5 .", [["the linearized system", "TREATMENT", 13, 34], ["linear systems", "TEST", 128, 142]]], ["By a direct calculation, using the continuity with respect to the data of the solution to the state system it can be easily proved that x \u03bb \u03b5 \u2192 x \u03b5 := (s, a, i, l, r) strongly in C([0, T ]), as \u03bb \u2192 0, so that (2.10) stands for the system in variations.", [["T", "TEST", 185, 186]]], ["We introduce the backward dual system for the variables (p \u03b5 , q \u03b5 , d \u03b5 , e \u03b5 , f \u03b5 ) asThe approximating optimality conditionsWe recall that the projection of a point z on a set K \u2282 R d , d \u2208 N, is defined by P K (z) := (I d + \u03ba\u2202I K ) \u22121 (z), for all k > 0, I d being the identity operator.The approximating optimality conditionsProposition 2.5.", [["I K", "PROTEIN", 231, 234], ["the variables", "TEST", 42, 55], ["z", "TEST", 169, 170], ["a set K", "TEST", 174, 181], ["K", "TEST", 233, 234], ["\u2212", "TEST", 237, 238], ["z", "TEST", 241, 242], ["all k", "TEST", 249, 254]]], ["Let us multiply the equations for s, a, i, l, r in (2.10) by p \u03b5 , q \u03b5 , d \u03b5 , e \u03b5 , f \u03b5 , respectively and integrate over (0, T ).", [["\u03b5", "PROTEIN", 75, 76], ["\u03b5", "PROTEIN", 81, 82], ["\u03b5", "PROTEIN", 87, 88], ["the equations", "TEST", 16, 29], ["s", "TEST", 34, 35]]], ["By integrating by parts and taking into account the equations in the dual system and the initial conditions in the system in variations, we obtainThe approximating optimality conditionsOn the other hand, for (l * A,\u03b5 , l * I,\u03b5 ) optimal in (P \u03b5 ) we can write J \u03b5 (l \u03bb A,\u03b5 , l \u03bb I,\u03b5 ) \u2265 J \u03b5 (l * A,\u03b5 , l * I,\u03b5 ).The approximating optimality conditionsBy replacing the expression of the cost functional J \u03b5 , performing some algebra, dividing by \u03bb and passing to the limit as \u03bb \u2192 0 we obtainThe approximating optimality conditionsBy comparison with (2.20) we deduceThe approximating optimality conditionsRecall the setting of \u03c9 A and \u03c9 I and choose, in particular, l A = l * A,\u03b5 , meaning that we keep l * A,\u03b5 fixed and give a variation only to l * I,\u03b5 .", [["\u03c9 I", "GENE_OR_GENE_PRODUCT", 633, 636], ["\u03b5", "CELL_LINE", 281, 282], ["J \u03b5", "PROTEIN", 402, 405], ["\u03c9 A", "PROTEIN", 625, 628], ["\u03c9 I", "PROTEIN", 633, 636], ["the equations in the dual system", "PROBLEM", 48, 80], ["\u03b5", "TEST", 215, 216], ["J", "TEST", 287, 288], ["optimality conditions", "OBSERVATION", 582, 603]]], ["There exists T loc , such that for T < T loc we haveThe optimality conditions for problem (P )independently of \u03b5.The optimality conditions for problem (P )Proof.", [["T loc", "GENE_OR_GENE_PRODUCT", 13, 18], ["T loc", "PROBLEM", 13, 18], ["T < T loc", "TREATMENT", 35, 44]]], ["Let us choose y 1 < L, \u03c1 > 0 and \u03b8 \u2208 R, with |\u03b8| = 1 such that y 1 + \u03c1\u03b8 \u2264 L, where L 0 < L. Then, we have y 1 \u00b1 \u03c1 \u2264 L and this holds if \u03c1 \u2264 L \u2212 y 1 .", [["\u03c1", "PROTEIN", 136, 137], ["Let us", "TEST", 0, 6], ["\u03c1", "TEST", 23, 24], ["y", "TEST", 63, 64], ["we", "TEST", 98, 100], ["y", "TEST", 106, 107], ["this holds", "TEST", 122, 132]]], ["We haveThe optimality conditions for problem (P )Let us define \u03d5(y) = 1 2 (y + ) 2 , \u03d5 : [0, \u221e) \u2192 [0, \u221e).", [["[0, \u221e) \u2192 [0, \u221e", "SIMPLE_CHEMICAL", 89, 103], ["The optimality conditions", "TEST", 7, 32], ["problem", "TEST", 37, 44], ["\u2192", "TEST", 96, 97]]], ["Its subdifferential \u2202\u03d5(y) = y + and \u03d5(y)\u2212\u03d5(z) \u2264 \u2202\u03d5(y)(y \u2212z) for all z \u2264 L. In the second term on the left-hand side of (2.27) we setThe optimality conditions for problem (P )is the characteristic function of the set indicated as subscript.The optimality conditions for problem (P )Using the relation for the subdifferential of \u03d5 and integrating by parts the first term on the left-hand side of (2.27) we haveThe optimality conditions for problem (P )Since y 1 + \u03c1\u03b8 \u2264 L, e \u03b5 (T ) = 0, using eq.", [["left-hand", "ANATOMY", 101, 110], ["left-hand", "ANATOMY", 376, 385], ["\u03d5", "PROTEIN", 327, 328], ["Its subdifferential", "TEST", 0, 19], ["z", "TEST", 43, 44], ["y \u2212z", "TEST", 54, 58], ["all z", "TEST", 64, 69], ["the second term", "TEST", 78, 93], ["y", "TEST", 456, 457], ["left", "ANATOMY_MODIFIER", 101, 105], ["left", "ANATOMY_MODIFIER", 376, 380]]], ["We getThe optimality conditions for problem (P )Here, \u03b5 and G \u03b5 consist in sums of the constant coefficients of the equations in the dual system plus the L \u221e -norms of the time dependent coefficients.", [["G \u03b5", "SIMPLE_CHEMICAL", 60, 63]]], ["These sums also include l * 2 A,\u03b5 and l * 2 I,\u03b5 .", [["l * 2 I", "GENE_OR_GENE_PRODUCT", 38, 45], ["\u03b5", "GENE_OR_GENE_PRODUCT", 46, 47]]], ["By the Gronwall's lemma, the previous inequality yields the estimateThe optimality conditions for problem (P )\u221a T e G\u03b5T , (2.31) the right-hand side being bounded independently of \u03b5, since A * \u03b5 , I * \u03b5 tend uniformly to A * , I * , l * A,\u03b5 \u2192 l * A , l * I,\u03b5 \u2192 l * I , G \u03b5 \u2192 G which is constant.The optimality conditions for problem (P )We go back to (2.29) and using (2.31) we writeThe optimality conditions for problem (P )We have to prove that the coefficients of \u03c1 and E \u03b5 are positive, at least on a small interval.", [["right-hand", "ANATOMY", 133, 143], ["G \u03b5 \u2192 G", "GENE_OR_GENE_PRODUCT", 269, 276], ["\u03c1", "GENE_OR_GENE_PRODUCT", 467, 468], ["E \u03b5", "GENE_OR_GENE_PRODUCT", 473, 476], ["\u03b5", "PROTEIN", 180, 181], ["I * \u03b5", "PROTEIN", 197, 202], ["\u03b5", "PROTEIN", 257, 258], ["T", "TEST", 112, 113], ["\u03b5T", "TEST", 117, 119], ["A", "TEST", 237, 238], ["\u2192", "TEST", 241, 242], ["A", "TEST", 247, 248], ["I", "TEST", 255, 256], ["\u03b5", "TEST", 257, 258], ["\u2192", "TEST", 259, 260], ["I", "TEST", 265, 266], ["G", "TEST", 269, 270], ["G", "TEST", 275, 276], ["right", "ANATOMY_MODIFIER", 133, 138], ["hand", "ANATOMY", 139, 143], ["constant", "OBSERVATION_MODIFIER", 286, 294], ["small", "OBSERVATION_MODIFIER", 505, 510]]], ["Since the approximating optimal solution tends uniformly to the optimal solution in (P ), we infer thatThe optimality conditions for problem (P )We note that the function t \u2192 4\u00b5 L \u03b1 0 e G\u03b5t t \u221a t is positive, strictly increasing for t > 0 and vanish at 0.", [["the function", "TEST", 158, 170], ["t", "TEST", 171, 172], ["\u2192", "TEST", 173, 174], ["positive", "PROBLEM", 199, 207]]], ["We haveThe optimality conditions for problem (P )Then, there exists T 1 > 0 such that (2.33) takes place on (0, T 1 ).", [["T", "TEST", 68, 69]]], ["Next, we show that \u03c1(1 \u2212 4\u00b5 L \u03b1 0 e G\u03b5T T \u221a T ) \u2212 (F 0 + 4\u03b1 0 F 1,\u03b5 T \u221a T e G\u03b5T ) > 0 for t \u2208 (0, T 2 ).", [["L \u03b1 0 e G\u03b5T T \u221a T", "TEST", 28, 45], ["\u2212", "TEST", 48, 49], ["F", "TEST", 51, 52], ["T", "TEST", 68, 69], ["G\u03b5T", "TEST", 76, 79]]], ["Indeed, this comes toThe optimality conditions for problem (P )The function t \u2192 F 0 + 4\u03b1 0 (F 1,\u03b5 + \u03c1\u00b5 L )t \u221a te Gt is positive, strictly increasing and equal with F 0 at 0 and we note thatThe optimality conditions for problem (P )This implies that there exists T 2 > 0 such that (2.34) is satisfied on (0, T 2 ).", [["Gt", "PROTEIN", 113, 115], ["The function t \u2192 F", "TEST", 63, 81], ["\u03b5", "TEST", 96, 97], ["t \u221a te Gt", "TEST", 106, 115], ["positive", "PROBLEM", 119, 127], ["positive", "OBSERVATION", 119, 127]]], ["We recall that we let y 1 \u2208 (0, L 0 ) and if we choose \u03c1 \u2208 (L 0 \u2212 y 1 , L \u2212 y 1 ) it follows that (2.35), y 1 + \u03c1 \u2264 L and y 1 \u2212 \u03c1 \u2264 L hold.", [["y", "TEST", 106, 107], ["y", "TEST", 122, 123]]], ["The last one is true because by the choice of \u03c1 we have y 1 \u2212 \u03c1 \u2264 2y 1 \u2212 L 0 \u2264 L 0 < L. By (2.32)-(2.34) we can write thatThe optimality conditions for problem (P )for T \u2208 (0, T loc ), T loc := min{T 1 , T 2 }.The optimality conditions for problem (P )(2.36)The optimality conditions for problem (P )More exactly, T 1 and T 2 are the solutions to We note that if v \u2208 BV ([0, T ]), then its distributional derivative dv dt := \u00b5 belongs to (L \u221e (0, T )) * , and in virtue of the Lebesgue decomposition, it is represented by the sum of the absolutely continuous part and the singular partThe optimality conditions for problem (P )where D (0, T ) is the space of Schwartz distributions on (0, T ).The optimality conditions for problem (P )In the next theorem we shall pass to the limit in the approximating optimality conditions.", [["T 2", "GENE_OR_GENE_PRODUCT", 322, 325], ["Lebesgue", "SIMPLE_CHEMICAL", 477, 485], ["T \u2208", "TEST", 168, 171], ["T loc", "TEST", 185, 190], ["min{T", "TEST", 194, 199], ["The optimality conditions", "PROBLEM", 210, 235], ["BV", "TEST", 367, 369]]], ["To this end, we introduce the systemThe optimality conditions for problem (P )whereThe optimality conditions for problem (P )We also defineThe optimality conditions for problem (P )We denote by N K (z) the normal cone to K at z, Theorem 2.8.", [["Theorem", "TEST", 229, 236]]], ["Let T < T loc , let (l * A , l * I ) be optimal in (P ) with the corresponding state X * and let us consider {(l * A,\u03b5 , l * I,\u03b5 ), X * \u03b5 } optimal in (P \u03b5 ).", [["Let T", "GENE_OR_GENE_PRODUCT", 0, 5], ["X * \u03b5 }", "SIMPLE_CHEMICAL", 132, 139], ["optimal", "TEST", 140, 147]]], ["Recalling Proposition 2.4 and the continuity property from Proposition 2.1, we have l * A,\u03b5 \u2192 l * A , l * I,\u03b5 \u2192 l * I and X * \u03b5 \u2192 X * weak* in W 1,\u221e (0, T ) and uniformly on [0, T ].The optimality conditions for problem (P )By (2.26) each component of the solution to the dual system, but e \u03b5 , follows to be bounded in L \u221e (0, T ).", [["Proposition", "TEST", 59, 70], ["\u2192", "TEST", 128, 129], ["weak", "TEST", 134, 138], ["W", "TEST", 143, 144], ["\u221e", "TEST", 147, 148], ["T", "TEST", 153, 154], ["dual system", "ANATOMY", 272, 283]]], ["Moreover, by (2.13)-(2.15), (2.17) it follows thatThe optimality conditions for problem (P )and uniformly in [0, T ], as \u03b5 \u2192 0.The optimality conditions for problem (P )The component (e \u03b5 ) \u03b5 is bounded in L \u221e (0, T ) by (2.30) and its derivative is in L 1 (0, T ), by (2.25).", [["T", "TEST", 113, 114], ["L", "ANATOMY_MODIFIER", 206, 207]]], ["These imply that e \u03b5 \u2208 BV ([0, T ]) and by Helly's theorem (see e.g., [2] , p.", [["Helly's theorem", "TEST", 43, 58]]], ["Now, we assert that (e \u03b5 ) \u03b5 and 1 \u03b5 (L * \u03b5 \u2212 L) + \u03b5 are weak* compact in (L \u221e (0, T )) * , the dual of L \u221e (0, T ).", [["\u03b5", "PROTEIN", 51, 52], ["compact", "TEST", 63, 70], ["the dual", "TEST", 92, 100]]], ["Let us consider the linear operator \u03a8 : C([0, T ]) \u2192 L \u221e (0, T ), \u03a8z = \u03a8, which maps a continuous function into the corresponding class of equivalence \u03a8 (of all functions a.e. equal).", [["\u03a8", "PROTEIN", 71, 72], ["\u03a8", "PROTEIN", 151, 152]]], ["Its adjoint \u03a8 * : (L \u221e (0, T )) * \u2192 M([0, T ]), is defined by (\u03a8 * \u00b5)(z) := \u00b5(\u03a8z) for any z \u2208 C([0, T ]).", [["M", "TEST", 36, 37], ["z", "TEST", 70, 71], ["\u00b5", "TEST", 76, 77], ["\u03a8z", "TEST", 78, 80], ["any z \u2208 C", "TEST", 86, 95]]], ["If (\u00b5 n ) n is bounded in (L \u221e (0, T )) * and also in M([0, T ]), then (\u03a8 * \u00b5 n ) n is bounded in M([0, T ]) and using the Alaoglu theorem it follows that (\u03a8 * \u00b5 n ) n is weak* sequentially compact in M([0, T ]).", [["the Alaoglu theorem", "TEST", 119, 138]]], ["Passing to the limit in \u00b5 n (\u03a8z) = (\u03a8 * \u00b5 n )(z) we get \u00b5(\u03a8z) = (\u03a8 * \u00b5)(z) for any \u03a8 \u2208 L \u221e (0, T ) which is of the form \u03a8z with z \u2208 C([0, T ]).", [["z", "TEST", 46, 47], ["\u03a8z", "TEST", 58, 60], ["\u00b5", "TEST", 69, 70], ["z", "TEST", 72, 73], ["any", "TEST", 79, 82], ["\u03a8", "TEST", 83, 84], ["\u03a8z", "TEST", 120, 122], ["z", "TEST", 128, 129], ["C", "TEST", 132, 133]]], ["The left-hand side of (2.23) converges and since the normal cone is maximal monotone, hence strongly-strongly closed it follows thatThe optimality conditions for problem (P )which implies the second relation in (2.51).", [["left-hand", "ANATOMY", 4, 13], ["left", "ANATOMY_MODIFIER", 4, 8], ["hand", "ANATOMY", 9, 13]]], ["We introduce the linearized system for problem (P 0 )The optimality conditions for problem (P )for t \u2265 0, with the initial conditionThe optimality conditions for problem (P )whereThe optimality conditions for problem (P )We introduce the backward dual system for the variables (p, q, d, e, f ) as Let N K0 (\u03b6 1 , \u03b6 2 ) be the normal cone to the set K 0 \u2282 R 2 .", [["the linearized system", "TREATMENT", 13, 34], ["the variables", "TEST", 263, 276], ["normal", "OBSERVATION", 326, 332]]], ["We recall that N K0 (\u03b6 1 , \u03b6 2 ) = \u2202I K0 (\u03b6 1 , \u03b6 2 ), where \u2202I K0 (\u03b6 1 , \u03b6 2 ) is the subdifferential of the indicator set of K 0 , that isThe optimality conditions for problem (P )Let N K+ (z) be the normal cone to the set K + , that isThe optimality conditions for problem (P )Proposition 3.2.", [["K", "CHEMICAL", 127, 128], ["K", "CHEMICAL", 188, 189], ["K", "CHEMICAL", 225, 226], ["N", "CHEMICAL", 15, 16], ["K +", "SIMPLE_CHEMICAL", 225, 228], ["I K0", "PROTEIN", 62, 66], ["I K0", "TEST", 36, 40], ["problem", "PROBLEM", 170, 177], ["P", "TEST", 179, 180], ["Let N K", "TEST", 182, 189], ["the set K", "TEST", 217, 226], ["normal", "OBSERVATION", 202, 208]]], ["Let us multiply the equations for s, a, i, l, r in (3.2) by p \u03b5 , q \u03b5 , d \u03b5 , e \u03b5 , f \u03b5 , respectively and integrate over (0, T ).", [["\u03b5", "PROTEIN", 74, 75], ["\u03b5", "PROTEIN", 80, 81], ["\u03b5", "PROTEIN", 86, 87], ["the equations", "TEST", 16, 29], ["s", "TEST", 34, 35]]], ["By integrating by parts we obtain12)Since (\u03b2 * I , A * 0 , I * 0 ) is optimal in (P 0 ) we have J(\u03b2 \u03bb I , A \u03bb 0 , I \u03bb 0 ) \u2265 J(\u03b2 * I , A * 0 , I * 0 ) and we deduce12)By comparison with (3.13) and recalling the setting of u, w, v, we have12)for all \u03b2 I (t) \u2208 K + , a.e. t \u2208 (0, T ) and ( A 0 , I 0 ) \u2208 K 0 .", [["K", "CHEMICAL", 258, 259], ["optimal", "TEST", 70, 77], ["J", "TEST", 96, 97], ["I", "TEST", 102, 103], ["J", "TEST", 124, 125], ["I", "TEST", 130, 131], ["we deduce", "TEST", 154, 163], ["u", "TEST", 221, 222], ["K", "TEST", 258, 259], ["t", "TEST", 269, 270], ["\u2208", "TEST", 271, 272], ["T", "TEST", 277, 278], ["A", "TEST", 287, 288], ["K", "TEST", 301, 302]]], ["In particular, by setting ( A 0 , I 0 ) = (A * 0 , I * 0 ), (3.15) yields (p(t) \u2212 q(t))S * (t)I * (t) \u2212 \u03b1 1 \u03b2 * I (t) \u2208 N K+ (\u03b2 * I (t)), a.e. t \u2208 (0, T ), (3.16) which implies (3.11) .", [["N", "CHEMICAL", 120, 121], ["yields", "TEST", 67, 73], ["\u2212", "TEST", 102, 103], ["\u03b1", "TEST", 104, 105], ["t", "TEST", 115, 116], ["K", "TEST", 122, 123], ["t \u2208", "TEST", 143, 146], ["T", "TEST", 151, 152]]], ["Then, let us set \u03b2 I = \u03b2 * I .", [["\u03b2 * I", "GENE_OR_GENE_PRODUCT", 23, 28], ["\u03b2 * I", "PROTEIN", 23, 28]]], ["This implies (3.12) , because N K0 is maximal monotone in R 2 , and \u0393 : R 2 \u2192 R 2 is positive, so (\u0393 + N K0 ) \u22121 is Lipschitz.12)Remark 3.3.", [["N", "CHEMICAL", 30, 31], ["R 2", "GENE_OR_GENE_PRODUCT", 78, 81], ["maximal monotone", "TEST", 38, 54], ["so", "TEST", 95, 97], ["\u0393", "TEST", 99, 100], ["Lipschitz", "TEST", 116, 125], ["Lipschitz", "ANATOMY", 116, 125]]], ["By (3.11) and the fact that the optimal state is nonnegative, it is clear that 4 System stability and determination of the reproduction rate12)In this section we investigate the system stability, which will help to derive an expression for the reproduction rate.", [["the reproduction rate", "TEST", 119, 140], ["the reproduction rate", "TEST", 240, 261]]], ["Once identified \u03b2 I (t), one can consider its average over (0, T ) and use it for the stability analysis.", [["\u03b2 I", "GENE_OR_GENE_PRODUCT", 16, 19], ["\u03b2 I (t)", "PROTEIN", 16, 23], ["the stability analysis", "TEST", 82, 104]]], ["An average can be set for \u03b2 A , too.", [["\u03b2 A", "PROTEIN", 26, 29]]], ["The use of the average can be more accurate if (0, T ) is short or if the epidemic has reached a plateau, where the rates do not have large variations.", [["the rates", "TEST", 112, 121], ["large", "OBSERVATION_MODIFIER", 134, 139], ["variations", "OBSERVATION", 140, 150]]], ["We recall that N = 1.12)The system (A, I, L) with a positive susceptible population S \u221e is asymptotically stable if and only if12)Moreover, all solutions (starting from any nonnegative initial condition) tend to a stationary state, that is exists and S \u221e < S \u221e .12)Proof.", [["S \u221e", "CELL_LINE", 84, 87], ["a positive susceptible population S", "PROBLEM", 50, 85]]], ["If \u03be = 0, the stationary solutions are found as (S \u221e , 0, 0, 0, R \u221e ), and we choose S \u221e , R \u221e \u2208 [0, N ].", [["the stationary solutions", "TEST", 10, 34]]], ["We consider the linearized system, extract the system for the infected compartments A, I, L, and define its matrix12)with k 1 , k 2 given in (1.9) and k 3,\u221e = \u03b2 A S \u221e \u2212 k 1 .", [["compartments", "ANATOMY", 71, 83], ["the linearized system", "TREATMENT", 12, 33], ["k", "TEST", 122, 123], ["k", "TEST", 128, 129], ["k", "TEST", 151, 152], ["\u221e", "TEST", 155, 156], ["A S", "TEST", 161, 164], ["k", "TEST", 169, 170], ["infected", "OBSERVATION", 62, 70]]], ["The characteristic equation has a negative solution \u03bb = \u2212\u00b5 L and two solutions to the equation12)We prove that the solutions to (4.4) have the real part negative, meaning that the polynomial P (\u03bb) is Hurwitz.", [["P", "DNA", 191, 192], ["Hurwitz", "PROBLEM", 200, 207]]], ["Since by (4.6) we see that S (t) \u2264 0 it follows that S is monotonically decreasing and so it tends to a limit S \u221e \u2265 0.", [["monotonically", "OBSERVATION_MODIFIER", 58, 71], ["decreasing", "OBSERVATION_MODIFIER", 72, 82]]], ["Then, by (4.5)-(4.6) we have12)and deduce by the formula of variation of constants and integration by parts, that12)We calculate the last term12)and get12)We note that A is Hurwitz and recall that e At \u2264 M e \u2212\u03b3t , where \u03b3 < min j {\u2212Re(\u03bb j ); \u03bb j are the eigenvalues of A} and \u00b7 is the norm in R 3 .", [["R 3", "GENE_OR_GENE_PRODUCT", 293, 296], ["the eigenvalues", "TEST", 250, 265], ["A}", "TEST", 269, 271]]], ["Otherwise, if S \u221e \u2265 S \u221e , we see that the polynomial is no longer Hurwitz and so system (A, I, L) is not asymptotically stable.", [["no longer", "UNCERTAINTY", 56, 65], ["stable", "OBSERVATION", 120, 126]]], ["Moreover, lim t\u2192\u221e R(t) = N \u2212(S(t)+A(t)+I(t)+L(t)) = N \u2212S \u221e := R \u221e and we note that R \u221e = N \u2212 S \u221e > N \u2212 S \u221e = N \u2212 k1k2 \u03b2 \u2265 0, according to (4.1).12)We prove that condition (4.2) is necessary, too.", [["N", "CHEMICAL", 25, 26], ["N \u2212 S \u221e", "SIMPLE_CHEMICAL", 89, 96], ["Moreover", "TEST", 0, 8], ["k", "TEST", 113, 114]]], ["It means that if S \u221e is a steady state and lim t\u2192\u221e (A(t), I(t), L(t)) = (0, 0, 0), it follows that S \u221e should satisfy (4.2).", [["S \u221e", "SIMPLE_CHEMICAL", 99, 102]]], ["It follows that the above corresponding polynomial P (\u03bb) is not Hurwitz and this implies that the system (A, I, L) is not asymptotically stable, meaning that (A(t), I(t), L(t)) does no longer tend to 0 as t \u2192 \u221e.12)The fact that the value \u03b2 k1k2 appears as a critical value for the system, gives a justification to define the reproduction rate as R 0 = k 2 \u03b2 A + \u03c3\u03b2 I (\u03c3 + \u00b5 A + l A )(\u00b5 I + l I )12).12)(4.9)12)Its epidemiologic interpretation will be given further.ConclusionsWe solved an inverse and a control problem related to an epidemic model for SARS-CoV-2, with five compartments: susceptible S, undetected infected asymptomatic A, undetected infected symptomatic I, detected by testing and isolated L, and recovered R. By an optimal control technique we identified the rate of infection \u03b2 * I of the susceptible individuals by the infective I class and the number of undetected individuals in the classes A and I at a time set t = 0.", [["SARS", "DISEASE", 552, 556], ["infection", "DISEASE", 785, 794], ["\u03b2 * I", "GENE_OR_GENE_PRODUCT", 795, 800], ["\u03b2 k1k2", "PROTEIN", 238, 244], ["\u03c3\u03b2 I", "PROTEIN", 362, 366], ["\u03c3", "PROTEIN", 368, 369], ["SARS-CoV", "SPECIES", 552, 560], ["the value", "TEST", 228, 237], ["the reproduction rate", "TEST", 321, 342], ["k", "TEST", 352, 353], ["I", "TEST", 365, 366], ["Its epidemiologic interpretation", "TEST", 410, 442], ["a control problem", "PROBLEM", 501, 518], ["an epidemic model", "TEST", 530, 547], ["SARS", "PROBLEM", 552, 556], ["CoV", "TEST", 557, 560], ["susceptible S", "PROBLEM", 588, 601], ["infected asymptomatic A", "PROBLEM", 614, 637], ["infected symptomatic I", "PROBLEM", 650, 672], ["testing", "TEST", 686, 693], ["infection", "PROBLEM", 785, 794], ["stable", "OBSERVATION_MODIFIER", 137, 143], ["no longer", "UNCERTAINTY", 182, 191], ["infected", "OBSERVATION_MODIFIER", 614, 622], ["infected", "OBSERVATION_MODIFIER", 650, 658], ["symptomatic", "OBSERVATION", 659, 670], ["infection", "OBSERVATION", 785, 794], ["infective", "OBSERVATION", 839, 848]]], ["Their estimation was relied on the observation of the number of the isolated and recovered people at time t = 0 and at another later time T. It turned out that the \u03b2 * I is the projection of a point depending on the optimal states and the solution to the dual system, on the set of positive real numbers and the point (A * 0 , I * 0 ) is uniquely determined by (3.12) .", [["\u03b2 * I", "GENE_OR_GENE_PRODUCT", 164, 169], ["\u03b2 * I", "PROTEIN", 164, 169], ["people", "SPECIES", 91, 97]]], ["Knowing the evolution of \u03b2 * I during (0, T ) and the initial values A * 0 and I * 0 one can estimate the transient evolution of the compartments after the time T. Then, the control of the infected classes A and I was done, by means of the coefficients l A and l I related to the testing action.", [["\u03b2 * I", "GENE_OR_GENE_PRODUCT", 25, 30], ["\u03b2 * I", "PROTEIN", 25, 30], ["the testing action", "TEST", 276, 294], ["transient", "OBSERVATION_MODIFIER", 106, 115], ["evolution", "OBSERVATION_MODIFIER", 116, 125], ["infected", "OBSERVATION", 189, 197]]], ["The controllers were provided by expressions depending on the optimal states for this problem and the solution to the singular dual system.ConclusionsThe investigation of the system asymptotic stability enhanced the determination of the reproduction rate R 0 , defined in (4.9), under the assumption of constant coefficients in the state system.", [["the reproduction rate", "TEST", 233, 254], ["constant coefficients in the state system", "PROBLEM", 303, 344]]], ["Theorem 5.1 characterizes the system behavior under the assumption that the disease induces life immunity.", [["Theorem", "TEST", 0, 7], ["disease", "OBSERVATION", 76, 83]]], ["It indicates an asymptotic extinction of the disease, following by the globally asymptotic stability of the solution to a steady state ( S \u221e , 0, 0, 0, N \u2212 S \u221e ), where S \u221e does not exceed the value S \u221e given by (4.2) .", [["the disease", "PROBLEM", 41, 52], ["a steady state", "TEST", 120, 134], ["asymptotic", "OBSERVATION_MODIFIER", 16, 26], ["extinction", "OBSERVATION", 27, 37], ["disease", "OBSERVATION", 45, 52]]], ["Moreover, if R 0 S \u221e < 1, the epidemic extinguishes, while the case R 0 S \u221e > 1 shows a massive outbreak, R 0 S \u221e = 1 being a bifurcation point.ConclusionsFinally, we underline that, in order to avoid much more calculations in a model with many equations, we used a restraint model with less compartments, including however the most relevant ones.", [["the epidemic extinguishes", "TEST", 26, 51], ["a massive outbreak", "PROBLEM", 86, 104], ["a restraint model", "TREATMENT", 264, 281], ["massive", "OBSERVATION_MODIFIER", 88, 95], ["outbreak", "OBSERVATION", 96, 104], ["bifurcation", "OBSERVATION", 126, 137]]], ["Also, other parameters, as for example \u03b2 A can be identified and numerical simulations will be provided in a forthcoming paper.", [["\u03b2 A", "GENE_OR_GENE_PRODUCT", 39, 42], ["\u03b2 A", "PROTEIN", 39, 42]]]], "PMC4747987": [["IntroductionSepsis is a life-threatening condition caused by an injurious host response to infection with an estimated incidence of over 19 million cases per year worldwide [1, 2].", [["IntroductionSepsis", "DISEASE", 0, 18], ["infection", "DISEASE", 91, 100], ["infection", "PROBLEM", 91, 100]]], ["Sepsis plays a prominent role in patients admitted to intensive care units (ICUs) where it is highly associated with morbidity and mortality [3].", [["Sepsis", "DISEASE", 0, 6], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["Sepsis", "PROBLEM", 0, 6], ["morbidity", "PROBLEM", 117, 126], ["prominent", "OBSERVATION_MODIFIER", 15, 24]]], ["During sepsis, triggering of inflammatory and coagulation cascades, together with endothelial damage, invariably leads to activation of platelets [4, 5].", [["endothelial", "ANATOMY", 82, 93], ["platelets", "ANATOMY", 136, 145], ["sepsis", "DISEASE", 7, 13], ["endothelial damage", "DISEASE", 82, 100], ["endothelial", "TISSUE", 82, 93], ["platelets", "CELL", 136, 145], ["platelets", "CELL_TYPE", 136, 145], ["sepsis", "PROBLEM", 7, 13], ["inflammatory and coagulation cascades", "PROBLEM", 29, 66], ["endothelial damage", "PROBLEM", 82, 100], ["platelets", "TEST", 136, 145], ["sepsis", "OBSERVATION", 7, 13], ["inflammatory", "OBSERVATION_MODIFIER", 29, 41], ["coagulation cascades", "OBSERVATION", 46, 66], ["endothelial damage", "OBSERVATION", 82, 100]]], ["Platelet activation can be further stimulated by direct interactions with pathogens [4, 6].", [["Platelet", "ANATOMY", 0, 8], ["Platelet", "CELL", 0, 8], ["Platelet activation", "TREATMENT", 0, 19]]], ["Platelets are essential components of primary hemostasis and in addition can aid the host in eliminating invading pathogens by facilitating a variety of bactericidal effector mechanisms [4, 6, 7].", [["Platelets", "ANATOMY", 0, 9], ["Platelets", "CELL", 0, 9], ["Platelets", "CELL_TYPE", 0, 9], ["Platelets", "TEST", 0, 9], ["primary hemostasis", "TREATMENT", 38, 56], ["invading pathogens", "PROBLEM", 105, 123], ["bactericidal effector mechanisms", "TREATMENT", 153, 185], ["essential", "OBSERVATION_MODIFIER", 14, 23], ["components", "OBSERVATION_MODIFIER", 24, 34], ["primary hemostasis", "OBSERVATION", 38, 56]]], ["However, during uncontrolled infection platelet activation contributes to sepsis complications [4, 8].", [["platelet", "ANATOMY", 39, 47], ["infection", "DISEASE", 29, 38], ["sepsis", "DISEASE", 74, 80], ["platelet", "CELL", 39, 47], ["uncontrolled infection platelet activation", "PROBLEM", 16, 58], ["sepsis complications", "PROBLEM", 74, 94], ["uncontrolled", "OBSERVATION_MODIFIER", 16, 28], ["infection", "OBSERVATION", 29, 38], ["sepsis", "OBSERVATION", 74, 80]]], ["Indeed, several preclinical studies have shown beneficial effects of antiplatelet therapy in sepsis models [4].IntroductionAntiplatelet drugs such as clopidogrel or acetylsalicyclic acid are widely used in the secondary prevention of cardiovascular, cerebrovascular, and peripheral arterial thrombosis.", [["Antiplatelet", "ANATOMY", 123, 135], ["cardiovascular", "ANATOMY", 234, 248], ["cerebrovascular", "ANATOMY", 250, 265], ["peripheral arterial", "ANATOMY", 271, 290], ["sepsis", "DISEASE", 93, 99], ["clopidogrel", "CHEMICAL", 150, 161], ["acetylsalicyclic acid", "CHEMICAL", 165, 186], ["cardiovascular, cerebrovascular, and peripheral arterial thrombosis", "DISEASE", 234, 301], ["clopidogrel", "CHEMICAL", 150, 161], ["acetylsalicyclic acid", "CHEMICAL", 165, 186], ["antiplatelet", "CELL", 69, 81], ["clopidogrel", "SIMPLE_CHEMICAL", 150, 161], ["acetylsalicyclic acid", "SIMPLE_CHEMICAL", 165, 186], ["cardiovascular", "ANATOMICAL_SYSTEM", 234, 248], ["peripheral arterial", "MULTI-TISSUE_STRUCTURE", 271, 290], ["several preclinical studies", "TEST", 8, 35], ["antiplatelet therapy", "TREATMENT", 69, 89], ["sepsis models", "PROBLEM", 93, 106], ["IntroductionAntiplatelet drugs", "TREATMENT", 111, 141], ["clopidogrel", "TREATMENT", 150, 161], ["acetylsalicyclic acid", "TREATMENT", 165, 186], ["peripheral arterial thrombosis", "PROBLEM", 271, 301], ["antiplatelet therapy", "OBSERVATION", 69, 89], ["cardiovascular", "ANATOMY", 234, 248], ["cerebrovascular", "ANATOMY", 250, 265], ["peripheral", "ANATOMY_MODIFIER", 271, 281], ["arterial", "ANATOMY", 282, 290], ["thrombosis", "OBSERVATION", 291, 301]]], ["To date, there has been no randomized controlled clinical trial investigating the effect of antiplatelet therapy in sepsis.", [["sepsis", "DISEASE", 116, 122], ["antiplatelet", "CELL", 92, 104], ["antiplatelet therapy", "TREATMENT", 92, 112], ["sepsis", "PROBLEM", 116, 122], ["no", "UNCERTAINTY", 24, 26], ["antiplatelet therapy", "OBSERVATION", 92, 112], ["sepsis", "OBSERVATION", 116, 122]]], ["Retrospective studies showed a beneficial effect of pre-existing therapy with an antiplatelet drug with respect to organ failure, duration of ICU and hospital stay, and mortality in critically ill patients [4, 8, 9].", [["organ", "ANATOMY", 115, 120], ["organ failure", "DISEASE", 115, 128], ["critically ill", "DISEASE", 182, 196], ["organ", "ORGAN", 115, 120], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205], ["Retrospective studies", "TEST", 0, 21], ["pre-existing therapy", "TREATMENT", 52, 72], ["an antiplatelet drug", "TREATMENT", 78, 98], ["organ failure", "PROBLEM", 115, 128], ["organ", "ANATOMY", 115, 120], ["failure", "OBSERVATION", 121, 128]]], ["However, most studies in critically ill patients with infection were small and/or included patient groups that were not matched for potential confounding factors, such as comorbidity and other chronic medication.", [["critically ill", "DISEASE", 25, 39], ["infection", "DISEASE", 54, 63], ["patients", "ORGANISM", 40, 48], ["patient", "ORGANISM", 91, 98], ["patients", "SPECIES", 40, 48], ["patient", "SPECIES", 91, 98], ["infection", "PROBLEM", 54, 63], ["potential confounding factors", "PROBLEM", 132, 161], ["comorbidity", "PROBLEM", 171, 182], ["other chronic medication", "TREATMENT", 187, 211], ["infection", "OBSERVATION", 54, 63]]], ["In addition, the effect of antiplatelet therapy on the host response to critical illness has not been studied in patients.IntroductionThe aim of the present prospective observational study was to determine the association between pre-existing antiplatelet therapy and presentation and outcome of sepsis, and induction of biomarkers providing insight into hallmark host responses, making use of a large well-defined cohort of patients admitted to the ICU.", [["critical illness", "DISEASE", 72, 88], ["sepsis", "DISEASE", 296, 302], ["antiplatelet", "CELL", 27, 39], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 425, 433], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 425, 433], ["antiplatelet therapy", "TREATMENT", 27, 47], ["critical illness", "PROBLEM", 72, 88], ["the present prospective observational study", "TEST", 145, 188], ["pre-existing antiplatelet therapy", "TREATMENT", 230, 263], ["sepsis", "PROBLEM", 296, 302], ["biomarkers", "TEST", 321, 331], ["antiplatelet therapy", "OBSERVATION", 243, 263], ["sepsis", "OBSERVATION", 296, 302]]], ["We hypothesized that chronic antiplatelet therapy may improve sepsis outcome by mitigating the derailed host response.Study design, patients, and definitions ::: MethodsThis study was conducted as part of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) project, a prospective observational study in the mixed ICUs of two tertiary teaching hospitals (Academic Medical Center in Amsterdam and University Medical Center Utrecht) in the Netherlands between January 2011 and January 2014 (ClinicalTrials.gov identifier NCT01905033) [10, 11].", [["sepsis", "DISEASE", 62, 68], ["Sepsis", "DISEASE", 256, 262], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["chronic antiplatelet therapy", "TREATMENT", 21, 49], ["sepsis outcome", "PROBLEM", 62, 76], ["Methods", "TREATMENT", 162, 169], ["This study", "TEST", 169, 179], ["Sepsis", "PROBLEM", 256, 262], ["a prospective observational study", "TEST", 279, 312], ["chronic", "OBSERVATION_MODIFIER", 21, 28], ["antiplatelet therapy", "OBSERVATION", 29, 49], ["Sepsis", "OBSERVATION", 256, 262]]], ["Both ICUs comply with the Surviving Sepsis Guidelines [12].", [["Sepsis", "DISEASE", 36, 42]]], ["Dedicated observers prospectively collected the following data from all patients: demographics, comorbidities (including the Charlson comorbidity index [13]), chronic medication use, ICU admission characteristics (including the Acute Physiology and Chronic Health Evaluation (APACHE) IV score and the acute physiology score [14]), and daily physiological measurements, severity scores (including Sequential Organ Failure Assessment (SOFA) scores [15]), and culture results.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["the Acute Physiology", "PROBLEM", 224, 244], ["Chronic Health Evaluation", "TEST", 249, 274], ["IV score", "TEST", 284, 292], ["the acute physiology score", "PROBLEM", 297, 323], ["daily physiological measurements", "TEST", 335, 367], ["severity scores", "PROBLEM", 369, 384], ["Sequential Organ Failure Assessment", "TEST", 396, 431], ["SOFA) scores", "TEST", 433, 445], ["culture results", "TEST", 457, 472], ["chronic", "OBSERVATION_MODIFIER", 159, 166], ["Acute", "OBSERVATION_MODIFIER", 228, 233], ["Chronic", "OBSERVATION_MODIFIER", 249, 256]]], ["Organ failure was defined as a SOFA score of 3 or greater, except for cardiovascular failure for which a score of 1 or more was used [16].", [["Organ", "ANATOMY", 0, 5], ["cardiovascular", "ANATOMY", 70, 84], ["Organ failure", "DISEASE", 0, 13], ["cardiovascular failure", "DISEASE", 70, 92], ["Organ failure", "PROBLEM", 0, 13], ["a SOFA score", "TEST", 29, 41], ["cardiovascular failure", "PROBLEM", 70, 92], ["failure", "OBSERVATION", 6, 13], ["cardiovascular", "ANATOMY", 70, 84], ["failure", "OBSERVATION", 85, 92]]], ["Shock was defined as the use of vasopressors (noradrenaline) for hypotension in a dose of 0.1 \u03bcg/kg/min during at least 50 % of the ICU day.", [["noradrenaline", "CHEMICAL", 46, 59], ["hypotension", "DISEASE", 65, 76], ["noradrenaline", "CHEMICAL", 46, 59], ["noradrenaline", "SIMPLE_CHEMICAL", 46, 59], ["Shock", "PROBLEM", 0, 5], ["vasopressors (noradrenaline)", "TREATMENT", 32, 60], ["hypotension", "PROBLEM", 65, 76]]], ["The plausibility of infection was post hoc scored on the basis of all available evidence and classified on a 4-point scale (none, possible, probable, or definite) according to Centers for Disease Control and Prevention [17] and International Sepsis Forum consensus definitions [18], as described in detail previously [10].", [["infection", "DISEASE", 20, 29], ["Sepsis", "DISEASE", 242, 248], ["infection", "PROBLEM", 20, 29], ["Disease Control", "TREATMENT", 188, 203], ["infection", "OBSERVATION", 20, 29], ["Sepsis", "OBSERVATION", 242, 248]]], ["Daily (at admission and at 6 A.M. thereafter) left-over plasma (obtained from blood drawn for patient care) was stored within 4 h at \u221280 \u00b0C. The medical ethical committees of both study centers gave approval for an opt-out consent method (IRB no. 10-056C).", [["plasma", "ANATOMY", 56, 62], ["blood", "ANATOMY", 78, 83], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["blood", "TEST", 78, 83], ["left", "ANATOMY_MODIFIER", 46, 50]]], ["The Municipal Personal Records Database was consulted to determine survival up to 1 year after ICU admission.Study design, patients, and definitions ::: MethodsFor the current analysis we selected all patients included in the MARS study between January 2011 and July 2013 with sepsis, diagnosed within 24 h after admission, defined as a definite or probable infection [10] combined with at least one of general, inflammatory, hemodynamic, organ dysfunction, or tissue perfusion parameters derived from the 2001 International Sepsis Definitions Conference [19].", [["organ", "ANATOMY", 439, 444], ["tissue", "ANATOMY", 461, 467], ["sepsis", "DISEASE", 277, 283], ["infection", "DISEASE", 358, 367], ["Sepsis", "DISEASE", 525, 531], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 201, 209], ["organ", "ORGAN", 439, 444], ["tissue", "TISSUE", 461, 467], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 201, 209], ["Methods", "TREATMENT", 153, 160], ["the current analysis", "TEST", 164, 184], ["sepsis", "PROBLEM", 277, 283], ["infection", "PROBLEM", 358, 367], ["inflammatory, hemodynamic, organ dysfunction", "PROBLEM", 412, 456], ["tissue perfusion parameters", "TEST", 461, 488], ["sepsis", "OBSERVATION", 277, 283], ["probable", "UNCERTAINTY", 349, 357], ["infection", "OBSERVATION", 358, 367], ["inflammatory", "OBSERVATION", 412, 424]]], ["Readmissions, admissions for elective surgery, and patients transferred from another ICU were excluded, except for patients referred to one of the study centers on the day of admission.Biomarker measurements ::: MethodsAll measurements were done in EDTA anticoagulated plasma obtained within 24 h after admission (day 0) and days 2 and 4.", [["plasma", "ANATOMY", 269, 275], ["EDTA", "CHEMICAL", 249, 253], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 115, 123], ["EDTA", "SIMPLE_CHEMICAL", 249, 253], ["plasma", "ORGANISM_SUBSTANCE", 269, 275], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 115, 123], ["elective surgery", "TREATMENT", 29, 45], ["the study", "TEST", 143, 152], ["Biomarker measurements", "TEST", 185, 207], ["Methods", "TREATMENT", 212, 219], ["All measurements", "TEST", 219, 235]]], ["Assays are described in the online supplement.", [["Assays", "TEST", 0, 6]]], ["Normal biomarker values were acquired from EDTA plasma from 27 age- and gender-matched healthy volunteers, from whom written informed consent was obtained.Statistical analysis ::: MethodsData analyses were performed in R (v3.1.1).", [["plasma", "ANATOMY", 48, 54], ["EDTA", "CHEMICAL", 43, 47], ["plasma", "ORGANISM_SUBSTANCE", 48, 54], ["volunteers", "ORGANISM", 95, 105], ["EDTA plasma", "TEST", 43, 54], ["Statistical analysis", "TEST", 155, 175], ["MethodsData analyses", "TEST", 180, 200]]], ["Baseline characteristics of study groups were compared with the Chi-square test for categorical variables and t test or Wilcoxon rank sum test for continuous variables.", [["study groups", "TEST", 28, 40], ["the Chi-square test", "TEST", 60, 79], ["categorical variables", "TEST", 84, 105], ["t test", "TEST", 110, 116], ["Wilcoxon rank sum test", "TEST", 120, 142]]], ["Mixed-effects models were executed to analyze repeated measurements.", [["repeated measurements", "TEST", 46, 67]]], ["Propensity score matching and Cox proportional hazards regression analyses were performed as described in the online supplement.", [["Propensity score matching", "PROBLEM", 0, 25], ["Cox proportional hazards regression analyses", "PROBLEM", 30, 74]]], ["To account for random effects of propensity matching, appropriate tests were used in the propensity-matched cohort: paired t test, Wilcoxon signed-rank test, McNemar test, stratified log-rank test, and Cox frailty model.", [["appropriate tests", "TEST", 54, 71], ["paired t test", "TEST", 116, 129], ["McNemar test", "TEST", 158, 170], ["stratified log-rank test", "TEST", 172, 196], ["Cox frailty model", "TEST", 202, 219]]], ["Because of missing plasma samples in both groups (discharge, death, logistics), a paired test was not suitable to compare plasma sample measurements in the matched cohort.", [["plasma samples", "ANATOMY", 19, 33], ["plasma sample", "ANATOMY", 122, 135], ["death", "DISEASE", 61, 66], ["plasma samples", "ORGANISM_SUBSTANCE", 19, 33], ["plasma", "ORGANISM_SUBSTANCE", 122, 128], ["missing plasma samples", "PROBLEM", 11, 33], ["a paired test", "TEST", 80, 93], ["plasma sample measurements", "TEST", 122, 148]]], ["P values below 0.05 were considered significant.Patients ::: ResultsA total of 6994 admissions were included in the MARS study from January 2011 until July 2013, of which 1483 involved an admission diagnosis of sepsis.", [["sepsis", "DISEASE", 211, 217], ["Patients", "ORGANISM", 48, 56], ["Patients", "SPECIES", 48, 56], ["P values", "TEST", 0, 8], ["the MARS study", "TEST", 112, 126], ["sepsis", "PROBLEM", 211, 217], ["sepsis", "OBSERVATION", 211, 217]]], ["A total of 129 transfers from other ICUs and 250 readmissions were excluded; prior use of medication could not be retrieved in 44 cases.", [["medication", "TREATMENT", 90, 100]]], ["In addition, 88 patients admitted for elective surgery were excluded.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["elective surgery", "TREATMENT", 38, 54]]], ["As a result, 972 patients were included for analysis (523 in AMC, 449 in UMCU), of whom 267 (27.5 %) were on chronic antiplatelet therapy prior to ICU admission.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["analysis", "TEST", 44, 52], ["chronic antiplatelet therapy", "TREATMENT", 109, 137]]], ["Acetylsalicylic acid was the most commonly used antiplatelet drug (95.9 %), whereas clopidogrel and dipyridamole were used by 16.1 and 12.4 % of the patients on antiplatelet therapy, respectively; 67 patients (25.1 %) were on more than one antiplatelet drug.", [["Acetylsalicylic acid", "CHEMICAL", 0, 20], ["clopidogrel", "CHEMICAL", 84, 95], ["dipyridamole", "CHEMICAL", 100, 112], ["Acetylsalicylic acid", "CHEMICAL", 0, 20], ["clopidogrel", "CHEMICAL", 84, 95], ["dipyridamole", "CHEMICAL", 100, 112], ["Acetylsalicylic acid", "SIMPLE_CHEMICAL", 0, 20], ["clopidogrel", "SIMPLE_CHEMICAL", 84, 95], ["dipyridamole", "SIMPLE_CHEMICAL", 100, 112], ["patients", "ORGANISM", 149, 157], ["antiplatelet", "CELL", 161, 173], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 149, 157], ["patients", "SPECIES", 200, 208], ["Acetylsalicylic acid", "TREATMENT", 0, 20], ["antiplatelet drug", "TREATMENT", 48, 65], ["clopidogrel", "TREATMENT", 84, 95], ["dipyridamole", "TREATMENT", 100, 112], ["antiplatelet therapy", "TREATMENT", 161, 181], ["one antiplatelet drug", "TREATMENT", 236, 257]]], ["Patients with antiplatelet therapy were older than those without, and more frequently men.", [["Patients", "ORGANISM", 0, 8], ["antiplatelet", "CELL", 14, 26], ["men", "ORGANISM", 86, 89], ["Patients", "SPECIES", 0, 8], ["men", "SPECIES", 86, 89], ["antiplatelet therapy", "TREATMENT", 14, 34]]], ["As expected, cardiovascular disease was much more prevalent in antiplatelet therapy users, together with diabetes mellitus and COPD; non-users had a greater frequency of malignancies.", [["cardiovascular", "ANATOMY", 13, 27], ["antiplatelet", "ANATOMY", 63, 75], ["malignancies", "ANATOMY", 170, 182], ["cardiovascular disease", "DISEASE", 13, 35], ["diabetes mellitus", "DISEASE", 105, 122], ["COPD", "DISEASE", 127, 131], ["malignancies", "DISEASE", 170, 182], ["cardiovascular", "ANATOMICAL_SYSTEM", 13, 27], ["antiplatelet", "CELL", 63, 75], ["malignancies", "CANCER", 170, 182], ["cardiovascular disease", "PROBLEM", 13, 35], ["antiplatelet therapy", "TREATMENT", 63, 83], ["diabetes mellitus", "PROBLEM", 105, 122], ["COPD", "PROBLEM", 127, 131], ["malignancies", "PROBLEM", 170, 182], ["cardiovascular", "ANATOMY", 13, 27], ["disease", "OBSERVATION", 28, 35], ["COPD", "OBSERVATION", 127, 131], ["malignancies", "OBSERVATION", 170, 182]]], ["In accordance, antiplatelet therapy users were also more frequently on other vasoactive drugs, including statins, ACE inhibitors, beta-blockers, and calcium channel blockers.", [["antiplatelet", "ANATOMY", 15, 27], ["statins", "CHEMICAL", 105, 112], ["calcium", "CHEMICAL", 149, 156], ["statins", "CHEMICAL", 105, 112], ["calcium", "CHEMICAL", 149, 156], ["antiplatelet", "CELL", 15, 27], ["statins", "SIMPLE_CHEMICAL", 105, 112], ["ACE", "GENE_OR_GENE_PRODUCT", 114, 117], ["beta-blockers", "SIMPLE_CHEMICAL", 130, 143], ["calcium channel blockers", "SIMPLE_CHEMICAL", 149, 173], ["antiplatelet therapy", "TREATMENT", 15, 35], ["other vasoactive drugs", "TREATMENT", 71, 93], ["statins", "TREATMENT", 105, 112], ["ACE inhibitors", "TREATMENT", 114, 128], ["beta-blockers", "TREATMENT", 130, 143], ["calcium channel blockers", "TREATMENT", 149, 173]]], ["Sites of infection and causative pathogens did not differ between users and non-users of antiplatelet agents (Supplemental Table 1).", [["infection", "DISEASE", 9, 18], ["infection", "PROBLEM", 9, 18], ["causative pathogens", "PROBLEM", 23, 42], ["antiplatelet agents", "TREATMENT", 89, 108], ["infection", "OBSERVATION", 9, 18]]]], "b6e8ffbcb91c70ea9688676135228b4cb1173883": [["I. INTRODUCTION\"In the next influenza pandemic, be it now or in the future, be the virus mild or virulent, the single most important weapon against the disease will be a vaccine.", [["influenza pandemic", "DISEASE", 28, 46], ["the virus mild", "PROBLEM", 79, 93], ["virulent", "PROBLEM", 97, 105], ["the disease", "PROBLEM", 148, 159], ["a vaccine", "TREATMENT", 168, 177]]], ["This evocative sentence was written in May 2009 by John M. Barry, in the early phases of what soon after become the H1N1 2009 pandemic.", [["pandemic", "PROBLEM", 126, 134]]], ["In his essay, Barry summarised the mishandling of the deadly 1918 Spanish flu highlighting the importance of precise, effective and honest information in the onset of health crises.I. INTRODUCTIONEleven years later we find ourselves dealing with another pandemic.", [["health crises", "PROBLEM", 167, 180]]], ["The cause is not a novel strain of influenza, but these words are, unfortunately, still extremely relevant.", [["influenza", "DISEASE", 35, 44], ["influenza", "PROBLEM", 35, 44], ["influenza", "OBSERVATION", 35, 44]]], ["In fact, as the SARS-CoV-2 sweeps the world and the vaccine is just a far vision of hope, the most important weapons to reduce the burden of the disease are non-pharmaceutical interventions [2, 3] .", [["SARS", "DISEASE", 16, 20], ["the SARS", "TEST", 12, 20], ["the vaccine", "TREATMENT", 48, 59], ["the disease", "PROBLEM", 141, 152], ["non-pharmaceutical interventions", "TREATMENT", 157, 189], ["disease", "OBSERVATION", 145, 152]]], ["Social distancing became paramount, gatherings have been cancelled, mobility within and across countries have been dramatically reduced.", [["dramatically", "OBSERVATION_MODIFIER", 115, 127], ["reduced", "OBSERVATION_MODIFIER", 128, 135]]], ["As happened in 1918, despite early evidences from China [5, 6] , the virus was first equated, by many, to the normal seasonal flu.", [["flu", "DISEASE", 126, 129], ["the virus", "PROBLEM", 65, 74], ["seasonal", "OBSERVATION_MODIFIER", 117, 125], ["flu", "OBSERVATION", 126, 129]]], ["As happened in 1918, many national and regional governments organised campaigns aimed at boosting social activities (and thus local economies) actively trying to convince people that their cities were safe and that * andre.panisson@isi.it \u2020 n.perra@greenwich.ac.uk the spreading was isolated in far away locations.", [["people", "ORGANISM", 171, 177], ["people", "SPECIES", 171, 177]]], ["A series of surveys conducted in late February provide a glimpse of the possible effects of these approaches.", [["these approaches", "TREATMENT", 92, 108]]], ["They report that citizens of several European countries, despite the grim news coming from Asia, were overly optimistic about the health emergency placing their risk of infections to be 1% or less [9] .", [["infections", "DISEASE", 169, 179], ["infections", "PROBLEM", 169, 179], ["infections", "OBSERVATION", 169, 179]]], ["As happened in 1918, the countries that reacted earlier rather than later were able to control the virus with significant less victims [10] [11] [12] [13] [14] .I. INTRODUCTIONHistory repeats itself, but the context often is radically different.", [["the virus", "PROBLEM", 95, 104], ["significant less victims", "PROBLEM", 110, 134]]], ["In 1918, news circulated slowly via news papers, controlled by editorial choices, and of course words of mouth.", [["mouth", "ANATOMY", 105, 110], ["mouth", "ORGANISM_SUBDIVISION", 105, 110], ["mouth", "ANATOMY", 105, 110]]], ["Today these platforms and websites are far more popular, integral part of society and instrumental pieces of the national and international news circulations.", [["society", "OBSERVATION", 74, 81], ["instrumental pieces", "OBSERVATION", 86, 105]]], ["As such, they are fundamental drivers of people perception, opinions, and thus behaviours.", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47]]], ["For example, about 60% of adults in the USA consulted online sources to gather health information [15] .I. INTRODUCTIONWith respect to past epidemics and pandemics, studies on traditional news coverage of the 2009 H1N1 pandemic highlighted the importance of framing and its effect on people's perception, behaviours (such as vaccination intent), stigmatisation of cultures at the epicentre of the outbreak, and how these factors differ across countries/cultures [16] [17] [18] [19] [20] [21] .", [["H1N1", "DISEASE", 214, 218], ["[16] [17] [18] [19] [20]", "CHEMICAL", 462, 486], ["adults", "ORGANISM", 26, 32], ["people", "ORGANISM", 284, 290], ["[16] [17] [18] [19] [20", "SIMPLE_CHEMICAL", 462, 485], ["people", "SPECIES", 284, 290], ["pandemics", "PROBLEM", 154, 163], ["stigmatisation of cultures", "PROBLEM", 346, 372], ["cultures", "TEST", 453, 461]]], ["During Zika epidemic in 2016, public attention was synchronised across US states, driven by news coverage about the outbreak and independently of the real local risk of infection [22] .", [["infection", "DISEASE", 169, 178], ["infection", "PROBLEM", 169, 178], ["infection", "OBSERVATION", 169, 178]]], ["With respect to COVID-19 pandemic itself, a recent study clearly shows how Google searches for \"coronavirus\" in the USA spiked significantly right after the announcement of the first confirmed case in each state [23] .", [["COVID", "TEST", 16, 21], ["a recent study", "TEST", 42, 56], ["\"coronavirus", "PROBLEM", 95, 107]]], ["Several studies based on Twitter data also highlight how misinformation and low quality information about COVID-19, although overall limited, spread before the local outbreak and rapidly took off once the local epidemic started.", [["Several studies", "TEST", 0, 15], ["Twitter data", "TEST", 25, 37], ["COVID", "TEST", 106, 111]]], ["In fact, posts on Twitter [28] [29] [30] [31] [32] [33] , Facebook [34] , and Reddit [35, 36] , page views in Wikipedia [37, 38] and searches on Google [39, 40] have been used to study, nowcast and predict the spreading of infectious diseases as well as the prevalence of noncommunicable illnesses.", [["infectious diseases", "DISEASE", 223, 242], ["noncommunicable illnesses", "DISEASE", 272, 297], ["infectious diseases", "PROBLEM", 223, 242], ["noncommunicable illnesses", "PROBLEM", 272, 297], ["infectious", "OBSERVATION", 223, 233]]], ["Therefore, in the current full-fledged digital society, information is not only key to inform people's behaviour but can be used to develop an unprecedented understanding of such behaviours, as well as of the phenomena driving them.I. INTRODUCTIONThe context where COVID-19 is unfolding is thus very heterogeneous and complex.", [["COVID-19", "CHEMICAL", 265, 273], ["COVID-19", "CHEMICAL", 265, 273], ["people", "ORGANISM", 94, 100], ["COVID-19", "DNA", 265, 273], ["people", "SPECIES", 94, 100], ["COVID", "TEST", 265, 270], ["unfolding", "OBSERVATION", 277, 286], ["very", "OBSERVATION_MODIFIER", 295, 299], ["heterogeneous", "OBSERVATION", 300, 313], ["complex", "OBSERVATION_MODIFIER", 318, 325]]], ["Traditional and social media are integral parts of our perception and opinions, have the potential to trigger behaviour change and thus influence the pandemic spreading.", [["behaviour change", "PROBLEM", 110, 126], ["the pandemic spreading", "PROBLEM", 146, 168]]], ["Such complex landscape must be characterized in order to understand the public attention and response to media coverage.", [["Such complex landscape", "PROBLEM", 0, 22], ["media coverage", "TREATMENT", 105, 119], ["complex", "OBSERVATION_MODIFIER", 5, 12], ["landscape", "OBSERVATION", 13, 22]]], ["Here, we tackle this challenge by assembling an heterogeneous dataset which includes 227, 768 news and 13, 448 YouTube videos published by traditional media, 278, 456, 892 views of topical Wikipedia pages, 107, 898 submissions and 3, 829, 309 comments from 417, 541 distinct users on Reddit, as well as epidemic data in four different countries: Italy, United Kingdom, United States, and Canada.I. INTRODUCTIONFirst, we explore how media coverage and epidemic progression influence public attention and response.", [["Reddit", "TEST", 284, 290], ["epidemic data", "TEST", 303, 316], ["media coverage", "TREATMENT", 432, 446], ["heterogeneous", "OBSERVATION_MODIFIER", 48, 61]]], ["To achieve this, we analyze news volume and COVID-19 incidence with respect to Wikipedia page views volume and Reddit comments.", [["COVID", "TREATMENT", 44, 49]]], ["Our results show that public attention and response are mostly driven by media coverage rather than disease spreading.", [["disease spreading", "PROBLEM", 100, 117]]], ["Furthermore, we observe typical saturation and memory effects of public collective attention.", [["typical saturation", "PROBLEM", 24, 42], ["public collective attention", "TREATMENT", 65, 92]]], ["We show that, while attentions of news outlets and online users towards different topics are in good accordance, interesting deviations emerge in their temporal patterns.", [["temporal", "ANATOMY_MODIFIER", 152, 160]]], ["Also, we highlight that, at the end of our observation period, general interest grows towards topics about the resumption of activities after lockdown, the search for a vaccine against Sars-Cov-2, acquired immunity and antibodies tests.", [["antibodies", "PROTEIN", 219, 229], ["lockdown", "TREATMENT", 142, 150], ["a vaccine", "TREATMENT", 167, 176], ["Sars", "TEST", 185, 189], ["Cov", "TEST", 190, 193], ["antibodies tests", "TEST", 219, 235]]], ["Overall, the research presented here offers insights to interpret public perception/response to the current global health emergency, raises interrogatives about the effects of attention saturation on collective awareness, risk perception and thus on tendencies towards behavioural changes.II. IMPACT OF MEDIA COVERAGE AND EPIDEMIC PROGRESSION ON COLLECTIVE ATTENTIONHow is collective attention shaped by news media coverage and epidemic progression?", [["II", "CHEMICAL", 289, 291], ["attention saturation", "TEST", 176, 196], ["risk perception", "PROBLEM", 222, 237], ["behavioural changes", "PROBLEM", 269, 288], ["news media coverage", "TREATMENT", 404, 423], ["epidemic progression", "PROBLEM", 428, 448], ["MEDIA COVERAGE", "OBSERVATION", 303, 317]]], ["To tackle this important question, we collected an heterogeneous dataset that includes COVID-19 related news articles and Youtube videos published online by mainstream information media, relevant posts and relative discussion of geolocalized Reddit users, and country-specific views to Wikipedia pages related to COVID-19 for Italy, United Kingdom, United States and Canada (see subsections A, B, C of Methods and Materials for details).", [["COVID", "TEST", 87, 92]]], ["This choice aims to provide an overview of media coverage and a proxy of public attention and response.", [["media coverage", "TREATMENT", 43, 57]]], ["On the one hand, the study of news articles and videos allows us to estimate the exposure of the public to COVID-19 pandemic in traditional news media.", [["the study", "TEST", 17, 26], ["COVID", "TEST", 107, 112]]], ["On the other hand, the study of users discussions and response on social media (through Reddit) and information seeking (through Wikipedia page views) allows us to quantify the reaction of individuals to both the COVID-19 pandemic and news exposure.", [["pandemic", "DISEASE", 222, 230], ["the study", "TEST", 19, 28], ["the reaction of individuals", "PROBLEM", 173, 200]]], ["As mentioned in the introduction, previous studies showed the usefulness of social media, internet use and search trends to analyze health-related information streams and monitor public reaction to infectious diseases [41] [42] [43] [44] [45] .II. IMPACT OF MEDIA COVERAGE AND EPIDEMIC PROGRESSION ON COLLECTIVE ATTENTIONHence, we consider volume of comments of geolocalized users on the subreddit /r/Coronavirus 1 to explore the public discussion in reaction to media covering the epidemic in the various countries, while we consider the number of views of relevant Wikipedia pages about COVID-19 pandemic to quantify users interest.", [["infectious diseases", "DISEASE", 198, 217], ["II", "CHEMICAL", 244, 246], ["[41] [42] [43] [44]", "CHEMICAL", 218, 237], ["[42] [43] [44", "SIMPLE_CHEMICAL", 223, 236], ["previous studies", "TEST", 34, 50], ["the subreddit /r/Coronavirus", "TREATMENT", 384, 412], ["media", "TREATMENT", 463, 468], ["MEDIA COVERAGE", "OBSERVATION", 258, 272]]], ["In fact, while Reddit posts can be regarded as a general indicator of the online discussion surrounding the global health emergency, the number of access to COVID-19 related Wikipedia pages is a proxy of health information seeking behaviour (HISB).", [["COVID", "TEST", 157, 162]]], ["HISB is the act through which individuals retrieve and acquire new knowledge about a specific topic related to health [46, 47] , and it is likely to be triggered on a population scale by a disrupting event, such as the threaten of a previously unknown disease [48, 49] .", [["likely to be", "UNCERTAINTY", 139, 151]]], ["Normalized weekly volume of news articles and Youtube videos (news)), Reddit comments (reddit), Wikipedia views (wikipedia) related to COVID-19 pandemic and COVID-19 incidence (covid inc.) in different countries.II. IMPACT OF MEDIA COVERAGE AND EPIDEMIC PROGRESSION ON COLLECTIVE ATTENTIONOur analysis starts by comparing, in Figure 1 , the weekly volume of news and videos published on Youtube, Wikipedia views, and Reddit comments of geolocalized users in comparison with the weekly COVID-19 incidence in the four countries considered.", [["II", "CHEMICAL", 212, 214], ["COVID", "TEST", 135, 140], ["COVID", "TREATMENT", 157, 162], ["COLLECTIVE ATTENTIONOur analysis", "TEST", 269, 301], ["MEDIA COVERAGE", "OBSERVATION", 226, 240]]], ["It can be seen how, as COVID-19 spreads, both media coverage and public interest grow in time.", [["COVID", "TEST", 23, 28], ["both media coverage", "TREATMENT", 41, 60]]], ["However, public attention, quantified by the number of Reddit comments and Wikipedia views, sharply decreases after reaching a peak, despite the volume of news and COVID-19 incidence remaining high.", [["Wikipedia views", "TEST", 75, 90], ["COVID", "TEST", 164, 169], ["sharply", "OBSERVATION_MODIFIER", 92, 99], ["decreases", "OBSERVATION_MODIFIER", 100, 109]]], ["Furthermore, the peak in public attention consistently anticipates the maximum media exposure and maximum COVID-19 incidence.II. IMPACT OF MEDIA COVERAGE AND EPIDEMIC PROGRESSION ON COLLECTIVE ATTENTIONThe correlation between media coverage, public attention, and the epidemic progression is quantified more in details in Figure 2 .", [["II", "CHEMICAL", 125, 127], ["maximum COVID", "TEST", 98, 111], ["media coverage", "TREATMENT", 226, 240], ["public attention", "TREATMENT", 242, 258], ["the epidemic progression", "PROBLEM", 264, 288], ["peak", "OBSERVATION_MODIFIER", 17, 21], ["MEDIA COVERAGE", "OBSERVATION", 139, 153]]], ["The plot shows that news coverage of each country is strongly correlated with COVID-19 incidence (both global and domestic), and slightly less with the volume of Reddit comments and Wikipedia views, which, in turn, are much less correlated with COVID-19 incidence (both global and domestic).", [["The plot", "TEST", 0, 8], ["COVID", "TEST", 78, 83], ["Wikipedia views", "TEST", 182, 197], ["COVID", "TEST", 245, 250]]], ["This holds for all countries under consideration and highlights how the disease spreading triggers media coverage, and how the public response is more likely driven by such news exposure in each country rather than COVID-19 progression.", [["the disease spreading", "PROBLEM", 68, 89], ["media coverage", "TREATMENT", 99, 113], ["more likely", "UNCERTAINTY", 146, 157]]], ["Beyond these observations, it is interesting to notice from Figure 2 that Italy is the only country where news volume shows higher correlation with domestic rather than global incidence.", [["news volume", "TEST", 106, 117]]], ["This suggests that Italian media coverage follows more closely the internal evolution rather than the global one, at odds with respect to other countries.", [["Italian media coverage", "TREATMENT", 19, 41]]], ["This is probably due to Italy being the location of the first COVID-19 outbreak outside Asia.", [["probably due to", "UNCERTAINTY", 8, 23]]], ["This observation is supported by Figure 3 , showing the citation share of Italian locations by Italian news media, before and after the first COVID-19 death was confirmed in Italy on 2020/02/20.", [["death", "DISEASE", 151, 156]]], ["After this date, Italian locations represent about 74% of all places cited by Italian media (in our dataset), with an increase of 45% with respect to the same statistics calculated before.", [["increase", "OBSERVATION_MODIFIER", 118, 126]]], ["Similar effects, though generally less intense, can be observed also in the other countries.", [["generally", "OBSERVATION_MODIFIER", 24, 33], ["less intense", "OBSERVATION_MODIFIER", 34, 46]]], ["Therefore, while media coverage is generally well synchronized with the global COVID-19 incidence, the media attention gradually shifts towards the internal evolution of the pandemic as soon as domestic outbreaks erupt.", [["media coverage", "TREATMENT", 17, 31], ["pandemic", "OBSERVATION", 174, 182]]], ["Indeed, previous studies showed how at the beginning of February 2020 people were overly optimistic regarding the risks associated with the new virus circulating in Asia, and how their perception sharply changed after first cases were confirmed in their countries [9, 53] .II. IMPACT OF MEDIA COVERAGE AND EPIDEMIC PROGRESSION ON COLLECTIVE ATTENTIONTo explore more systematically the relationship between media coverage, public attention and epidemic progression, we consider a linear regression model to nowcast, separately for each country, collective public attention (quantified with the number of comments by geolocalized Reddit users or visits to relevant Wikipedia pages) given the volume of media coverage or the COVID-19 incidence as independent variables.", [["II", "CHEMICAL", 273, 275], ["people", "ORGANISM", 70, 76], ["people", "SPECIES", 70, 76], ["previous studies", "TEST", 8, 24], ["media coverage", "TREATMENT", 406, 420], ["epidemic progression", "PROBLEM", 443, 463], ["the volume of media coverage", "TREATMENT", 686, 714], ["the COVID", "TREATMENT", 718, 727], ["MEDIA COVERAGE", "OBSERVATION", 287, 301]]], ["We found that the model considering only COVID-19 incidence has much less predictive power than the ones considering me- dia coverage (see Table II in Methods and Material).", [["COVID", "TEST", 41, 46], ["me- dia coverage", "TREATMENT", 117, 133]]], ["This implies that public attention actually saturates in response to news exposure and gives us the chance to quantify the rate at which this phenomenon happens.II. IMPACT OF MEDIA COVERAGE AND EPIDEMIC PROGRESSION ON COLLECTIVE ATTENTIONThe results presented so far are in very good accordance with findings obtained in previous contexts related to epidemics and pandemics.", [["II", "CHEMICAL", 161, 163], ["epidemics", "PROBLEM", 350, 359], ["pandemics", "PROBLEM", 364, 373], ["MEDIA COVERAGE", "OBSERVATION", 175, 189]]], ["Indeed, a similar media-driven spiky unfolding of public attention, measured through the information seeking and public discussions of online users, has been observed during the 2009 H1N1 influenza pandemic [57, 58] , the 2016 Zika outbreak [59] , the seasonal flu [60] and during more localized public health emergency such as the 2013 measles outbreak in Netherlands [61] .", [["influenza", "DISEASE", 188, 197], ["measles", "DISEASE", 337, 344], ["H1N1 influenza pandemic", "SPECIES", 183, 206], ["the seasonal flu", "TEST", 248, 264]]], ["Our findings confirm the central role of media, showing how media exposure is capable of shaping and driving collective attention during a national and global health emergency.II. IMPACT OF MEDIA COVERAGE AND EPIDEMIC PROGRESSION ON COLLECTIVE ATTENTIONMedia exposure is an important factor that can influence individual risk perception as well [62] [63] [64] .", [["II", "CHEMICAL", 176, 178], ["central", "ANATOMY_MODIFIER", 25, 32], ["MEDIA COVERAGE", "OBSERVATION", 190, 204]]], ["This becomes an even greater concern in a context where the most effective strategy to fight the spreading are containment measures based on individuals' behaviour.", [["containment measures", "TREATMENT", 111, 131]]], ["For this reason, in the next section we characterize media coverage and online users response more specifically in terms of content produced and consumed.III. DYNAMICS OF CONTENT PRODUCTION AND CONSUMPTIONWhile collective attention and media coverage are well correlated in terms of volume, the content and topics discussed by media and consumed by online users may not be as synchronized [65, 66] .", [["media coverage", "TREATMENT", 53, 67], ["media coverage", "TREATMENT", 236, 250]]], ["We then apply a topic modelling approach on the content of this news article set.", [["a topic modelling approach", "TREATMENT", 14, 40]]], ["A complete list of the 64 topics extracted with the most frequent words is provided in the Supplementary Information.III. DYNAMICS OF CONTENT PRODUCTION AND CONSUMPTIONWe consider the number of articles published on a certain topic as a proxy of general interest of traditional media towards it, while we measure the collective interest of Reddit users by the number of comments under the news articles on a specific topic.", [["traditional media", "TREATMENT", 266, 283]]], ["We find a diverse and heterogeneous set of topics.", [["diverse", "OBSERVATION_MODIFIER", 10, 17], ["heterogeneous", "OBSERVATION_MODIFIER", 22, 35]]], ["Among others, we recognize topics about the global spreading of the virus (Outbreaks, WHO, CDC), COVID-19 symptoms, treatment, hospitals and care facilities (Symptoms, Medical Treatment, Medical Staff, Care Facilities), the economic impact of the pandemic and responses from the governments to the upcoming crisis (Economy, Money), different societal aspects (Sports, Religious Services, Education), and also the possible interven- Overall, the attention of traditional media and Reddit users towards different topics are in good accordance.", [["the virus", "PROBLEM", 64, 73], ["COVID", "TEST", 97, 102], ["symptoms", "PROBLEM", 106, 114], ["treatment", "TREATMENT", 116, 125], ["Symptoms", "PROBLEM", 158, 166], ["traditional media", "TREATMENT", 458, 475]]], ["We observe a maximum absolute mismatch in interest share of 2.61%.", [["a maximum absolute mismatch", "PROBLEM", 11, 38], ["maximum", "OBSERVATION_MODIFIER", 13, 20], ["absolute mismatch", "OBSERVATION", 21, 38]]], ["Nonetheless, we observe that Reddit users are slightly more interested to topics regarding health (Symptoms, Medical Treatment), non-pharmaceutical interventions and personal protective equipment (Social Distancing, Face Masks), studies and information on the epidemic (Research, Surveys, Santa Clara Study, CDC), and also to specific public figures such as Anthony Fauci.", [["Symptoms", "PROBLEM", 99, 107], ["Medical Treatment", "TREATMENT", 109, 126], ["non-pharmaceutical interventions", "TREATMENT", 129, 161], ["personal protective equipment", "TREATMENT", 166, 195]]], ["Since the study suggests a lower mortality rate, the preprint has been quickly leveraged to support protest against lockdowns 2 , while substantial flaws have been detected in the scientific methodology of the paper 3 .", [["the study", "TEST", 6, 15], ["a lower mortality rate", "PROBLEM", 25, 47], ["lower", "OBSERVATION_MODIFIER", 27, 32]]], ["However, topics showing a similar overall statistics may present a mismatch in temporal patterns.", [["a mismatch in temporal patterns", "PROBLEM", 65, 96], ["mismatch", "OBSERVATION", 67, 75], ["temporal", "ANATOMY_MODIFIER", 79, 87]]], ["In Figure 5 we represent each topic as a single point: its x-coordinate (y-coordinate) indicates when such topic reached 50% of its total relevance in news outlets (on Reddit) during the analysis interval (see subsection E of Methods and Materials for a formal definition of the relevance of a topic).", [["the analysis interval", "TEST", 183, 204]]], ["Among these, we recognize themes centred on early COVID-19 outbreaks (i.e., Chinese, Japanese, Iranian and Italian outbreaks), the events related to cruise ships, specific countries (i.e., Israel, Singapore and Malaysia), and also topics regarding (early) health issues such as Symptoms, Confirmed Cases and the CDC.III. DYNAMICS OF CONTENT PRODUCTION AND CONSUMPTIONOn the contrary, topics in the top right became relevant toward the end of the analysis interval (early May).", [["Symptoms", "PROBLEM", 278, 286], ["CONSUMPTIONOn the contrary", "TREATMENT", 356, 382], ["right", "ANATOMY_MODIFIER", 402, 407]]], ["Reasonably, we find here topics about the resumption of activities after lockdown (i.e. Reopening), the feasibility and timing of a possible vaccine against Sars-Cov-2 (i.e. Vaccine), and discussions regarding acquired immunity and antibodies tests (i.e. Immunity).", [["antibodies", "PROTEIN", 232, 242], ["lockdown", "TREATMENT", 73, 81], ["vaccine", "TREATMENT", 141, 148], ["Sars", "PROBLEM", 157, 161], ["antibodies tests", "TEST", 232, 248]]], ["In-between, we find all other topics clustered around end of March and mid-April 2020, the period when the general discussion surrounding COVID-19 pandemic aroused sharply, as also shown in Figure 1 .III. DYNAMICS OF CONTENT PRODUCTION AND CONSUMPTIONNote that the diagonal (plotted as a dashed line) in Figure 5 separates topics according to their temporal evolution.", [["mid-April", "TREATMENT", 71, 80], ["COVID", "TEST", 138, 143], ["a dashed line", "TREATMENT", 286, 299], ["temporal", "OBSERVATION_MODIFIER", 349, 357]]], ["Above (below) the diagonal, we find topics whose interest on Reddit grows slowly (quickly) with respect to the media coverage.", [["the media coverage", "TREATMENT", 107, 125]]], ["Therefore, above the diagonal the interest of Reddit users is mainly triggered by media exposure, while below it the interest grows faster and declines rapidly despite sustained media exposure.", [["Reddit", "CHEMICAL", 46, 52]]], ["While the top-left and bottom-right regions are empty, indicating that, as a first approximation, temporal patterns of attention by traditional media and Reddit users are well-synchronized, interesting deviations from the diagonal are observable.", [["top-left and bottom-right regions", "DNA", 10, 43], ["top", "OBSERVATION_MODIFIER", 10, 13], ["left", "ANATOMY_MODIFIER", 14, 18], ["bottom", "ANATOMY_MODIFIER", 23, 29], ["right", "ANATOMY_MODIFIER", 30, 35], ["regions", "ANATOMY_MODIFIER", 36, 43], ["empty", "OBSERVATION", 48, 53], ["diagonal", "ANATOMY_MODIFIER", 222, 230]]], ["For example, above the diagonal one can find mainly topics related to various outbreaks, economics and politics, for which the interests on Reddit follows the media coverage.", [["the media coverage", "TREATMENT", 155, 173], ["diagonal", "ANATOMY_MODIFIER", 23, 31], ["various", "OBSERVATION_MODIFIER", 70, 77], ["outbreaks", "OBSERVATION", 78, 87]]], ["Below the diagonal, we observe topics more related to everyday life, such as Schools, Medical Staff, Care Facilities, and Lockdown, for which the attention on Reddit accelerates with respect to media coverage, and then declines rapidly.", [["media coverage", "TREATMENT", 194, 208], ["diagonal", "ANATOMY_MODIFIER", 10, 18]]], ["This ensures a proper comparison with topics extracted from news published and explains the absence of points in the bottom right corner of Figure 5 .IV. CONCLUSIONSIn this work, we characterized the response of online users to both media coverage and COVID-19 pandemic progression.", [["both media coverage", "TREATMENT", 228, 247], ["COVID", "TREATMENT", 252, 257], ["bottom", "ANATOMY_MODIFIER", 117, 123], ["right", "ANATOMY_MODIFIER", 124, 129]]], ["As a first step, we focused on the impact of media coverage on collective attention in different countries, characterized as volumes of country-specific Wikipedia pages views and comments of geolocalized Reddit users.", [["media coverage", "TREATMENT", 45, 59]]], ["We showed that collective attention was mainly driven by media coverage rather than epidemic progression, rapidly saturated, and decreased despite media coverage and COVID-19 incidence remaining high.", [["media coverage", "TREATMENT", 57, 71], ["epidemic progression", "PROBLEM", 84, 104], ["media coverage", "TREATMENT", 147, 161], ["COVID", "TEST", 166, 171], ["rapidly", "OBSERVATION_MODIFIER", 106, 113], ["saturated", "OBSERVATION_MODIFIER", 114, 123], ["decreased", "OBSERVATION_MODIFIER", 129, 138]]], ["This trend is very similar to that observed during other outbreaks [57] [58] [59] [60] [61] .", [["[57] [58] [59] [60]", "CHEMICAL", 67, 86], ["[57] [58] [59] [60", "SIMPLE_CHEMICAL", 67, 85]]], ["Also, we showed how media coverage sharply shifted to the domestic situation as soon as the first death was confirmed in the home country, discussing the implications for re-shaping individuals perception of risk [9, 53] .IV. CONCLUSIONSAs a second step, we focused on the dynamics of content production and consumption.", [["death", "DISEASE", 98, 103]]], ["We modeled topics published in mainstream media and discussed on Reddit, showing that Reddit users were generally more interested in health, data regarding the new disease, and interventions needed to halt the spreading with respect to media exposure.", [["mainstream media", "TREATMENT", 31, 47], ["the new disease", "PROBLEM", 156, 171], ["interventions", "TREATMENT", 177, 190], ["new", "OBSERVATION_MODIFIER", 160, 163], ["disease", "OBSERVATION", 164, 171]]], ["By taking into account the dynamics of topics extracted, we show that, while their temporal patterns are generally synchronized, the public attention for topics related to politics and economics is mainly triggered by media exposure, while the interests for topics more related to daily life accelerates on Reddit with respect to media coverage.IV. CONCLUSIONSOf course, our research comes with limitations.", [["Reddit", "TREATMENT", 307, 313], ["media coverage", "TREATMENT", 330, 344]]], ["First, we characterized the exposure of individuals to COVID-19 pandemic by considering only news articles and Youtube videos published online by major news outlets.", [["COVID", "TEST", 55, 60]]], ["Second, a 2013 Pew Internet Study found that Reddit users are more likely young males [70] , showing that around 15% of male internet users aged between 18 and 29 declare to use Reddit, compared to the 5% of women in the same age range and to the 8% of men aged between 30 and 49.", [["women", "ORGANISM", 208, 213], ["men", "ORGANISM", 253, 256], ["women", "SPECIES", 208, 213], ["men", "SPECIES", 253, 256], ["Internet Study", "TEST", 19, 33]]], ["Besides socio-demographic biases, other works suggested also that Reddit has become more and more a self-referential community, reinforcing the tendency to focus on its own contents rather than external sources [72] .", [["Reddit", "CHEMICAL", 66, 72]]], ["A similar argument may be raised for Wikipedia searches.", [["may be", "UNCERTAINTY", 19, 25]]], ["Indeed, the usage of Internet, especially for information seeking purposes, can vary across people with different socio-demographic backgrounds [73] [74] [75] [76] .", [["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98]]], ["First, many studies already characterized public response during the current and past health emergencies through the lens of Twitter [25, 43, 45, 58, 59, [77] [78] [79] [80] .", [["many studies", "TEST", 7, 19]]], ["Second, several studies have reported high prevalence of bots as drivers of low quality information and discussions on COVID-19 on this platform [24, 25, [81] [82] [83] .", [["COVID-19", "CHEMICAL", 119, 127], ["several studies", "TEST", 8, 23], ["COVID", "TEST", 119, 124]]], ["Thus, careful and challenging extra steps would be necessary to isolate, identify, and distinguish organic discussions/reactions possibly originated from traditional media from those sparked by social bots.", [["challenging extra steps", "TREATMENT", 18, 41], ["reactions", "PROBLEM", 119, 128]]], ["Therefore, since people are highly reactive to the news they are exposed to, in the beginning of an outbreak, the quality and type of information provided might have critical effects on risk perception, behaviours, and ultimately on the unfolding of the disease.", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23], ["the disease", "PROBLEM", 250, 261], ["reactive", "OBSERVATION_MODIFIER", 35, 43], ["disease", "OBSERVATION", 254, 261]]], ["On the other hand, however, we found that collective online attention saturates and declines rapidly despite media exposure and disease circulation remaining high.", [["media exposure", "TREATMENT", 109, 123], ["disease circulation", "TEST", 128, 147], ["high", "OBSERVATION_MODIFIER", 158, 162]]], ["Attention saturation has the potential to affect collective awareness, perceived risk and ultimately propensity towards virtuous individual behavioural changes aimed at mitigating the spreading.", [["Attention saturation", "TEST", 0, 20], ["virtuous individual behavioural changes", "PROBLEM", 120, 159], ["spreading", "OBSERVATION_MODIFIER", 184, 193]]], ["Furthermore, especially in case of unknown viruses, attention saturation might exacerbate the spreading of low quality information, which is likely to spread in the early phases of the outbreak when the characteristics of the disease are uncertain.", [["unknown viruses", "PROBLEM", 35, 50], ["attention saturation", "TEST", 52, 72], ["the disease", "PROBLEM", 222, 233], ["viruses", "OBSERVATION", 43, 50], ["low quality", "OBSERVATION_MODIFIER", 107, 118], ["likely to", "UNCERTAINTY", 141, 150], ["early phases", "OBSERVATION_MODIFIER", 165, 177], ["disease", "OBSERVATION", 226, 233]]], ["Future works are needed to characterize the actual effects of attention saturation on human perceptions during a global health emergency.IV. CONCLUSIONSOur findings suggest that public health authorities should consider to reinforce specific communication channels, such as social media platforms, in order to compensate the (natural) phenomenon of attention saturation.", [["human", "ORGANISM", 86, 91], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["social media platforms", "TREATMENT", 274, 296], ["attention saturation", "TEST", 349, 369]]], ["Indeed, these channels have the potential to create a more durable engagement with people, through a continuous loop of direct interactions.", [["people", "ORGANISM", 83, 89], ["people", "SPECIES", 83, 89]]], ["However, the CDC didn't even have a Twitter account in 2009 during H1N1 pandemic (the account was created in May 2010).", [["H1N1 pandemic", "DISEASE", 67, 80]]], ["Therefore, there is great need to further reinforce and engage people through these channels.", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69]]], ["An example can be represented by participatory surveillance platforms all over the world such as Influenzanet, Flu Near You and FluTracking [84] [85] [86] , which have the potential of delivering in-depth targeted information to individuals during public health emergencies, to promote the exchange of information between people and public health authorities, with the potential to enhance the level of engagement in the community [87] .V. METHODS AND MATERIALIn this section we provide general information about the data sets collected and the methods used.A. News Articles and VideosWe collect news articles using News API, a service that allows to download articles published online in a variety of countries and languages [88] .", [["people", "ORGANISM", 322, 328], ["people", "SPECIES", 322, 328], ["the data sets", "TEST", 513, 526], ["the methods", "TREATMENT", 541, 552]]], ["We select \"relevant\" articles considering those citing one of the following keywords: 'coronavirus', 'covid19', 'covid-19', 'ncov-19', 'sars-cov-2'.", [["coronavirus", "ORGANISM", 87, 98], ["covid19", "GENE_OR_GENE_PRODUCT", 102, 109], ["coronavirus", "SPECIES", 87, 98], ["covid", "TEST", 113, 118], ["ncov", "TEST", 125, 129]]], ["In doing so, we download title and description of all videos and select as relevant those that mention one of the following keywords: 'coronavirus', 'virus', 'covid', 'covid19', 'sars', 'sars-cov-2', 'sarscov2'.A. News Articles and VideosThe reach of each channel (measured by number of subscribers) varies quite drastically from more than 9 million for CNN (USA) to about 12 thousand for Ansa (Italy).", [["sars", "ANATOMY", 179, 183], ["coronavirus", "SPECIES", 135, 146], ["'coronavirus'", "TREATMENT", 134, 147], ["cov", "TEST", 192, 195]]], ["In total, the YouTube dataset consist of 13, 448 videos: 3, 325 by Italian, 3, 525 by British, 6, 288 by American, ans 310 by Canadian channels.A. News Articles and VideosIt is important to underline that, while there is a good overlap between the sources of news articles and videos, some do not match.", [["YouTube dataset", "DNA", 14, 29]]], ["In the Supplementary Information, we provide a complete list of news outlets and Youtube channels considered.B. Reddit data setReddit is a social content aggregation website where users can post, comment and vote content.", [["Youtube channels", "PROTEIN", 81, 97]]], ["It is structured in subcommunities (i.e. subreddits), centered around a variety of topics.B. Reddit data setReddit has already proven to be suitable for a variety of research purposes, ranging from the study of user engagement and interactions between highly related communities [90, 91] to post-election political analyses [92] .", [["research purposes", "TEST", 166, 183], ["political analyses", "TEST", 305, 323], ["structured", "OBSERVATION_MODIFIER", 6, 16]]], ["Also, it has been used to study the impact of linguistic differences in news titles [93] and to explore recent web-related issues such as hate speech [94] or cyberbullying [95] as well as health related issues like mental illness [96] , also providing insights about the opioid epidemics [77, 97] .B. Reddit data setWe used the Reddit API to collect all submissions and comments published in Reddit under the subreddit /r/Coronavirus from 15/02/2020 to 15/05/2020.", [["illness", "DISEASE", 222, 229], ["mental illness", "PROBLEM", 215, 229], ["Coronavirus", "PROBLEM", 422, 433]]], ["Final data contains 107, 898 submissions and 3, 829, 309 comments from 417, 541 distinct users.B. Reddit data setFor the submissions, we then selected entries with links to English news outlets.", [["Final data", "TEST", 0, 10]]], ["We used the same approach as described in [97] , that found the use of regular expressions as reliable, resulting in high correlation with census data in the US, although we acknowledge a potential higher bias at country level due to heterogeneities in Reddit population coverage and users demographics.", [["a potential higher bias", "PROBLEM", 186, 209], ["heterogeneities", "PROBLEM", 234, 249], ["Reddit population coverage", "TREATMENT", 253, 279]]], ["By removing inconsistent self reporting we were able to assign a country to 789, 909 distinct users, from which 41, 465 have written at least one comment in the subreddit r/Coronavirus (13, 811 from USA, 6, 870 from Canada, 3, 932 from UK and 445 from Italy).C. Wikipedia data setWikipedia has become a popular digital data source to study health information seeking behaviour [57, 99] , and to monitor and forecast the spreading of infectious diseases [100, 101] .", [["setWikipedia", "CHEMICAL", 277, 289], ["infectious diseases", "DISEASE", 433, 452], ["infectious diseases", "PROBLEM", 433, 452]]], ["We choose the articles directly related to COVID-19 and the ones in the 'see also' section of each page at the time of the analysis, 2020/02/07 -2020/05/15, including country-specific articles (see Supplementary Information for full list of web pages considered).C. Wikipedia data setExcept for the Italian, where the language is highly indicative of the location, the number of the access to English pages are almost evenly distributed among English-speaking countries.", [["the analysis", "TEST", 119, 131]]], ["The total volume of views at day d from a country c is then given by the sum over all the articles a and projects p, namely y c (d) = a,p y c a,p (d).D. Linear regression approach to model collective attentionAbove we showed how media coverage, COVID-19 incidence, and public attention are correlated even across four different countries.", [["Linear regression approach", "TREATMENT", 153, 179], ["public attention", "TREATMENT", 269, 285]]], ["To move a step forward in this analysis, we considered a linear regression model that predicts for each country the public response given the news exposure.", [["this analysis", "TEST", 26, 39], ["a linear regression model", "TREATMENT", 55, 80]]], ["To include \"memory effects\" in the public response to media coverage, we consider also a modified version of this simple model, in which we weight cumulative news articles volume time series with an exponential decaying term [22] .", [["media coverage", "TREATMENT", 54, 68], ["a modified version", "TREATMENT", 87, 105], ["this simple model", "TREATMENT", 109, 126]]], ["Formally, we define the new variable:D. Linear regression approach to model collective attentionWhere \u03c4 is a free parameter that sets the memory time scale and is tuned with cross-validation (more details in the Supplementary Information).", [["\u03c4", "PROTEIN", 102, 103]]], ["These two models are compared to a linear regression that considers only COVID-19 incidence to predict public collective attention.", [["a linear regression", "PROBLEM", 33, 52], ["COVID", "TEST", 73, 78]]], ["Many topic analysis frameworks are extensions of well known algorithms, considered as state-of-the-art for topic modeling.", [["topic modeling", "PROBLEM", 107, 121]]], ["Nonnegative matrix factorization (NMF) [67] is the counterpart of LDA for the matrix factorization community.E. Topic ModelingAlthough there are many approaches to temporal and hierarchical topic modeling [104] [105] [106] , we choose to apply NMF to the dataset, and then build time-varying intensities for each topic using the articles publication date.", [["Nonnegative matrix factorization", "TEST", 0, 32], ["matrix", "OBSERVATION_MODIFIER", 12, 18], ["temporal", "OBSERVATION_MODIFIER", 164, 172]]], ["We apply TF-IDF normalization [108] and extract a total of K = 64 topics through NMF:E. Topic Modelingwhere 2 F is the Frobenius norm and X \u2208 R |D|\u00d7|V| is the matrix resulting form TF-IDF normalization, subject to the constraint that the values in W \u2208 R |D|\u00d7K and H \u2208 R K\u00d7|V| must be nonnegative.", [["matrix", "CELLULAR_COMPONENT", 159, 165], ["|V", "GENE_OR_GENE_PRODUCT", 272, 274], ["TF", "PROTEIN", 9, 11], ["TF", "PROTEIN", 181, 183], ["K", "TEST", 59, 60], ["the matrix", "TEST", 155, 165], ["TF", "TEST", 181, 183], ["K", "TEST", 258, 259]]], ["The nonnegative factorization is achieved using the projected gradient method with sparseness constraints, as described in [109, 110] .", [["the projected gradient method", "TREATMENT", 48, 77], ["sparseness constraints", "PROBLEM", 83, 105]]], ["The matrix H is then used as a transformation basis for other datasets, e.g. with a new matrix X we fix H and calculate a new W according to Eq.", [["matrix H", "GENE_OR_GENE_PRODUCT", 4, 12], ["a new matrix", "TREATMENT", 82, 94]]], ["For the news outlets dataset, sE.", [["sE", "DNA", 30, 32]]], ["Therefore, given t 0 and t f as the start/end of our analysis interval, and givenE.", [["t 0", "DNA", 17, 20]]], ["Topic Modelingk , the coordinates of Figure 5 are the t 1/2 such thatACKNOWLEDGMENTSAuthors would like to thank the startup Quick Algorithm for providing the platform https://covid19.scops.ai/ scops/home/, where the data collected during COVID-19 pandemic were visualized in real-time.", [["the platform https://covid19.scops.ai/ scops/home/", "TEST", 154, 204], ["the data", "TEST", 212, 220], ["COVID", "TEST", 238, 243], ["pandemic", "PROBLEM", 247, 255]]], ["D.P. and M.T. acknowledge support from the Lagrange Project of the Institute for Scientific Interchange Foundation (ISI Foundation) funded by Fondazione Cassa di Risparmio di Torino (Fondazione CRT).", [["Fondazione Cassa di Risparmio di Torino (Fondazione CRT", "TREATMENT", 142, 197]]], ["M.S/ and A.P. acknowledge support from the Research Project \"Casa Nel Parco\" (POR FESR 14/20 -CANP -Cod.", [["Cod", "PROTEIN", 100, 103]]], ["The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.", [["data collection", "TEST", 41, 56], ["analysis", "TEST", 61, 69], ["no", "UNCERTAINTY", 16, 18]]], ["CONTRIBUTIONS N.G, M.S., D.P., A.P. and N.P. conceptualized the study.", [["the study", "TEST", 60, 69]]], ["N.G. and A.P. provided visualization.", [["visualization", "TEST", 23, 36]]], ["All authors (N.G., N.P., D.P., M.S., A.P., M.T., F.C.) discussed the research design, reviewed, edited, and approved the manuscript. : From left to right: ratio between UK media interest and general media interest for different topics; ratio between UK Reddit users interest and general Reddit users interest for different topics; differences between these two quantities for different topics.", [["left", "ANATOMY_MODIFIER", 140, 144], ["right", "ANATOMY_MODIFIER", 148, 153]]], ["In the fisrt two plots, topics to the left of the dashed line (on 1) are less discussed in by UK media/users with respect to the general discussion, while topics to the right are more discussed.", [["left", "ANATOMY_MODIFIER", 38, 42], ["dashed line", "OBSERVATION", 50, 61], ["right", "ANATOMY_MODIFIER", 169, 174]]], ["In the last plot, positive (negative) bars indicated that UK Reddit users pay generally more (less) attention to that topic with respect to UK media.", [["UK", "GENE_OR_GENE_PRODUCT", 140, 142]]], ["Figure 7 : From left to right: ratio between US media interest and general media interest for different topics; ratio between US Reddit users interest and general Reddit users interest for different topics; differences between these two quantities for different topics.", [["left", "ANATOMY_MODIFIER", 16, 20], ["right", "ANATOMY_MODIFIER", 24, 29]]], ["In the fisrt two plots, topics to the left of the dashed line (on 1) are less discussed in by US media/users with respect to the general discussion, while topics to the right are more discussed.", [["left", "ANATOMY_MODIFIER", 38, 42], ["dashed line", "OBSERVATION", 50, 61], ["right", "ANATOMY_MODIFIER", 169, 174]]], ["Figure 8 : From left to right: ratio between Canadian media interest and general media interest for different topics; ratio between Canadian Reddit users interest and general Reddit users interest for different topics; differences between these two quantities for different topics.", [["left", "ANATOMY_MODIFIER", 16, 20], ["right", "ANATOMY_MODIFIER", 24, 29]]], ["In the fisrt two plots, topics to the left of the dashed line (on 1) are less discussed in by Canadian media/users with respect to the general discussion, while topics to the right are more discussed.", [["left", "ANATOMY_MODIFIER", 38, 42], ["dashed line", "OBSERVATION", 50, 61], ["right", "ANATOMY_MODIFIER", 175, 180]]], ["In the last plot, positive (negative) bars indicated that Canadian Reddit users pay generally more (less) attention to that topic with respect to Canadian media.", [["Canadian media", "TREATMENT", 146, 160]]]], "94ee339d4a96928f84b6ae01027c30512d19c579": [["The COVID-19 pandemic has completely disrupted our normal surgical and clinical routine.", [["The COVID", "TEST", 0, 9]]], ["Here in Bergamo, the centre of the Italian epidemic, we felt small and incompetent at the beginning.", [["small and incompetent", "PROBLEM", 61, 82], ["small", "OBSERVATION_MODIFIER", 61, 66], ["incompetent", "OBSERVATION", 71, 82]]], ["In these weeks we are putting our willingness at the service of our patients and colleagues.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76]]]], "03c2675b18075a5caea4e1c6bdfca2833564bbdf": [["In response to the COVID-19 pandemic, UK Infection Prevention & Control (IP&C) guidelines have been published on using personal protective equipment (PPE) in various healthcare settings [1] .", [["Infection", "DISEASE", 41, 50], ["the COVID", "TEST", 15, 24], ["UK Infection Prevention", "TREATMENT", 38, 61], ["Control (IP&C) guidelines", "TREATMENT", 64, 89], ["personal protective equipment", "TREATMENT", 119, 148], ["Infection", "OBSERVATION", 41, 50]]], ["Improper PPE use can compromise the protection afforded by it [2] .", [["PPE", "CHEMICAL", 9, 12]]], ["The IP&C guidelines [1] highlight actions which may constitute a PPE 'breach'.", [["The IP&C guidelines", "TREATMENT", 0, 19]]], ["In response to a Cochrane review [3] calling for research into barriers to proper PPE use, we investigated the most common types of breaches observed across several inpatient wards.", [["breaches", "OBSERVATION", 132, 140]]], ["The results highlight areas of practice that could be improved to optimise PPE use and reduce nosocomial transmission of infection [4] .", [["infection", "DISEASE", 121, 130], ["nosocomial transmission of infection", "PROBLEM", 94, 130], ["infection", "OBSERVATION", 121, 130]]]]}